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Insertable cardiac monitors (ICMs) are leadless subcutaneous implantable cardiac devices that 
continuously monitor the heart rhythm and automatically record arrhythmias, providing the physician 
information on the presence, type, frequency and duration of arrhythmias. 
 The first ICM was introduced in the late 1980 (Medtronic, Inc., Minneapolis, MN, USA). It had 
the size of a pacemaker (53 x 60 x 8mm) and was implanted similarly (subcutaneous pocket). Since 
then, technical advancements have resulted into smaller devices, easier implantation techniques, 
improved detection algorithm, longer battery longevity and availability of remote monitoring1, 2. ICMs 
were primarily designed to evaluate episodes of unexplained syncope and/or to obtain symptom-
rhythm correlation in patients with infrequent palpitations1, 3-5. However, the current ESC guideline 
have expanded the indication for an ICM to patients with unexplained syncope and inheritable cardiac 
disease at low risk of sudden cardiac death (SCD), such as those with hypertrophic cardiomyopathy, 
arrhythmogenic right ventricular cardiomyopathy, and inheritable primary arrhythmia syndrome4. 
Unexplained syncope in patients with inheritable cardiac disease may be associated with an arrhythmic 
event and is thus an important risk factor for SCD. The occurrence of unexplained syncope may qualify 
these patients for an implantable cardioverter-defibrillator (ICD). There may be several reasons to use an 
ICM in these patients. First, not all syncopal events are arrhythmogenic and proper adjudication of the 
syncopal event may prevent unnecessary ICD implantation. Second, the occurrence of (asymptomatic) 
ventricular arrhythmias (VA) is an important risk factor for SCD and continuous monitoring with an ICM 
may result in early VA detection. Third, symptomatic patients may be reassured when they know that 
their symptoms are not caused by VA. Currently, there is limited clinical evidence that the use of ICM for 
this purpose in this population is justified. Furthermore, there are several issues when using ICMs in this 
population which require further attention, such as device costs, data management, optimal duration 
of monitoring and clinical relevance of detected arrhythmias. The first part of the thesis is focused on 
evaluating the role of ICM in specific patient populations who are at potential risk of SCD and do not 
meet the current criteria for prophylactic ICD implantation. 
Subcutaneous ICD 
Transvenous ICDs are effective in preventing SCD and prolonging survival in selected patient 
populations6-9. Current guidelines recommend an ICD in patients resuscitated from near-fatal ventricular 
fibrillation and those with sustained ventricular tachycardia with syncope (secondary prevention)10, 11. 
Furthermore, randomized controlled trials have shown that patients with chronic heart failure secondary 
to ischemic or nonischemic cardiomyopathy and reduced left ventricular function (ejection fraction 
≤35%) benefit from an ICD for primary prevention7, 8. The use of an ICD for primary prevention in patients 
with congenital heart disease or inheritable cardiac disease is less clear and is based on a multiparametric 
analysis that takes into account the recognized risk factors for VA/SCD for the specific population10, 11. 
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 An important disadvantage of transvenous ICDs is the long-term risk of lead-related 
complications, such as lead failure and lead-related endocarditis12, 13. This may require lead extraction 
which is associated with significant periprocedural risks. To overcome the lead-related complications 
associated with a transvenous lead, an entirely subcutaneous ICD (S-ICD) was developed14. Other 
advantages of a S-ICD are the possibility of implantation without fluoroscopy, no need of vascular 
access and elimination of certain periprocedural complications (i.e., pneumothorax and tamponade)15. 
The S-ICD, however, does not provide pacing or antitachycardia pacing (ATP). The 2015 ESC guidelines 
recommend to consider a S-ICD as an alternative to a transvenous ICD in ICD candidates without need 
for pacing therapy for bradycardia, cardiac resynchronization therapy, and ATP11. The S-ICD may be ideal 
in those with limited vascular access, high infection risk, or young patients with a long-term need for ICD 
therapy, such as those with inheritable cardiac disease or congenital heart disease16. Several studies have 
shown the efficacy and safety of the S-ICD17-20. While earlier S-ICD cohorts (e.g., EFFORTLESS) comprised 
a large proportion of young patients with inherited cardiac disease without co-morbidity, a more 
contemporary S-ICD cohort showed a shift towards more co-morbidities than previous cohorts with 
S-ICD18, 21. However, even the contemporary S-ICD cohort is younger with more end-stage renal disease 
than cohorts with a transvenous ICD21. 
 Arrhythmia discrimination with a S-ICD depends on a surface electrogram and the specificity 
for supraventricular arrhythmias seems better in comparison to a transvenous ICD22. Unfortunately, 
inappropriate ICD shocks do occur and the main cause of inappropriate ICD shocks is T-wave 
oversensing20, 22-27. To avoid T-wave oversensing, the manufacturer recommends pre-implant ECG 
screening. Previously this was performed using a manual ECG-screening tool, but this has been replaced 
by an automatic screening tool (AST). The second part of the thesis is focused on the evaluation of AST 
in specific patient populations at potential risk of SCD, with a special emphasis on young patients with 




Aim and outline of the thesis
Part I – Clinical value of ICM for risk stratification
Part I of the thesis focuses on the clinical value of ICMs in patients with structural or electrical heart 
disease who are deemed to be at risk for VA/SCD based on their clinical profile. In Chapter 2 we discuss 
the current indications for ICMs and give an overview of the latest generation ICMs. Chapter 3 is a pilot 
study in which we compared the diagnostic yield of an ICM in patients with a normal heart and patients 
with structural or electrical heart disease. Subsequently, in Chapters 4-6 we evaluated the clinical value 
of ICMs in specific patient categories, including patients with congenital heart disease, hypertrophic 
cardiomyopathy and Brugada syndrome, respectively. 
 In Chapter 7 we evaluated the impact of a chronic total coronary occlusion (CTO) on 
the occurrence of recurrent ventricular arrhythmias in survivors of out-of-hospital cardiac arrest 
with coronary artery disease. This study formed the basis of the ongoing multicenter VACTOR study 
(Incidence of Ventricular Arrhythmias in patients with Chronic Total Occlusion Recanalization, NCT03475888) 
evaluating the role of an ICM for risk stratification in patients with a CTO.
Part II – Eligibility for a subcutaneous ICD
Part II aims to identify patients who may be suitable for a S-ICD. In Chapter 8 we retrospectively 
evaluated the potential eligibility for a S-ICD at the time of first replacement in a cohort of patients with a 
transvenous single-chamber ICD who did not need bradycardia pacing at the time of ICD implantation. 
 When a patient seems to be a suitable candidate for a S-ICD, it is recommended to perform 
a pre-implant ECG screening. This process has been automated by AST. In Chapter 9 we evaluated 
the eligibility for the S-ICD using two screening methods (conventional manual method versus AST) in 
different patient categories. Finally, in Chapter 10 we evaluated whether a standard 12-lead ECG can 
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Introduction: Recurrent unexplained syncope is a well-established indication for an insertable cardiac 
monitor (ICM). Recently, the indications for an ICM has been expanded.
Areas covered: This review article discusses the current indications for ICMs and gives an overview of 
the latest generation of commercially available ICMs. 
Expert commentary: The 2018 ESC Syncope guidelines have expanded the indications for an ICM to 
patients with inherited cardiomyopathy, inherited channelopathy, suspected unproven epilepsy, and 
unexplained falls. ICMs are also increasingly used for the detection of subclinical atrial fibrillation in patients 
with cryptogenic stroke. Whether treatment of subclinical atrial fibrillation with oral anticoagulation 
prevents recurrent stroke is yet unknown. The current generation of ICMs are smaller, easier to implant, 
have better diagnostics and are capable of remote monitoring. The Reveal LINQ (Medtronic) is the 
smallest ICM and has the most extensive performance and clinical data. The BioMonitor 2 (Biotronik) is 
the largest ICM but has excellent R-wave amplitudes, longest longevity and reliable remote monitoring. 
The Confirm Rx (Abbott) is capable to provide mobile data transmission enabled by a smartphone app. 
Future generation of ICMs will incorporate heart failures indices to facilitate remote monitoring of heart 
failure patients. 




Prolonged rhythm monitoring using a subcutaneous insertable cardiac monitor (ICM) has proven to be 
of incremental diagnostic value for a wide range of indications, especially in patients with unexplained 
recurrent syncope1. An ICM is not only useful for the detection of arrhythmias but can also rule out a 
cardiac cause of symptoms. In the most recent European Society of Cardiology (ESC) guidelines for the 
diagnosis and management of syncope there is an expansion of the indications for an ICM, including 
patients with suspected unproven epilepsy, unexplained falls, and patients with primary cardiomyopathy 
or inheritable arrhythmogenic disorders who are at low risk of sudden cardiac death (SCD)1. Technical 
advancements have resulted in smaller devices, easier implantation, improved atrial fibrillation (AF) 
detection, longer battery longevity and availability of remote monitoring. The aim of the present review 
is to provide an overview of the current indications (with a special focus on new indications), recent 
clinical trials, latest generation of ICMs, and future perspectives. 
2. Indications
The indications for an ICM has expanded over the years. Table 1 provides an overview of the current 
indications according to the most recent guidelines1-4.
2.1 Recurrent syncope
Syncope is a relatively common clinical symptom in the general population with a lifetime incidence of 
30-40% and is responsible for 3-6% of all emergency visits5. Despite extensive evaluation, a significant 
proportion of patients remain without a diagnosis6-8. Several studies from the ISSUE-investigators in 
the early 2000s demonstrated the diagnostic value of an ICM in different syncope populations such 
as those with neurally-mediated syncope, bundle branch block or structural heart disease9-11. A meta-
analysis of five randomized controlled trials comparing a conventional strategy (external loop recorder, 
tilt testing, and electrophysiological testing) to ICM implantation showed that an ICM provided a 3.6 
increased relative probability of a diagnosis compared with the conventional strategy (46% versus 12%)1, 
12-16. Furthermore, an ICM strategy was more cost-effective than a conventional strategy13, 14. Currently, an 
ICM is a well-established diagnostic tool in patients with recurrent unexplained syncope and should be 
employed in an early phase of evaluation17.
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Table 1. Recommendations for ICM implantation in current guidelines
2018 ESC guidelines for the diagnosis and management of syncope1 Class LOE
ICM is indicated in an early phase of evaluation in patients with recurrent syncope of 
uncertain origin, absence of high-risk criteria, and a high likelihood of recurrence within 
the battery life of the device8, 9, 15-17, 91, 92.
I A
ICM is indicated in patients with high-risk criteria in whom a comprehensive evaluation 
did not demonstrate a cause of syncope or lead to a specific treatment, and who do not 
have conventional indications for primary prevention ICD or pacemaker indication10-12, 93, 
94.
I A
ICM should be considered in patients with suspected or certain reflex syncope 
presenting with frequent or severe syncopal episodes17, 95, 96.
IIa B
Instead of an ICD, an ICM should be considered in HCM/ ARVC/ long QT syndrome or 
Brugada syndrome patients with recurrent episodes of unexplained syncope who are at 
low risk of SCD.
IIa C
ICM may be considered in patients in whom epilepsy was suspected but the treatment 
has proven ineffective34-37.
IIb B
ICM may be considered in patients with unexplained falls37, 42, 43. IIb B
Instead of an ICD, an ICM may be considered in patients with recurrent episodes of 
unexplained syncope with systolic impairment, but without a current indication for ICD. 
IIb C
2017 AHA/ACC/HRS guideline for management of patients with ventricular 
arrhythmias and the prevention of sudden cardiac death4
In patients with sporadic symptoms (including syncope) suspected to be related to 
ventricular arrhythmias, ICMs can be useful32, 97-99. 
IIa B
2016 ESC guidelines for the management of atrial fibrillation developed in 
collaboration with EACTS2
In stroke patients, additional ECG monitoring by long-term non-invasive ECG monitors or 
ICM should be considered to document silent atrial fibrillation47, 100.
IIa B
2015 ESC guidelines for the management of patients with ventricular 
arrhythmias and the prevention of sudden cardiac death3
ICMs are recommended when symptoms, e.g. syncope, are sporadic and suspected to be 
related to arrhythmias and when a symptom-rhythm correlation cannot be established 
by conventional diagnostic techniques99.
I B
Abbreviations: ARVC, arrhythmogenic right ventricular cardiomyopathy; HCM, hypertrophic cardiomyopathy; ICD, 
implantable cardioverter-defibrillator; ICM, implantable cardiac monitor. 
2.2 Risk stratification
2.2.1 Inherited cardiomyopathy or channelopathy
In patients with inherited cardiomyopathy or channelopathy, the occurrence of syncope is associated 
with a worse prognosis and may be a harbinger of SCD. Therefore, the occurrence of syncope in this 
population may be an indication for an implantable cardioverter-defibrillator (ICD)4. However, syncope 
in this population is not always secondary to a life-threatening tachyarrhythmia. In fact, recent studies in 
Brugada patients have shown that syncope is usually neurally mediated18, 19. Although systematic history 
taking may be helpful in differentiating arrhythmic (absence of prodromes and specific triggers) and 
nonarrhythmic syncope19, in clinical practice this distinction can be difficult. 
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 In this respect, ICMs might be helpful in establishing a clear symptom-rhythm correlation. 
A potential down-side of using an ICM, instead of implanting an ICD, is that the next syncopal event 
might potentially be fatal. The experience with ICMs in patients with inherited cardiomyopathy or 
channelopathy is limited. A Dutch study demonstrated that the diagnostic yield of ICMs (Reveal LINQ, 
Medtronic) is lower in patients with channelopathy in comparison to patients with structural heart disease 
and healthy control patients20. In this study, one of five patients with hypertrophic cardiomyopathy 
(HCM) received an ICD based on a documented nonsustained VT. The number of patients with inherited 
cardiomyopathy or channelopathy who receive an ICD based on the findings of the ICM varies per 
underlying diagnosis. Based on the available literature, no ICM patient with Brugada syndrome20-23, long 
QT syndrome20, 24, 25, arrhythmogenic right ventricular cardiomyopathy (ARVC)20, or noncompaction 
cardiomyopathy26 received an ICD during follow-up. This might be related to the duration of follow-
up. ICDs have been implanted based on ICM-findings in patients with catecholaminergic polymorphic 
VT (11%)24, hypertrophic cardiomyopathy (HCM) (20%)20, and Fabry cardiomyopathy (25%)27. Despite 
the limited available data, current guidelines give a class IIa indication for an ICM in patients with 
inherited cardiomyopathy (i.e., HCM and ARVC) or channelopathy (i.e., Brugada syndrome and long. QT 
syndrome) with recurrent episodes of unexplained syncope who are at low risk of SCD1, 28. ICMs may 
also be considered (class IIb indication) in HCM patients with frequent palpitations, in whom no cause is 
identified following prolonged ECG monitoring28. The J-wave syndromes expert consensus conference 
report recommends close follow-up with an ICM in presumably nonarrhythmic symptomatic patients 
(i.e., syncope, seizure or nocturnal agonal respiration) with Brugada or early repolarization syndrome29.
2.2.2 Post-myocardial infarction
Post-acute myocardial infarction patients with depressed left ventricular (LV) function are at risk of SCD. 
However, several randomized trials have shown that prophylactic ICDs do not improve survival when 
implanted in patients with LV dysfunction in the early phase after an acute myocardial infarction30, 31. 
The CARISMA study investigated the incidence and prognostic significance of arrhythmias using an 
ICM (Reveal Plus, Medtronic) in 297 patients with a LV function ≤40% post-acute myocardial infarction 
(3 to 21 days)32. During a mean follow-up of 1.9 years, the following arrhythmias were documented: 
new-onset AF (28%), nonsustained ventricular tachycardia (VT) (13%), high-degree atrioventricular (AV) 
block (10%), sinus bradycardia (7%), sinus arrest (5%), sustained VT (3%), and ventricular fibrillation (VF) 
(3%). High-degree AV block was the most powerful predictor of cardiac death. In the CARISMA study, 16 
patients had an electrogram recorded at the time of death, of whom 7 patients died suddenly33. In 6 of 7 
cases of SCD (86%), VF was documented at the time of death. The clinical usefulness of ICMs in patients 
surviving an acute myocardial infarction is currently unclear. In the most recent ESC Syncope guidelines, 
there is a class IIb indication for an ICM in patients with recurrent episodes of unexplained syncope with 
systolic impairment, but without a current indication for an ICD1.
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2.3 Suspected unproven epilepsy
Several studies have demonstrated that up to 1 in 4 patients with ‘epilepsy’ may be misdiagnosed34. The 
hypothesis is that seizure-like episodes in these patients are the result from cerebral hypoperfusion due 
to a cardiac arrhythmia. The REVISE study included 103 patients previously diagnosed with epilepsy 
but considered to have a definite or likely misdiagnosis of epilepsy after neurological review35. Patients 
had to suffer at least 3 transient loss of consciousness episodes in the year before enrollment. The ICM 
(Reveal Plus/DX, Medtronic) recorded profound bradyarrhythmia or asystole with convulsive features 
in 21% of patients and they were offered a pacemaker implantation. After pacing and withdrawal of 
antiepileptic drugs, 60% of these patients were rendered asymptomatic. In pooled data from six studies 
performed in 159 patients in whom epilepsy was suspected but the treatment was ineffective, 62% had 
an ICM-documented attack, with an arrhythmic cause being responsible in 26%1, 34-39. 
2.4 Unexplained falls
Unexplained falls are responsible for 14% of falls in older cohorts40. It is important to realize that syncope 
in elderly can present as an unexplained fall. An Irish study included recurrent fallers over the age of 50 
years with two or more unexplained falls presenting to an emergency department41. Seventy patients 
received an ICM (Reveal DX/XT, Medtronic). Fourteen patients (20%) demonstrated a cardiac arrhythmia 
which was attributable as the cause of their fall. Of the seventy patients, 14% received a pacemaker 
and 6% had treatment for supraventricular tachycardia. Early detection of an arrhythmogenic cause of 
falls may prevent future falls in this fragile population. In pooled data from four studies performed in 
176 patients with unexplained falls who received an ICM, 70% had an ICM-documented attack, with an 
arrhythmic cause being responsible in 14%1, 37, 41-43. 
2.5 Unexplained palpitations
In patients with infrequent episodes of palpitations short-term ambulatory ECG monitoring is usually 
insufficient. In the RUP study, 50 patients with infrequent (≤1 episode per month), sustained (>1 min) 
palpitations and initial negative diagnostic workup were randomized to conventional strategy (24-
h Holter recording, a 4-week period of ambulatory ECG monitoring with an external recorder, and 
electrophysiology study) or to an ICM (Reveal Plus, Medtronic) with 1-year monitoring44. The diagnostic 
yield was higher in the ICM group (73% versus 21%, P<0.001). Palpitations were completely eliminated in 
the patients with an arrhythmic diagnosis using ablation, pacemaker, or drugs. Furthermore, the overall 
cost per diagnosis in the ICM group was lower compared to the conventional strategy group. There is 
a class IIa indication for an ICM in selected patients with severe infrequent symptoms when other ECG 
monitoring systems fail to document the underlying cause45. 
2.6 Atrial fibrillation detection
The detection of AF can have therapeutic consequences for certain patient populations. Clinical AF is 
associated with a twofold increased risk of mortality and fivefold increased risk of stroke. Treatment with 
oral anticoagulation (OAC) can reduce these risks. Furthermore, previous studies have demonstrated that 
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device-detected subclinical AF (SCAF) has also important clinical consequences. In the ASSERT trial, SCAF 
(episodes of atrial rate >190 bpm with a duration of >6 minutes), was detected by a pacemaker or ICD in 
nearly 40% of patients during 2.5 years of follow-up. The presence of SCAF increased the risk for stroke by 
2.5-fold46. Currently, many studies have focused on the role of SCAF detected by devices, including ICMs. 
2.6.1 Cryptogenic stroke or embolic stroke of unknown origin (ESUS)
The cause of ischemic stroke remains uncertain in 20-40% of patients despite extensive testing, this is 
called cryptogenic stroke. Embolic stroke of unknown origin (ESUS) is a subcategory of cryptogenic 
stroke in patients with non-lacunar infarcts in the absence of an apparent cause. Recurrent stroke is 
common in cryptogenic stroke patients and early detection of SCAF in these patients may be important 
as timely use of OAC may prevent recurrent stroke. The CRYSTAL AF trial randomized 441 cryptogenic 
stroke patients (>40 years of age) to an ICM (Reveal XT, Medtronic) or conventional follow-up47. Sustained 
AF (>30 s) was observed more frequently in the ICM group in comparison to the control group (12% vs. 
2% at 1 year, P<0.001; 30% vs. 3% at 3 years, P<0.001). In addition, real-world data using the Medtronic 
Discovery Link database demonstrated that the 2-year AF detection rate was 21.5% in cryptogenic 
stroke patients receiving an ICM (Reveal LINQ, Medtronic)48. Intermittent monitoring for AF detection 
was shown to be inferior to continuous ICM monitoring with sensitivities ranging from 3% (annual 24-
hour Holter) to 30% (quarterly 7-day Holters). ICMs have been shown to be a cost-effective diagnostic 
tool for the prevention of recurrent stroke in cryptogenic stroke patients49. In the 2016 ESC AF guidelines 
there is a class IIa indication for an ICM in stroke patients to document SCAF. 
 Another strategy to prevent recurrent stroke in ESUS patients is to treat patients with OAC 
instead of aspirin. If this strategy is effective, then AF detection has less clinical implications. In the 
NAVIGATE-ESUS trial, 7,213 ESUS patients were randomized to 15 mg rivaroxaban (Xarelto, Bayer AG) or 
100 mg aspirin50. At the recommendation of the Data and Safety monitoring committee, this trial was 
terminated on Oct. 5, 2017, due to excess risk for bleeding in the rivaroxaban arm (hazard ratio 2.72, 95% 
CI 1.68-4.39) and the lack of benefit for the reduction of stroke risk. Furthermore, the RE-SPECT ESUS trial 
(N=5,390) also failed to demonstrate superiority of dabigatran to aspirin for the prevention of recurrent 
stroke (4.1% versus 4.8%, HR 0.85, P=0.1)51. The rate of major bleeding was similar in both arms. The 
results were presented at the World Stroke Congress in Montreal, Canada. In this respect, it is worth to 
mention that in CRYSTAL AF approximately half of the patients met the inclusion criteria for NAVIGATE-
ESUS and RE-SPECT ESUS. Approximately 65% of these patients did not have AF at 3 years and may thus 
not potentially benefit from OAC52. The ongoing ARCADIA and ATTICUS trials will demonstrate whether 
the non-vitamin K antagonist OAC (NOAC) apixaban will be beneficial in the prevention of recurrent 
stroke in ESUS patients in comparison to aspirin53, 54. 
2.6.2 Patients at risk of stroke
A significant number of strokes occur in patients with SCAF46. To improve stroke prevention, recognition 
of SCAF may be important in high risk patients. Several ICM trials (REVEAL AF, PREDATE AF, ASSERT-II) 
demonstrated a high incidence of SCAF in high-risk populations using ICMs55-57. The 1-year AF incidence 
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ranged from 20% to 31% in these studies55-57. In the largest of these ICM studies, the REVEAL-AF trial 
(Reveal XT/LINQ), 385 patients (mean age 72 years) were enrolled with a CHADS2 score of ≥3, or CHADS2 
score of 2 and at least one of the following risk factors: coronary artery disease, renal impairment, sleep 
apnea, or chronic obstructive pulmonary disease57. The rate of AF detection ( ≥6 minutes) was 29% and 
40% at 18 and 30 months, respectively. The mean time to AF detection was 141 days. 
 It is currently uncertain whether SCAF conveys the same thromboembolic risk as clinical 
AF46. Furthermore, it is also unknown whether OAC for SCAF is beneficial. Currently, there are 3 ongoing 
trials assessing the role of OAC in patients with device-detected SCAF (LOOP; ARTESiA; and NOAH). The 
Danish LOOP trial will randomize 6,000 participants 3:1 to a control group or ICM group (Reveal LINQ, 
Medtronic)58, 59. Participants should be 70-90 years at the time of screening and have at least one of 
the following risk factors: diabetes mellitus, hypertension, heart failure, or previous stroke. When an AF 
episode (≥6 minutes) is detected, OAC will be initiated. The primary endpoint will be time to stroke or 
systemic embolism. In the ARTESiA trial, approximately 4,000 patients with device-detected SCAF (either 
by pacemaker, defibrillator, or ICM) and additional risk factors for stroke will be randomized to receive 
either apixaban or aspirin60, 61. Patients with clinical AF will be excluded. The primary endpoint will be a 
composite of stroke, TIA and systemic embolism. Finally, the NOAH trial will randomize 3,400 patients 
with atrial high rate episodes (detected by pacemaker or ICD), aged 65 years or older with at least one 
other stroke risk factor, to edoxaban or no anticoagulation62, 63. The primary endpoint will be stroke or 
cardiovascular death. 
2.6.3 Post-ablation of atrial fibrillation
To establish the efficacy of catheter ablation, reliable determination of freedom of AF is important and 
several studies used the ICM after surgical or percutaneous ablation64-69. From a clinical perspective, 
continuous monitoring is useful to establish a symptom-rhythm correlation. It is well established that 
longer arrhythmia monitoring improves the yield of AF detection. The ABACUS study compared ICM 
(Reveal XT, Medtronic) to conventional monitoring (30-day transtelephonic monitoring at discharge and 
at 6 months) in 44 post-AF ablation patients69. ICMs detected more AF than conventional monitoring 
in the first 6 months postablation (47% vs. 18%, P=0.002). Furthermore, ICMs has been used to guide 
treatment of early recurrence (<3 months) of AF post-ablation. In one randomized study, patients 
underwent early reablation when AF was triggered by supraventricular arrhythmias or premature atrial 
beats as detected by the ICM (Reveal XT, Medtronic)70. This strategy resulted in long-term success rates of 
89%. According to the 2017 HRS/EHRA/ECAS/APHRS/ SOLAECE expert consensus statement on catheter 
and surgical ablation of AF, the minimal monitoring recommendations for paroxysmal or persistent AF 
recurrence post-ablation does not include an ICM, however, in the setting of clinical trials extended ECG 
monitoring is encouraged71. 
2.6.4 Discontinuation of oral anticoagulation
The 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical 
ablation of AF gives a class IIb indication for an ICM to screen for AF recurrence in patients in whom 
discontinuation of OAC is being considered based on patient values and preferences71. One study 
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assessed the feasibility of discontinuation of OAC after ablation based on AF detection by an ICM (Reveal 
XT, Medtronic)72. During a mean follow-up of 32 months, 41 of 65 patients (63%) had an AF burden <1 
hour per day and were able to stay off OAC. The other patients had to restart OAC. No stroke, TIA, or other 
thromboembolic event occurred during follow-up. 
 Furthermore, a small pilot study, REACT.COM, tested a targeted strategy of ICM-guided 
intermittent NOAC administration in patients with nonpermanent AF and a CHADS2 score 1 or 2
73. The 
hypothesis was that continuous monitoring using an ICM (Reveal XT, Medtronic) and the rapid onset of 
NOAC allowed targeted anticoagulation only around an AF episode (≥1 hour). Using this strategy there 
was a 94% reduction in the time on NOAC compared to chronic anticoagulation. During a mean follow-
up of 466 days there were no strokes among 59 patients. Large prospective trials are needed to evaluate 
the safety of these approaches. 
3. Current devices
Currently, there are 3 commercially-available ICMs: Reveal LINQ (Medtronic), BioMonitor 2 (Biotronik) 
and Confirm Rx (Abbott). Figure 1 and Table 2 provides an overview of the latest generation devices. At 
present, the majority of clinical and performance data is available from the Reveal LINQ device. 
Figure 1. Overview of current generation ICMs. Dimensions Reveal LINQ (Medtronic): 45 x 7 x 4 mm; Confirm Rx 
(Abbott/ St. Jude Medical): 49 x 9 x 3 mm; and BioMonitor 2 (Biotronik): 88 x 15 x6 mm. 
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- Volume (cc) 1.2 4.5 1.4
- Length (mm) 45 88 49
- Width (mm) 7 15 9.4
- Thickness (mm) 4 6.5 3.1
- Weight (g) 2.5 10.1 3.0
Features:
- Longevity (years) 3 4 2
- Remote monitoring Wireless connection to 
bedside transmitter
Wireless connection to 
bedside transmitter
BluetoothÒ connection to 
personal mobile device or 
mobile transmitter
- MRI conditional 1.5 and 3.0 T 1.5 and 3.0 T 1.5 T
- Total EGM storage (min) 60 60 60
Regulatory approval:
- CE Mark Jan 2014 Aug 2015 May 2017
- FDA Feb 2014 April 2016 Oct 2017
3.1 Initial experience
The first pilot studies focused on the sensing amplitude and remote monitoring transmission success rate. 
A small multicenter study of 30 patients implanted with Reveal LINQ, published in 2015, demonstrated a 
R-wave amplitude of 0.58±0.33 mV at implantation and a transmission success rate of 80%74. Incomplete 
data reception or patients being out of range were important reasons for transmission failures. A 
small Australian study of 30 patients implanted with BioMonitor 2, published in 2017, demonstrated a 
R-wave amplitude of 0.75±0.39mV at 1 week and a transmission success rate of 94%75. This high R-wave 
amplitude of the BioMonitor 2 has been reproduced by other groups, also when placed in the axillary 
region76. The long sensing dipole of the BioMonitor 2 not only provides better R-wave amplitude but 
also better P-wave visibility. A potential disadvantage is oversensing of the P-wave, as one small study 
demonstrated misclassification of episodes as AF or high ventricular rates due to P-wave oversensing in 
16% of 19 patients77. So far, there is no published data on the initial experience with Confirm Rx. 
3.2 Accuracy of atrial fibrillation detection
All modern ICMs are equipped with automatic AF detection. The AF detection algorithms differ per 
manufacturer but are primarily based on R-R interval irregularity. For example, the Reveal XT analyze 
R-R interval irregularity patterns during subsequent 2 minutes sampling periods using the Lorenz 
Plot method. Runs of ectopy with irregular coupling intervals, undersensing of beats, oversensing of 
myopotentials or underlying sinus arrhythmia may be sources of false positive AF detection. The Reveal 
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LINQ has an improved AF detection algorithm based on the recognition of a single P-wave between two 
R-waves using morphologic processing of the ECG signal (Figure 2). This improved detection algorithm 
has been tested using continuous Holter monitoring as the gold standard78. Valid Holter recordings 
(8442 hours) were analyzed from 206 patients with paroxysmal AF. The algorithm correctly identified 
98% of the total AF duration (duration sensitivity) and 99% of the total sinus or non-AF rhythm duration 
(duration specificity). The gross AF episode detection positive predictive value (PPV) was 55%. This 
implies that 55% of all detected AF episodes was true AF. Using real-world data from 3,759 patients, the 
gross AF episode detection PPV was 84%, 73%, and 26% for all AF episodes (≥2 min) and improved to 
97%, 95%, and 91% for detected AF episodes ≥1 hour in the syncope, known-AF and cryptogenic stroke 
cohorts, respectively79. Thus, the performance of the algorithm is dependent on the study population 
and the duration of detected AF episodes. 
 The BioMonitor 2 AF performance was tested in 92 patients with an indication for an ICM 
(AF in 44, syncope in 33, cryptogenic stroke in 15)80. Successful Holter recordings were completed in 82 
patients. The episode sensitivity was 97% for AF episodes longer than 6 minutes (131 of 134 episodes 
detected). The gross AF episode detection PPV was 73%. No data on AF performance of the Confirm Rx 
is currently available in the literature. 
3.3 Accuracy of bradycardia and pause detection
Inappropriate bradycardia and pause detection by ICMs are mainly caused by undersensing of 
premature ventricular beats and low-amplitude R-waves. The Reveal LINQ has an enhanced dual sense 
algorithm which substantially reduces inappropriate episode detection with a minimum reduction in 
true episode detection81. The original algorithm uses an auto-adjusting sensitivity threshold for R-wave 
(to avoid T-wave oversensing) with a short blanking period (150 ms). In the dual sense algorithm, a 
second sensing threshold is used with a long blanking (T-wave blanking: 530 ms; P-wave blanking: 
220 ms) and fixed lower sensitivity threshold for confirmation of long detection intervals (Figure 3). 
Using the original algorithm 61% of 4,904 bradycardia episodes and 39% of 2,582 pause episodes were 
appropriately detected in 161 patients with unexplained syncope. The enhanced algorithm reduced 
inappropriate bradycardia and pause episodes by 95% and 47%, respectively, with 1.7% and 0.6% 
reduction in appropriate episodes, respectively. This new algorithm reduces episode review burden and 
improves episode review yield. Currently, no data on the accuracy of bradycardia and pause detection is 
available for BioMonitor 2 and Confirm Rx. 
CHAPTER 2
32
Figure 2. P-sense algorithm in the Reveal LINQ. The inset illustrates the procedure for P-wave averaging every 4 beats 
that meet the rate (RR >700-780 ms) and irregularity criteria. Eventual found P-wave evidence accumulates into a 
total P-wave evidence score over a 2-minutes AF detection period. This algorithm reduces false detection of AF due 
to sinus arrhythmia or runs of ectopy with irregular coupling intervals. Reprinted with permission from78. 
3.4 In-office insertion
The miniaturization of ICMs has enabled the routine insertion of the device outside the traditional 
hospital setting (operating room, cardiac catheterization or electrophysiology laboratory)82. Advantages 
of the in-office setting are lower costs, reduced resource utilization, fewer delays and lower burden to 
patients83. In the RIO 2 trial 521 patients were randomized to undergo Reveal LINQ insertion in a hospital 
or office environment with a follow-up of 90 days84. The safety profile was excellent with an untoward 
event rate of 0.8% in the office and 0.9% in the hospital (noninferiority: P<0.001). Patients with increased 
risk of bleeding or necessity of general anesthesia should, however, be treated in the operating room. 
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Figure 3. Dual sense algorithm in the Reveal LINQ. Auto-adjusting sensing scheme (second panel) may lead 
to undersensing of wide-complex shortly coupled bigeminal premature ventricular contractions, leading to 
inappropriate bradycardia detection. The dual sense scheme (third panel) with a long blanking and fixed threshold 
provides a second look for long intervals sensed in the primary sense channel (second panel). Reprinted with 
permission from81.
3.5 Remote monitoring
All current generation ICMs are capable of remote monitoring. Previous ICM studies with Reveal DX/
XT (Medtronic) have shown that remote monitoring improves the diagnostic yield, limits the risk of 
memory saturation and reduces the time to diagnosis85. The BioMonitor 2 using the Home Monitoring 
system has demonstrated a high transmission success rate, ranging from 94% to 99%75, 86. The Reveal 
LINQ using the CareLink system has demonstrated a transmission success rate of 80%74. While Reveal 
LINQ and BioMonitor 2 use a handheld activator and a home-based bedside transmitter, the Confirm 
Rx connects directly to the myMerlin smartphone app via Bluetooth wireless technology. This may 
potentially improve patients’ empowerment, engagement, and compliance. There are no published 




ICMs has been a well-established diagnostic tool for patients with recurrent unexplained syncope. The 
most recent guidelines expand the indication for ICMs to less well-established populations such as 
patients with inherited cardiomyopathies, inherited channelopathies, suspected unproven epilepsy, and 
unexplained falls. Furthermore, an ICM should be considered to document subclinical AF in cryptogenic 
stroke patients. Technological advancements have resulted in smaller devices, improved arrhythmia 
detection algorithms, and capability of remote monitoring. The Reveal LINQ (Medtronic) is the smallest 
ICM and has the most extensive performance and clinical data. The BioMonitor 2 (Biotronik) is the largest 
ICM but has excellent R-wave amplitudes, longest longevity and very reliable remote monitoring. Confirm 
Rx (Abbott) has Bluetooth wireless technology enabling monitoring via the patient’s smartphone.
5. Expert commentary
An ICM is a valuable tool for the detection of arrhythmias in different patient populations, especially in 
patients with recurrent unexplained syncope. Recently, the indication for ICMs has expanded to other 
patient populations where the benefit is less clearly established. One of these patient populations 
are patients who are at moderate risk of SCD due to ventricular tachyarrhythmias, such as those with 
inherited cardiomyopathy or channelopathy. The rationale to use an ICM in this population seems logical. 
Risk stratification for SCD using clinical risk factors is often challenging and an ICD can have profound 
adverse effects. An ICM will make it possible to detect spontaneous ventricular tachyarrhythmias in an 
early phase and reassure patients in case of neurally mediated syncope. There are, however, several 
issues when using ICMs in this population which requires further attention, such as cost-effectiveness 
and optimal duration of monitoring. 
 Another field where ICMs have been used is the detection of SCAF in patients with cryptogenic 
stroke or patients at high risk of stroke. The most important question is whether treatment of SCAF with 
OAC will result in less (recurrent) stroke. Multiple randomized trials are currently ongoing to address this 
issue. Until we have solid evidence that treatment of SCAF is useful, the indication for an ICM in patients 
with cryptogenic stroke or patients with high risk of stroke is not firmly established. In this respect, data 
on the performance of AF detection of current and future ICMs are important.
 Finally, the last decade there has been an exponential increase in the availability of wearable 
technologies (e.g., wristbands, in-ear monitors, electronic shirts) to detect arrhythmias87. Limitations of 
wearable technology are issues with compliance and need for recharging. Furthermore, most wearable 
devices use photoplethysmography technology which is less accurate than conventional electrogram-
based monitoring. However, new algorithms have led to better arrhythmia detection, especially of 
atrial fibrillation. We expect that wearable technology will represent an important alternative for 
ICM considering the high consumer adoption of wearable technology (especially for the younger 
population), lower costs and noninvasive nature of the technology.




In the next 5 years, ICMs will not only be capable of detecting arrhythmias but will be enhanced with new 
diagnostic features. One of these important features is early detection of worsening heart failure in order 
to provide timely intervention and prevent heart failure hospitalization. Previous studies using wireless 
invasive pulmonary artery pressure monitoring (CardioMEMS) have demonstrated that monitoring and 
timely treatment reduces heart-failure-related hospital admissions88. Furthermore, the MulitSENSE study 
demonstrated that a new algorithm (HeartLogic), combining several physiological parameters which 
are available from an ICD, can also predict future heart failure events89. It is likely that Boston Scientific 
will incorporate HeartLogic in their ICM (LUX-Dx) which is still under development and is expected to be 
launched in 2019. Medtronic has also developed a heart failure algorithm for the Reveal LINQ. Currently, 
the LINQ HF study is enrolling patients to test the performance of this algorithm to predict subsequent 
acute decompensated heart failure events90. The expected study completion is in October 2018. The 
availability of heart failure diagnostics will be an important step forward in the evolution of ICMs. 
Key issues
• Recurrent unexplained syncope is a well-established indication for an ICM
• The indications for an ICM has been recently expanded to syncope patients with inherited 
cardiomyopathy or channelopathy, patients with suspected unproven epilepsy, and patients with 
unexplained falls. 
• The detection of subclinical AF can be important in cryptogenic stroke patients.
• Technological advancements have resulted in smaller devices, improved arrhythmia detection 
algorithms, and capability of remote monitoring.
• Future ICMs will probably incorporate heart failure diagnostics to improve remote monitoring of 
heart failure patients.
Annotated bibliography
*    Important study demonstrating that early application of an ICM allows a safe, specific, and effective 
therapy in patients with suspected neurally mediated syncope17.
*    This study provides important information on the incidence and prognostic significance of cardiac 
arrhythmias in patients with acute myocardial infarction and LV dysfunction32. 
*    Interesting study demonstrating that 20% of patients >50 years with unexplained falls have a 
modifiable cardiac arrhythmia41. 




**  Randomized trial demonstrating the superiority of ICM in comparison to conventional screening for 
the detection of AF in patients with cryptogenic stroke47. 
*    Important randomized study which will determine whether treatment of device-detected SCAF with 
apixaban reduces the risk of stroke or systemic embolism60. 




Papers of special note have been highlighted as:
* of interest
** of considerable interest
1. Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, Fedorowski A, Furlan R, Kenny RA, Martin 
A, Probst V, Reed MJ, Rice CP, Sutton R, Ungar A, van Dijk JG and Group ESCSD. 2018 ESC Guidelines for the 
diagnosis and management of syncope. Eur Heart J. 2018.
2. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks 
J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P and Group ESCSD. 2016 
ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 
2016;37:2893-2962.
3. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala 
R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C and 
Van Veldhuisen DJ. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the 
prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias 
and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association 
for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36:2793-867.
4. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow 
GC, Gillis AM, Hlatky MA, Granger CB, Hammill SC, Joglar JA, Kay GN, Matlock DD, Myerburg RJ and Page RL. 
2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of 
Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force 
on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2017.
5. Ganzeboom KS, Mairuhu G, Reitsma JB, Linzer M, Wieling W and van Dijk N. Lifetime cumulative incidence of 
syncope in the general population: a study of 549 Dutch subjects aged 35-60 years. J Cardiovasc Electrophysiol. 
2006;17:1172-6.
6. Kapoor WN. Evaluation and management of the patient with syncope. JAMA. 1992;268:2553-60.
7. Soteriades ES, Evans JC, Larson MG, Chen MH, Chen L, Benjamin EJ and Levy D. Incidence and prognosis of 
syncope. N Engl J Med. 2002;347:878-85.
8. Edvardsson N, Frykman V, van Mechelen R, Mitro P, Mohii-Oskarsson A, Pasquie JL, Ramanna H, Schwertfeger F, 
Ventura R, Voulgaraki D, Garutti C, Stolt P, Linker NJ and Investigators PS. Use of an implantable loop recorder to 
increase the diagnostic yield in unexplained syncope: results from the PICTURE registry. Europace. 2011;13:262-9.
9. Moya A, Brignole M, Menozzi C, Garcia-Civera R, Tognarini S, Mont L, Botto G, Giada F, Cornacchia D and 
International Study on Syncope of Uncertain Etiology I. Mechanism of syncope in patients with isolated syncope 
and in patients with tilt-positive syncope. Circulation. 2001;104:1261-7.
10. Brignole M, Menozzi C, Moya A, Garcia-Civera R, Mont L, Alvarez M, Errazquin F, Beiras J, Bottoni N, Donateo P and 
International Study on Syncope of Uncertain Etiology I. Mechanism of syncope in patients with bundle branch 
block and negative electrophysiological test. Circulation. 2001;104:2045-50.
CHAPTER 2
38
11. Menozzi C, Brignole M, Garcia-Civera R, Moya A, Botto G, Tercedor L, Migliorini R, Navarro X and International 
Study on Syncope of Uncertain Etiology I. Mechanism of syncope in patients with heart disease and negative 
electrophysiologic test. Circulation. 2002;105:2741-5.
12. Da Costa A, Defaye P, Romeyer-Bouchard C, Roche F, Dauphinot V, Deharo JC, Jacon P, Lamaison D, Bathelemy 
JC, Isaaz K and Laurent G. Clinical impact of the implantable loop recorder in patients with isolated syncope, 
bundle branch block and negative workup: a randomized multicentre prospective study. Arch Cardiovasc Dis. 
2013;106:146-54.
13. Farwell DJ, Freemantle N and Sulke N. The clinical impact of implantable loop recorders in patients with syncope. 
Eur Heart J. 2006;27:351-6.
14. Krahn AD, Klein GJ, Yee R and Skanes AC. Randomized assessment of syncope trial: conventional diagnostic 
testing versus a prolonged monitoring strategy. Circulation. 2001;104:46-51.
15. Podoleanu C, DaCosta A, Defaye P, Taieb J, Galley D, Bru P, Maury P, Mabo P, Boveda S, Cellarier G, Anselme F, 
Kouakam C, Delarche N, Deharo JC and investigators F. Early use of an implantable loop recorder in syncope 
evaluation: a randomized study in the context of the French healthcare system (FRESH study). Arch Cardiovasc 
Dis. 2014;107:546-52.
16. Sulke N, Sugihara C, Hong P, Patel N and Freemantle N. The benefit of a remotely monitored implantable loop 
recorder as a first line investigation in unexplained syncope: the EaSyAS II trial. Europace. 2016;18:912-8.
17. Brignole M, Sutton R, Menozzi C, Garcia-Civera R, Moya A, Wieling W, Andresen D, Benditt DG, Vardas P and 
International Study on Syncope of Uncertain Etiology G. Early application of an implantable loop recorder 
allows effective specific therapy in patients with recurrent suspected neurally mediated syncope. Eur Heart J. 
2006;27:1085-92.
18. Giustetto C, Cerrato N, Ruffino E, Gribaudo E, Scrocco C, Barbonaglia L, Bianchi F, Bortnik M, Rossetti G, Carvalho 
P, Riccardi R, Castagno D, Anselmino M, Bergamasco L and Gaita F. Etiological diagnosis, prognostic significance 
and role of electrophysiological study in patients with Brugada ECG and syncope. Int J Cardiol. 2017;241:188-193.
19. Olde Nordkamp LR, Vink AS, Wilde AA, de Lange FJ, de Jong JS, Wieling W, van Dijk N and Tan HL. Syncope in 
Brugada syndrome: prevalence, clinical significance, and clues from history taking to distinguish arrhythmic 
from nonarrhythmic causes. Heart Rhythm. 2015;12:367-75.
20. Sakhi R, Theuns D, Bhagwandien RE, Michels M, Schinkel AFL, Szili-Torok T, Zijlstra F, Roos-Hesselink JW and 
Yap SC. Value of implantable loop recorders in patients with structural or electrical heart disease. Journal of 
interventional cardiac electrophysiology : an international journal of arrhythmias and pacing. 2018;52:203-208.
21. Champagne J, Philippon F, Gilbert M, Molin F, Blier L, Nault I, Sarrazin JF, Charbonneau L, Dufort L, Drolet B, 
Chahine M and O’Hara GE. The Brugada syndrome in Canada: a unique French-Canadian experience. Can J 
Cardiol. 2007;23 Suppl B:71B-75B.
22. Kubala M, Aissou L, Traulle S, Gugenheim AL and Hermida JS. Use of implantable loop recorders in patients with 
Brugada syndrome and suspected risk of ventricular arrhythmia. Europace. 2012;14:898-902.
23. Sacher F, Arsac F, Wilton SB, Derval N, Denis A, de Guillebon M, Ramoul K, Bordachar P, Ritter P, Hocini M, Clementy 
J, Jais P and Haissaguerre M. Syncope in Brugada syndrome patients: prevalence, characteristics, and outcome. 
Heart Rhythm. 2012;9:1272-9.
INSERTABLE CARDIAC MONITORS 
39
2
24. Avari Silva JN, Bromberg BI, Emge FK, Bowman TM and Van Hare GF. Implantable Loop Recorder Monitoring for 
Refining Management of Children With Inherited Arrhythmia Syndromes. J Am Heart Assoc. 2016;5.
25. Frangini PA, Cecchin F, Jordao L, Martuscello M, Alexander ME, Triedman JK, Walsh EP and Berul CI. How revealing 
are insertable loop recorders in pediatrics? Pacing Clin Electrophysiol. 2008;31:338-43.
26. Stollberger C, Keller H, Steger C and Finsterer J. Implantable loop-recorders in myopathic and non-myopathic 
patients with left ventricular hypertrabeculation/noncompaction. Int J Cardiol. 2013;163:146-8.
27. Weidemann F, Maier SK, Stork S, Brunner T, Liu D, Hu K, Seydelmann N, Schneider A, Becher J, Canan-Kuhl S, 
Blaschke D, Bijnens B, Ertl G, Wanner C and Nordbeck P. Usefulness of an Implantable Loop Recorder to Detect 
Clinically Relevant Arrhythmias in Patients With Advanced Fabry Cardiomyopathy. Am J Cardiol. 2016;118:264-74.
28. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, 
Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, 
Tillmanns C and Watkins H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: 
the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of 
Cardiology (ESC). Eur Heart J. 2014;35:2733-79.
29. Antzelevitch C, Yan GX, Ackerman MJ, Borggrefe M, Corrado D, Guo J, Gussak I, Hasdemir C, Horie M, Huikuri 
H, Ma C, Morita H, Nam GB, Sacher F, Shimizu W, Viskin S and Wilde AA. J-Wave syndromes expert consensus 
conference report: Emerging concepts and gaps in knowledge. Heart Rhythm. 2016;13:e295-324.
30. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, Fain E, Gent M, Connolly SJ and Investigators 
D. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 
2004;351:2481-8.
31. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, Kornacewicz-Jach Z, Sredniawa 
B, Lupkovics G, Hofgartner F, Lubinski A, Rosenqvist M, Habets A, Wegscheider K, Senges J and Investigators I. 
Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361:1427-36.
32. Bloch Thomsen PE, Jons C, Raatikainen MJ, Moerch Joergensen R, Hartikainen J, Virtanen V, Boland J, Anttonen O, 
Gang UJ, Hoest N, Boersma LV, Platou ES, Becker D, Messier MD, Huikuri HV, Cardiac A and Risk Stratification After 
Acute Myocardial Infarction Study G. Long-term recording of cardiac arrhythmias with an implantable cardiac 
monitor in patients with reduced ejection fraction after acute myocardial infarction: the Cardiac Arrhythmias 
and Risk Stratification After Acute Myocardial Infarction (CARISMA) study. Circulation. 2010;122:1258-64.
33. Gang UJ, Jons C, Jorgensen RM, Abildstrom SZ, Haarbo J, Messier MD, Huikuri HV, Thomsen PE and investigators 
C. Heart rhythm at the time of death documented by an implantable loop recorder. Europace. 2010;12:254-60.
34. Zaidi A, Clough P, Cooper P, Scheepers B and Fitzpatrick AP. Misdiagnosis of epilepsy: many seizure-like attacks 
have a cardiovascular cause. J Am Coll Cardiol. 2000;36:181-4.
35. Petkar S, Hamid T, Iddon P, Clifford A, Rice N, Claire R, McKee D, Curtis N, Cooper PN and Fitzpatrick AP. Prolonged 
implantable electrocardiographic monitoring indicates a high rate of misdiagnosis of epilepsy--REVISE study. 
Europace. 2012;14:1653-60.
36. Ho RT, Wicks T, Wyeth D and Nei M. Generalized tonic-clonic seizures detected by implantable loop recorder 
devices: diagnosing more than cardiac arrhythmias. Heart Rhythm. 2006;3:857-61.
CHAPTER 2
40
37. Maggi R, Rafanelli M, Ceccofiglio A, Solari D, Brignole M and Ungar A. Additional diagnostic value of implantable 
loop recorder in patients with initial diagnosis of real or apparent transient loss of consciousness of uncertain 
origin. Europace. 2014;16:1226-30.
38. Kanjwal K, Karabin B, Kanjwal Y and Grubb BP. Differentiation of convulsive syncope from epilepsy with an 
implantable loop recorder. Int J Med Sci. 2009;6:296-300.
39. Simpson CS, Barlow MA, Krahn AD, Klein GJ, Yee R and Skanes AC. Recurrent seizure diagnosed by the insertable 
loop recorder. J Interv Card Electrophysiol. 2000;4:475-9.
40. Bhangu J, Hall P, Devaney N, Bennett K, Carroll L, Kenny RA and McMahon CG. The prevalence of unexplained 
falls and syncope in older adults presenting to an Irish urban emergency department. Eur J Emerg Med. 2018.
41. Bhangu J, McMahon CG, Hall P, Bennett K, Rice C, Crean P, Sutton R and Kenny RA. Long-term cardiac monitoring 
in older adults with unexplained falls and syncope. Heart. 2016;102:681-6.
42. Armstrong VL, Lawson J, Kamper AM, Newton J and Kenny RA. The use of an implantable loop recorder in the 
investigation of unexplained syncope in older people. Age Ageing. 2003;32:185-8.
43. Ryan DJ, Nick S, Colette SM and Roseanne K. Carotid sinus syndrome, should we pace? A multicentre, randomised 
control trial (Safepace 2). Heart. 2010;96:347-51.
44. Giada F, Gulizia M, Francese M, Croci F, Santangelo L, Santomauro M, Occhetta E, Menozzi C and Raviele A. 
Recurrent unexplained palpitations (RUP) study comparison of implantable loop recorder versus conventional 
diagnostic strategy. J Am Coll Cardiol. 2007;49:1951-6.
45. Brignole M, Vardas P, Hoffman E, Huikuri H, Moya A, Ricci R, Sulke N, Wieling W, Committee ESD, Auricchio A, Lip 
GY, Almendral J, Kirchhof P, Aliot E, Gasparini M, Braunschweig F, Document R, Lip GY, Almendral J, Kirchhof P, 
Botto GL and Committee ESD. Indications for the use of diagnostic implantable and external ECG loop recorders. 
Europace. 2009;11:671-87.
46. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, 
Carlson M, Themeles E, Kaufman ES, Hohnloser SH and Investigators A. Subclinical atrial fibrillation and the risk 
of stroke. N Engl J Med. 2012;366:120-9.
47. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, Rymer MM, Thijs V, Rogers T, Beckers F, 
Lindborg K, Brachmann J and Investigators CA. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 
2014;370:2478-86.
48. Ziegler PD, Rogers JD, Ferreira SW, Nichols AJ, Richards M, Koehler JL and Sarkar S. Long-term detection of 
atrial fibrillation with insertable cardiac monitors in a real-world cryptogenic stroke population. Int J Cardiol. 
2017;244:175-179.
49. Diamantopoulos A, Sawyer LM, Lip GY, Witte KK, Reynolds MR, Fauchier L, Thijs V, Brown B, Quiroz Angulo ME 
and Diener HC. Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with 
cryptogenic stroke. Int J Stroke. 2016;11:302-12.
50. Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Wang Y, 
Davalos A, Shamalov N, Mikulik R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonkowska A, Eckstein J, Gagliardi RJ, 
Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni D, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, 
Brouns R, Endres M, Muir KW, Bornstein N, Ozturk S, O’Donnell MJ, De Vries Basson MM, Pare G, Pater C, Kirsch B, 
Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh A, Benavente OR, Joyner C, Themeles E, Connolly SJ and 
INSERTABLE CARDIAC MONITORS 
41
2
Investigators NE. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med. 
2018;378:2191-2201.
51. Diener HC, Easton JD, Granger CB, Cronin L, Duffy C, Cotton D, Brueckmann M, Sacco RL and Investigators R-SE. 
Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and 
safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke 
of Undetermined Source (RE-SPECT ESUS). Int J Stroke. 2015;10:1309-12.
52. Verma N, Ziegler PD, Liu S and Passman RS. Incidence of atrial fibrillation among patients with an embolic stroke 
of undetermined source: Insights from insertable cardiac monitors. Int J Stroke. 2018:1747493018798554.
53. Columbia University. AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke 
(ARCADIA).
54. University Hospital Tuebingen. Apixaban for Treatment of Embolic Stroke of Undetermined Source (ATTICUS).
55. Healey JS, Alings M, Ha A, Leong-Sit P, Birnie DH, de Graaf JJ, Freericks M, Verma A, Wang J, Leong D, Dokainish H, 
Philippon F, Barake W, McIntyre WF, Simek K, Hill MD, Mehta SR, Carlson M, Smeele F, Pandey AS, Connolly SJ and 
Investigators A-I. Subclinical Atrial Fibrillation in Older Patients. Circulation. 2017;136:1276-1283.
56. Nasir JM, Pomeroy W, Marler A, Hann M, Baykaner T, Jones R, Stoll R, Hursey K, Meadows A, Walker J and 
Kindsvater S. Predicting Determinants of Atrial Fibrillation or Flutter for Therapy Elucidation in Patients at Risk for 
Thromboembolic Events (PREDATE AF) Study. Heart Rhythm. 2017;14:955-961.
57. Reiffel JA, Verma A, Kowey PR, Halperin JL, Gersh BJ, Wachter R, Pouliot E, Ziegler PD and Investigators RA. 
Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk 
Population: The REVEAL AF Study. JAMA Cardiol. 2017;2:1120-1127.
58. Diederichsen SZ, Haugan KJ, Kober L, Hojberg S, Brandes A, Kronborg C, Graff C, Holst AG, Nielsen JB, Krieger D 
and Svendsen JH. Atrial fibrillation detected by continuous electrocardiographic monitoring using implantable 
loop recorder to prevent stroke in individuals at risk (the LOOP study): Rationale and design of a large randomized 
controlled trial. Am Heart J. 2017;187:122-132.
59. Rigshospitalet. Atrial Fibrillation Detected by Continuous ECG Monitoring (LOOP).
60. Lopes RD, Alings M, Connolly SJ, Beresh H, Granger CB, Mazuecos JB, Boriani G, Nielsen JC, Conen D, Hohnloser 
SH, Mairesse GH, Mabo P, Camm AJ and Healey JS. Rationale and design of the Apixaban for the Reduction of 
Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. Am Heart J. 
2017;189:137-145.
61. Population Health Research Institute. Apixaban for the Reduction of Thrombo-Embolism in Patients With 
Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA).
62. Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC, Goette A, Huening A, Lip GYH, Simantirakis E 
and Vardas P. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the 
Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. 
Am Heart J. 2017;190:12-18.




64. Gersak B, Pernat A, Robic B and Sinkovec M. Low rate of atrial fibrillation recurrence verified by implantable loop 
recorder monitoring following a convergent epicardial and endocardial ablation of atrial fibrillation. J Cardiovasc 
Electrophysiol. 2012;23:1059-66.
65. Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Turov A, Shirokova N and Karaskov A. Ablation of 
paroxysmal and persistent atrial fibrillation: 1-year follow-up through continuous subcutaneous monitoring. J 
Cardiovasc Electrophysiol. 2011;22:369-75.
66. Hanke T, Charitos EI, Stierle U, Karluss A, Kraatz E, Graf B, Hagemann A, Misfeld M and Sievers HH. Twenty-four-
hour holter monitor follow-up does not provide accurate heart rhythm status after surgical atrial fibrillation 
ablation therapy: up to 12 months experience with a novel permanently implantable heart rhythm monitor 
device. Circulation. 2009;120:S177-84.
67. Pecha S, Aydin MA, Ahmadzade T, Hartel F, Hoffmann B, Steven D, Willems S, Reichenspurner H and Wagner FM. 
Implantable loop recorder monitoring after concomitant surgical ablation for atrial fibrillation (AF): insights from 
more than 200 continuously monitored patients. Heart Vessels. 2016;31:1347-53.
68. Perez-Castellano N, Fernandez-Cavazos R, Moreno J, Canadas V, Conde A, Gonzalez-Ferrer JJ, Macaya C and 
Perez-Villacastin J. The COR trial: a randomized study with continuous rhythm monitoring to compare the 
efficacy of cryoenergy and radiofrequency for pulmonary vein isolation. Heart Rhythm. 2014;11:8-14.
69. Kapa S, Epstein AE, Callans DJ, Garcia FC, Lin D, Bala R, Riley MP, Hutchinson MD, Gerstenfeld EP, Tzou W, 
Marchlinski FE, Frankel DS, Cooper JM, Supple G, Deo R, Verdino RJ, Patel VV and Dixit S. Assessing arrhythmia 
burden after catheter ablation of atrial fibrillation using an implantable loop recorder: the ABACUS study. J 
Cardiovasc Electrophysiol. 2013;24:875-81.
70. Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Turov A, Shirokova N and Karaskov A. Use of an 
implantable monitor to detect arrhythmia recurrences and select patients for early repeat catheter ablation for 
atrial fibrillation: a pilot study. Circ Arrhythm Electrophysiol. 2011;4:823-31.
71. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen 
PS, Chen SA, Chung MK, Cosedis Nielsen J, Curtis AB, Davies DW, Day JD, d’Avila A, Natasja de Groot NMS, Di 
Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, 
Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai 
K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, 
Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma 
A, Wilber DJ, Yamane T and Document R. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement 
on catheter and surgical ablation of atrial fibrillation. Europace. 2018;20:e1-e160.
72. Zuern CS, Kilias A, Berlitz P, Seizer P, Gramlich M, Muller K, Duckheim M, Gawaz M and Schreieck J. Anticoagulation 
after catheter ablation of atrial fibrillation guided by implantable cardiac monitors. Pacing Clin Electrophysiol. 
2015;38:688-93.
73. Passman R, Leong-Sit P, Andrei AC, Huskin A, Tomson TT, Bernstein R, Ellis E, Waks JW and Zimetbaum P. Targeted 
Anticoagulation for Atrial Fibrillation Guided by Continuous Rhythm Assessment With an Insertable Cardiac 
Monitor: The Rhythm Evaluation for Anticoagulation With Continuous Monitoring (REACT.COM) Pilot Study. J 
Cardiovasc Electrophysiol. 2016;27:264-70.
INSERTABLE CARDIAC MONITORS 
43
2
74. Purerfellner H, Sanders P, Pokushalov E, Di Bacco M, Bergemann T, Dekker LR and Reveal LUSI. Miniaturized 
Reveal LINQ insertable cardiac monitoring system: First-in-human experience. Heart Rhythm. 2015;12:1113-9.
75. Ooi SY, Ng B, Singarayar S, Hellestrand K, Illes P, Mohamed U, Razak S, Weerasooriya R and BioMonitor 2 Study I. 
BioMonitor 2 Pilot Study: Early Experience With Implantation of the Biotronik BioMonitor 2 Implantable Cardiac 
Monitor. Heart Lung Circ. 2017.
76. Bisignani G, De Bonis S, Bisignani A, Mancuso L and Giacopelli D. Sensing performance, safety, and patient 
acceptability of long-dipole cardiac monitor: An innovative axillary insertion. Pacing Clin Electrophysiol. 
2018;41:277-283.
77. Lacour P, Dang PL, Huemer M, Parwani AS, Attanasio P, Pieske B, Boldt LH, Haverkamp W and Blaschke F. 
Performance of the New BioMonitor 2-AF Insertable Cardiac Monitoring System: Can Better be Worse? Pacing 
Clin Electrophysiol. 2017;40:516-526.
78. Purerfellner H, Pokushalov E, Sarkar S, Koehler J, Zhou R, Urban L and Hindricks G. P-wave evidence as a method 
for improving algorithm to detect atrial fibrillation in insertable cardiac monitors. Heart Rhythm. 2014;11:1575-
83.
79. Mittal S, Rogers J, Sarkar S, Koehler J, Warman EN, Tomson TT and Passman RS. Real-world performance of an 
enhanced atrial fibrillation detection algorithm in an insertable cardiac monitor. Heart Rhythm. 2016;13:1624-30.
80. Noelker G, Busch M, Schmitt J, Roithinger F, Young G, Taborsky M and Piorkowski C. The BioMonitor 2 Master 
Study: Early Experience With a New Insertable Cardiac Monitor. Circulation. 2018;136:A16347.
81. Passman RS, Rogers JD, Sarkar S, Reiland J, Reisfeld E, Koehler J and Mittal S. Development and validation of a 
dual sensing scheme to improve accuracy of bradycardia and pause detection in an insertable cardiac monitor. 
Heart Rhythm. 2017;14:1016-1023.
82. Steffel J, Wright DJ, Schafer H, Rashid-Fadel T and Lewalter T. Insertion of miniaturized cardiac monitors outside 
the catheter operating room: experience and practical advice. Europace. 2017;19:1624-1629.
83. Kanters TA, Wolff C, Boyson D, Kouakam C, Dinh T, Hakkaart L and Rutten-Van Molken MP. Cost comparison of 
two implantable cardiac monitors in two different settings: Reveal XT in a catheterization laboratory vs. Reveal 
LINQ in a procedure room. Europace. 2016;18:919-24.
84. Rogers JD, Sanders P, Piorkowski C, Sohail MR, Anand R, Crossen K, Khairallah FS, Kaplon RE, Stromberg K and 
Kowal RC. In-office insertion of a miniaturized insertable cardiac monitor: Results from the Reveal LINQ In-Office 
2 randomized study. Heart Rhythm. 2017;14:218-224.
85. Furukawa T, Maggi R, Bertolone C, Ammirati F, Santini M, Ricci R, Giada F and Brignole M. Effectiveness of remote 
monitoring in the management of syncope and palpitations. Europace. 2011;13:431-7.
86. Ciconte G, Vicedomini G, Giacopelli D, Calovic Z, Conti M, Spinelli B, Saviano M, Santinelli V and Pappone C. 
Feasibility of Remote Monitoring Using a Novel Long-Dipole Insertable Cardiac Monitor. JACC Clin Electrophysiol. 
2018;4:559-561.
87. Cheung CC, Krahn AD and Andrade JG. The Emerging Role of Wearable Technologies in Detection of Arrhythmia. 
Can J Cardiol. 2018;34:1083-1087.
88. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, Strickland W, Neelagaru S, Raval 
N, Krueger S, Weiner S, Shavelle D, Jeffries B, Yadav JS and Group CTS. Wireless pulmonary artery haemodynamic 
monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658-66.
CHAPTER 2
44
89. Boehmer JP, Hariharan R, Devecchi FG, Smith AL, Molon G, Capucci A, An Q, Averina V, Stolen CM, Thakur PH, 
Thompson JA, Wariar R, Zhang Y and Singh JP. A Multisensor Algorithm Predicts Heart Failure Events in Patients 
With Implanted Devices: Results From the MultiSENSE Study. JACC Heart Fail. 2017;5:216-225.
90. Medtronic Cardiac Rhythm and Heart Failure. Reveal LINQ™ Heart Failure (LINQ HF).
91. Linker NJ, Voulgaraki D, Garutti C, Rieger G, Edvardsson N and Investigators PS. Early versus delayed implantation 
of a loop recorder in patients with unexplained syncope--effects on care pathway and diagnostic yield. Int J 
Cardiol. 2013;170:146-51.
92. Lacunza-Ruiz FJ, Moya-Mitjans A, Martinez-Alday J, Baron-Esquivias G, Ruiz-Granell R, Rivas-Gandara N, Gonzalez-
Enriquez S, Leal-del-Ojo J, Arcocha-Torres MF, Perez-Villacastin J, Garcia-Heil N and Garcia-Alberola A. Implantable 
loop recorder allows an etiologic diagnosis in one-third of patients. Results of the Spanish reveal registry. Circ J. 
2013;77:2535-41.
93. Moya A, Garcia-Civera R, Croci F, Menozzi C, Brugada J, Ammirati F, Del Rosso A, Bellver-Navarro A, Garcia-Sacristan 
J, Bortnik M, Mont L, Ruiz-Granell R, Navarro X and Bradycardia detection in Bundle Branch Block s. Diagnosis, 
management, and outcomes of patients with syncope and bundle branch block. Eur Heart J. 2011;32:1535-41.
94. Krahn AD, Klein GJ, Norris C and Yee R. The etiology of syncope in patients with negative tilt table and 
electrophysiological testing. Circulation. 1995;92:1819-24.
95. Brignole M, Arabia F, Ammirati F, Tomaino M, Quartieri F, Rafanelli M, Del Rosso A, Rita Vecchi M, Russo V, 
Gaggioli G and Syncope Unit Project i. Standardized algorithm for cardiac pacing in older patients affected by 
severe unpredictable reflex syncope: 3-year insights from the Syncope Unit Project 2 (SUP 2) study. Europace. 
2016;18:1427-33.
96. Brignole M, Menozzi C, Moya A, Andresen D, Blanc JJ, Krahn AD, Wieling W, Beiras X, Deharo JC, Russo V, Tomaino 
M, Sutton R and International Study on Syncope of Uncertain Etiology I. Pacemaker therapy in patients with 
neurally mediated syncope and documented asystole: Third International Study on Syncope of Uncertain 
Etiology (ISSUE-3): a randomized trial. Circulation. 2012;125:2566-71.
97. Krahn AD, Klein GJ, Yee R, Takle-Newhouse T and Norris C. Use of an extended monitoring strategy in patients 
with problematic syncope. Reveal Investigators. Circulation. 1999;99:406-10.
98. Solbiati M, Costantino G, Casazza G, Dipaola F, Galli A, Furlan R, Montano N and Sheldon R. Implantable loop 
recorder versus conventional diagnostic workup for unexplained recurrent syncope. Cochrane Database Syst Rev. 
2016;4:CD011637.
99. Volosin K, Stadler RW, Wyszynski R and Kirchhof P. Tachycardia detection performance of implantable loop 
recorders: results from a large ‘real-life’ patient cohort and patients with induced ventricular arrhythmias. 
Europace. 2013;15:1215-22.
100. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, Vaid H, O’Donnell M, Laupacis A, Cote R, Sharma 
M, Blakely JA, Shuaib A, Hachinski V, Coutts SB, Sahlas DJ, Teal P, Yip S, Spence JD, Buck B, Verreault S, Casaubon 
LK, Penn A, Selchen D, Jin A, Howse D, Mehdiratta M, Boyle K, Aviv R, Kapral MK, Mamdani M, Investigators E and 
Coordinators. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370:2467-77.





Value of implantable loop recorders in patients with 
structural or electrical heart disease
Rafi  Sakhi, MD; Dominic A.M.J Theuns, PhD; Rohit E. Bhagwandien, MD; Michelle Michels, MD, 
PhD; Arend F.L Schinkel, MD, PhD; Tamas Szili-Torok, MD, PhD; F. Zijlstra, MD, PhD, Jolien W. Roos-
Hesselink, MD, PhD; Sing-Chien Yap, MD, PhD
Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the 
Netherlands.




Purpose: In patients with structural heart disease (SHD) or inherited primary arrhythmia syndrome 
(IPAS) the occurrence of unexplained syncope or palpitations can be worrisome as they are at increased 
risk of sudden cardiac death. An implantable loop recorder (ILR) can be a useful diagnostic tool. Our 
purpose was to compare the diagnostic yield, arrhythmia mechanism and management in patients with 
SHD, patients with IPAS and those without heart disease. 
Methods: Retrospective single-center study in consecutive patients who underwent an ILR implantation. 
Results: Between March 2013 and December 2016, a total of 94 patients received an ILR (SHD, n=20; 
IPAS, n=14; no SHD/IPAS, n=60). The type of symptoms at the time of implantation was similar between 
groups. During a median follow up of 10 months, 45% had an ILR-guided diagnosis. Patients with IPAS 
had a lower diagnostic yield (14%) in comparison to the other groups (no SHD/IPAS 47%, P=0.03; SHD 
60%, P=0.01 respectively). Furthermore, patients with SHD had a higher incidence of nonsustained VT in 
comparison to patients without SHD/IPAS (30% versus 3%, P<0.01). ILR-guided therapy was comparable 
between groups. In the SHD group, a high proportion (10%) received an implantable cardioverter-
defibrillator, however this was not statistically significant higher than the other groups (no SHD/IPAS 3%, 
IPAS 0%, P=0.08). 
Conclusions: In comparison to patients without heart disease, the diagnostic yield of an ILR was lower 
in patients with IPAS and the prevalence of ILR-diagnosed nonsustained VT was higher in patients with 
SHD.




Implantable loop recorders (ILRs) are increasingly being used for the detection of infrequent arrhythmia 
episodes. Several studies have demonstrated the incremental value of ILRs over intermittent monitoring 
strategies for the detection of arrhythmias in patients with recurrent syncope, undocumented 
palpitations and cryptogenic stroke1-4. ILRs might also be used as a diagnostic tool in patients at risk 
for ventricular tachyarrhythmias (VTs), such as those with structural heart disease (SHD) or inherited 
primary arrhythmia syndromes (IPAS)5-7. The occurrence of unexplained syncope or palpitations can be 
worrisome in these patients. The 2009 ESC syncope guidelines recommend to consider an ILR in non-
high risk patients with SHD or IPAS7. The recent J-wave expert consensus report also suggests the use 
of an ILR for close monitoring of Brugada patients with presumed non-arrhythmogenic syncope8. There 
is limited data comparing the value of an ILR in patients with and without SHD9, 10. Considering the 
nature of the underlying disease, we hypothesized that patients with SHD/IPAS would have a higher 
incidence of ventricular arrhythmias than patients without an underlying heart disease. The purpose of 
the present study was to evaluate diagnostic yield, arrhythmia mechanism and subsequent arrhythmia 
management in patients with and without SHD/IPAS receiving an ILR.
Methods
Study population
This observational cohort study involved consecutive patients who received an insertable ILR (Reveal 
LINQ, Medtronic Inc., Minneapolis, MN, USA) between March 2013 and December 2016 at our institution. 
The indication for the ILR was established by the treating physician and all patients gave informed 
consent for the implantation procedure. There were no patients who received an ILR for cryptogenic 
stroke. Patients with SHD included those with manifest heart disease at potential risk of arrhythmias 
including patients with coronary artery disease, inherited cardiomyopathy, infiltrative cardiomyopathy 
and congenital heart disease. Patients with IPAS included those with long QT syndrome, Brugada 
syndrome, catecholaminergic polymorphic VT. Carriers of a pathogenic mutation associated with 
cardiomyopathy or IPAS were also considered part of either the SHD or IPAS group. 
ILR implantation and follow-up
ILR implantation was performed as recommended by the manufacturer using the incision and insertion 
tool. The device was implanted subcutaneously over the fourth intercostal space on the left hemithorax, 
either 45° or parallel relative to the sternal border. The incision was usually closed with one braided 
absorbable suture. After implantation, the patient received the remote monitoring device, as well as 
instructions about its use for nightly automated transmissions. Patients were discharged at the same 
day of implantation. Programming was optimized to maintain a high specificity, at the cost of sensitivity: 
detection of bradycardia (30 beats per minute; 8 beats), pause (4.5 seconds), and tachycardia (176 beats 
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per minute; 16 beats). Atrial fibrillation (AF) detection was set to ‘AF only’. All devices were linked to the 
CareLink network for remote monitoring and all episodes (automatically recorded or patient-activated 
episodes) were transmitted on a daily basis.
 Ten days after implantation the patients were scheduled at the out-patient clinic to check 
their wound and interrogate their device. After this visit, patients were seen at the out-patient clinic 
every 6 months or earlier when necessary based on the transmitted episodes. The diagnosis was called 
ILR-guided if a symptom-rhythm correlation was established and/or if a VT was observed. 
Statistical analysis
Continuous data are presented as mean ± standard deviation if the data were normally distributed, 
or as median with interquartile range (25th and 75th percentile) otherwise. Categorical variables are 
presented by frequencies and percentages. Differences of continuous variables between groups 
were analyzed with the unpaired Student’s t-test or the Kruskal Wallis test, as appropriate. Differences 
between categorical variables were evaluated using the Chi-square test. In the case of a statistical 
difference between groups, posthoc pairwise analysis were performed.  Event rates were estimated 
with the Kaplan Meier method, and differences between event rates were compared by log-rank test. 
Paired comparisons were made using Cox regression analysis and described with hazard ratios and 95% 
confidence intervals. A P-value <0.05 was considered statistically significant. Statistical analyses were 
performed using SPSS version 21.
Results
Between March 2013 and December 2016, a total of 94 patients underwent an ILR implantation. There 
were 20 patients (21%) with SHD and 14 patients (15%) with IPAS. Figure 1 provides an overview of the 
different underlying diagnosis in patients with SHD/IPAS. Except a higher proportion of PCI in the SHD 
group, there were no differences in baseline characteristics between groups (Table 1). It is also important 
to note that the presenting symptoms were similar between groups.  
 During a median follow up of 10 months (interquartile range, 3-17 months), 42 patients (45%) 
had an ILR-guided diagnosis. The diagnostic yield was different between groups (Figure 2, Table 2). 
When performing pairwise comparisons, patients with IPAS had a lower diagnostic yield in comparison 
to patients with SHD (P=0.01) or patients without SHD/IPAS (P=0.03). Although patients with SHD and 
patients without SHD/IPAS had a similar diagnostic yield, the arrhythmia mechanism was different. Using 
pairwise comparison, patients with SHD had a higher incidence of nonsustained VT in comparison to 
patients without SHD/IPAS (P<0.01).   
 Although there was a difference in the ILR-documented arrhythmia mechanism, the ILR-based 
therapy was similar between groups (Table 3). Most patients received antiarrhythmic drug therapy or 
had their antiarrhythmic drug dose increased. A high proportion (10%) of patients in the SHD group 
received an ICD, however, this was not statistically significant higher than the other groups.
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Figure 1. Overview of patients with structural heart disease or inherited primary arrhythmia syndrome. Abbreviations: 
LQTS, long QT syndrome; CPVT, catecholaminergic polymorphic ventricular tachycardia.









-    Age (years), mean ± SD 44 ± 17 47 ± 21 47 ± 11 0.73
-    Female gender, n (%) 36 (60) 10 (50) 8 (57) 0.74
Symptoms:
-    (Near) syncope, n (%) 47 (78) 14 (70) 10 (71) 0.71
-    Palpitations, n (%) 40 (67) 10 (50) 6 (43) 0.17
-    Asymptomatic, n (%) - 1 (5) 1 (7) 0.15
Co-morbidity:
-    Hypertension, n (%) 6 (10) 4 (20) 3 (21) 0.37
-    Hypercholesterolemia, n (%) 8 (13) 2 (10) 1 (7) 0.79
-    Diabetes mellitus, n (%) 5 (8) 1 (5) - 0.51
-    Transient ischemic attack, n (%) 4 (7) 1 (5) - 0.61
-    Stroke, n (%) 2 (3) 2 (10) - 0.11
-    Epilepsy, n (%) 2 (3) - 2 (14) 0.11
-    Renal disease, n (%) - 1 (5) - 0.16
-    Prior PCI, n (%) - 3 (15) - <0.01
-    Prior CABG, n (%) - 1 (5) - 0.16
Abbreviations: CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention.
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Figure 2. Cumulative event rate for ILR-guided diagnosis








Any arrhythmia diagnosis, n (%) 28 (47) 12 (60) 2 (14) 0.03
-    Sinus arrest, n (%) 6 (10) 1 (5) 1 (7) 0.77
-    Paroxysmal AV block, n (%) 1 (2) 1 (5) - 0.56
-    Sinus bradycardia, * n (%) 2 (3) - - 0.56
-    Progressive ST, n (%) 2 (3) - - 0.56
-    Atrial fi brillation, n (%) 4 (7) - - 0.31
-    SVT, n (%) 9 (15) 2 (10) - 0.28
-    Nonsustained VT, n (%) 2 (3) 6 (30) 1 (7) <0.01
-    Sustained VT, n (%) 2 (3) 2 (10) - 0.31
No arrhythmia diagnosis, n (%) 32 (53) 8 (40) 12 (86) 0.03
Abbreviations: AV, atrioventricular; ST, sinus tachycardia; SVT, supraventricular tachycardia; VT, ventricular tachycardia. 
* <40 bpm for more than 10 seconds.
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Antiarrhythmic drug therapy, n (%) 9 (15) 7 (35) 2 (14) 0.14
Pacemaker, n (%) 9 (15) 3 (15) - 0.31
Catheter ablation, n (%) 8 (13) 1 (5) - 0.24
ICD, n (%)  2 (3) 2 (10) - 0.08
Abbreviations: ICD, implantable cardioverter-defibrillator.
 Four patients received an ICD, two of them had SHD. One patient with recurrent syncope and 
coronary artery disease with preserved ejection fraction received an ICD for sustained monomorphic 
fast VT. Another patient with hypertrophic obstructive cardiomyopathy received an ICD after 
experiencing non-sustained VT, which increased his estimated 5-years risk of SCD from 3.6% to 8.0%. 
Furthermore, 2 patients without SHD/IPAS received an ICD. One woman received an ICD for syncope and 
sustained monomorphic fast VT and another woman received an ICD after syncope and non-sustained 
polymorphic fast VT. No patient died suddenly during the study period.
Discussion
The present study demonstrates that ILR patients with SHD have a higher incidence of nonsustained 
ventricular arrhythmias. However, there was only a trend towards a higher proportion of patients 
receiving an ICD in the SHD group in comparison to the other groups.
 Studies which evaluated the performance of the ILR demonstrated a wide diagnostic yield 
ranging from 22% to 73% depending on the primary indication of the ILR1, 3. The diagnostic yield seems 
lower in patients with recurrent unexplained syncope than in patients with undocumented palpitations. 
Overall, the diagnostic yield in our study population was 45%, however, patients with IPAS had a lower 
diagnostic yield. The diagnostic yield in patients with and without SHD (60% versus 47%) was similar in 
our study. A previous Austrian prospective ILR study in 70 patients with unexplained syncope (including 
33 patients with SHD) found a similar diagnostic yield between patients with and without SHD (45% and 
51%, respectively)9. 
 Patients with SHD in our study experienced a high incidence of nonsustained ventricular 
arrhythmias, which is not surprising considering their predisposition to ventricular arrhythmias. A 
previous Italian ILR study in 103 patients with unexplained syncope (including 38 patients with SHD) 
also found a difference in arrhythmia mechanism between patients with and without SHD10. Patients 
with SHD were more likely to have paroxysmal/persistent AV block and tachyarrhythmias in comparison 
to patients without SHD. The incidence of ventricular arrhythmias was 5% in patients with SHD and 0% 
in patients without SHD10. Surprisingly, the incidence of ventricular arrhythmias in our IPAS group was 
low. This may be related to a lower threshold to implant an ILR in IPAS patients. 
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 Although recurrent unexplained syncope is an established indication for an ILR, a rather 
novel indication is the use of an ILR for risk stratification6, 7. An EHRA survey demonstrated that 19% 
of centers use ILRs in patients with borderline indications for ICD therapy5. Currently, the ILR does not 
play a major role in the current guidelines on the prevention of SCD11. In the most recent guidelines, 
ILRs are recommended after comprehensive diagnostic evaluation when symptoms (e.g. syncope) are 
sporadic and suspected to be related to arrhythmias11. In some patients with SHD/IPAS, individual risk 
stratification can be difficult due to atypical symptoms. In these patients, long-term monitoring by an 
ILR may provide valuable information by the documentation of ventricular arrhythmias. Furthermore, it 
might also provide reassurance in these patients when they know that their symptoms are not related to 
ventricular arrhythmias. Considering the fact that a purely diagnostic tool is implanted in patients at risk 
for VTs, it is of importance to be alerted of a potential life-threatening episode as soon as possible. This is 
possible due to the availability of daily remote transmissions lowering the delay to medical intervention. 
No patient in our study died suddenly. 
  Several small ILR studies in patients with SHD or IPAS demonstrated that the proportion 
of ILR patients that received an ICD varies. Based on the available literature, no ILR patient with 
Brugada syndrome12-14, long QT syndrome15, 16, hypertrophic cardiomyopathy9, or noncompaction 
cardiomyopathy17 received an ICD during follow-up. In contrast, ICDs were implanted, based on the 
findings of the ILR, in patients with catecholaminergic polymorphic VT (11%)15, congenital heart disease 
(0-9%)16, 18, 19, Fabry cardiomyopathy (25%)20, and SHD (0-28%)9, 10, 21. In our study, 10% of the SHD cohort 
received an ICD. Abovementioned data supports the use of ILRs in symptomatic patients with SHD for 
early detection of ventricular arrhythmias.
Study limitations
The present study is small and the patient population is highly selected, thereby limiting generalizability 
of the data. Furthermore, the lack of a control group (close follow-up with repeated ambulatory Holter 
monitoring) hampers conclusions on the incremental benefit of an ILR in comparison to alternative 
methods of monitoring. Therefore, all conclusions of the present study must be drawn with caution.
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Background: Sudden cardiac death (SCD) due to ventricular arrhythmias (VA) is an important mode of 
death in adults with congenital heart disease (CHD). Risk stratification is difficult in this heterogenous 
population. Insertable cardiac monitors (ICM) may be useful for risk stratification. Our purpose was to 
evaluate the use of ICM for the detection of VA in adults with CHD. 
Methods: In this prospective single-center observational study we included consecutive adults with 
CHD deemed at risk of VA who received an ICM between March 2013 and February 2019. The decision to 
implant an ICM was made in a Heart Team consisting of a cardiac electrophysiologist and a cardiologist 
specialized in CHD. 
Results: A total of 30 patients (mean age, 38 ± 15 years; 50% male) received an ICM. During a median 
follow-up of 16 months, 8 patients (27%) had documented nonsustained VA. Of these 8 patients, 3 
(10%) received a prophylactic ICD. Furthermore, ICM-detected arrhythmias were present in 22 patients 
(73%) leading to a change in clinical management in 16 patients (53%). Besides the patients receiving 
an ICD, 10 patients (33%) had a change in their antiarrhythmic drugs, 6 patients (20%) underwent an 
electrophysiology study, and 1 patient (3%) received a pacemaker. 
Conclusions: The detection of VA by the ICM contributed to the clinical decision to implant a prophylactic 
ICD. Furthermore, ICM-detected arrhythmias led to important changes in the clinical management. 
Therefore, long-term arrhythmia monitoring by an ICM seems valuable for risk stratification in adults 
with CHD. 




Sudden cardiac death (SCD) is an important mode of death in adults with congenital heart disease (CHD) 
and is mainly driven by ventricular arrhythmias (VA)1-4. Identification of patients with CHD at risk for VA 
is important to determine which patients may benefit from a prophylactic implantable cardioverter-
defibrillator (ICD). Risk stratification is hampered by the low predictive value of clinical risk factors5. This 
is not surprising considering Bayes theorem and the low absolute incidence of SCD in adults with CHD6. 
For patients with tetralogy of Fallot there is some guidance on selecting patients for a prophylactic 
ICD7, 8. In other CHD lesions, the decision is challenging and the indication for an ICD is largely based on 
systemic ventricular dysfunction, syncope and/or documented VA. The decision to implant an ICD is also 
hampered by potential ICD complications, such as shocks, device or lead malfunction, inappropriate 
shocks, and psychological burden9-11.
 Considering the clinical relevance of documented VA for risk stratification, we adopted 
a strategy focusing on early detection of VA using insertable/implantable cardiac monitors (ICMs). 
ICM-detected VA may provide a tipping point in decision-making in patients who are considered at 
risk of SCD but who do not qualify for an ICD according to current guidelines. Long-term arrhythmia 
monitoring using ICMs already have an established role in patients with recurrent syncope12. In the most 
recent ESC Syncope guidelines there is an expanding role for ICMs for risk stratification in patients with 
primary cardiomyopathy or inheritable arrhythmogenic disorders, but not for patients with CHD13. The 
purpose of the present study was to evaluate the strategy of using ICMs for the early detection of VA in 
adults with CHD who are deemed at risk of VA based on their clinical profile.
Methods
Study design
The Early Detection of Ventricular Arrhythmias in adults with Congenital Heart Disease using an insertable 
cardiac monitor (EDVA-CHD) study is a prospective observational study which included consecutive 
adults with CHD who received an ICM between March 2013 and February 2019. The starting date was 
chosen based on the availability of the Reveal LINQ (Medtronic Inc., Minneapolis, MN, USA) in our center. 
Patients who were deemed to be at risk of VA by their treating physician were eligible for an ICM. The 
reason for monitoring could be a combination of symptoms (e.g., (near)syncope, palpitations), prior 
nonsustained VA, wide QRS, and/or systemic ventricular dysfunction. The decision to implant an ICM was 
made in a Heart Team consisting of at least a cardiac electrophysiologist and a cardiologist specialized 
in CHD. The study was approved by the institutional review board of the Erasmus Medical Center. Our 
center is a tertiary referral center with the largest population of adults with CHD in the Netherlands. 
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Device programming and follow-up
All ICMs were implanted subcutaneously as recommended by the manufacturer using the incision and 
insertion tool. Furthermore, all patients received a handheld activator to indicate their symptoms when 
necessary. The ICM was usually programmed according to local settings: tachycardia-detection was set 
to 176 bpm for 16 beats; bradycardia-setting to 30 bpm for 8 beats; pause-setting to 4.5 sec; and atrial 
fibrillation (AF) setting to ‘AF only’. Based on the implanting physician preferences other settings could 
be programmed. All devices were connected to the Medtronic CareLink network for remote monitoring. 
Patients were discharged on the same day of implantation. Ten days after implantation the patients 
were seen at the out-patient clinic to check their wound and to interrogate the ICM. Afterwards, the 
patients were seen regularly at the outpatient clinic according to routine patient care. ICM check-ups 
were performed at the outpatient clinic every 6 months or earlier when necessary based on symptoms 
or transmitted episodes. Remote monitoring was performed on a daily basis during weekdays. 
Classification of episodes and endpoints
All patient activated episodes and automatically detected episodes were classified. In the case of an 
inappropriate automatically detected episode, the cause of inappropriate detection was specified, if 
possible. 
 The primary endpoint of the present study was the occurrence of VA. A regular broad complex 
tachycardia was considered a VA if there was a sudden onset and a change in the QRS morphology in 
comparison to the baseline rhythm (Figure 1A). An irregular broad complex tachycardia was considered 
a VA if there was a sudden onset and a polymorphic QRS morphology. A regular broad or small complex 
tachycardia was considered a supraventricular tachycardia (SVT) if there was a sudden onset and no 
change in QRS morphology (Figure 1B). In the case of doubt, a second electrophysiologist was consulted 
for the final diagnosis. 
 The secondary endpoint was the occurrence of other arrhythmias during follow-up. Finally, it 
was established whether a detected arrhythmia resulted in a change in patient management (‘actionable 
event’). 
Statistical analysis
Continuous data are presented as mean ± standard deviation or as median with corresponding 25th 
and 75th percentile, as appropriate. Categorical variables are presented by frequencies and percentages. 
Statistical analyses were performed using SPSS version 21.
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Figure 1. Example ICM-detected episode of (A) ventricular tachycardia, (B) supraventricular tachycardia with pre-





A total of 30 CHD patients (mean age, 38 ± 15 years; 50% male) received an ICM during the study 
period.  Baseline characteristics of the study population are listed in Table 1. The majority of patients had 
moderate or severe complexity CHD. The 3 most common diagnoses were aortic coarctation, tetralogy 
of Fallot (TOF) and d-transposition of the great arteries (d-TGA). The majority of patients had symptoms 
at the time of ICM implantation (93%). An impaired systemic ventricular function was present in 17 
patients (57%). A previous nonsustained VA was documented in 20% of the study population. A detailed 
patient-level description of CHD diagnosis, previous cardiac surgery, and reason for ICM is presented in 
Appendix A. There were no ICM- or procedure-related complications.  
Table 1. Clinical baseline characteristics 
Total group
(n=30)
Age, years 38 ± 15
Gender, male 15 (50%)
Hypertension 8 (27%)
Diabetes Mellitus 1 (3%)
Surgical repair 25 (83%)
Symptoms
-    Palpitations 12 (40%)
-    (near) Syncope 10 (33%)
-    Palpitations and (near) syncope 6 (20%)
-    Asymptomatic 2 (7%)
Congenital diagnosis
-    Aortic coarctation 7 (23%)
AVR 3 (10%)
-    Tetralogy of Fallot 5 (17%)
Transannular patch 2 (7%)
-    ASD 5 (17%)
Direct surgical closure of ASD 3 (10%)
-    TGA corrected by atrial switch 2 (7%)
Mustard repair 1 (7%)
-    TGA corrected by arterial switch 2 (7%)
-    Congenital corrected TGA 2 (7%)
Tricuspid valvuloplasty 1 (3%)
-    VSD 2 (7%)
VSD patch 2 (7%)
-    Other 5 (17%)
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Systemic systolic ventricular function
-    Normal (EF ≥55%) 13 (43%)
-    Mild impaired (EF 54-45%) 10 (33%)
-    Moderate impaired (EF 36-44%) 7 (23%)
Electrocardiography
-    Sinus rhythm 27 (90%)
-    Other rhythm 3 (10%)
-    PR interval, if sinus rhythm, ms 180 ± 49
-    QRS duration, ms 136 ± 31
-    QRS duration >120ms 17 (57%)
24-48h Holter monitoring
-    <1% PVCs 25 (83%)
-    1-10% PVCs 1 (3%)
-    Non-sustained VT 6 (20%)
-    Supra ventricular tachycardia 2 (7%)
Cardiac medication 19 (63%)
-    ACE-inhibitor/ ARB 8 (27%)
-    Diuretics 3 (10%)
-    Beta blocker 11 (37%)
-    Amiodarone/Sotalol/Digoxin 3 (10%)
-    Digoxin/calcium channel blocker 3 (10%)
-    Oral anticoagulants 6 (23%)
Data is presented as n (%), mean ± SD. Abbreviations: AVR, aortic valve replacement; ASD, atrial septal defect; TGA, 
transposition of the great arteries; VSD, ventricle septal defect; EF, ejection fraction; PVC, premature ventricular 
complex; VT, ventricular tachycardia; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker. 
ICM-detected episodes
During a median follow-up of 16 months (interquartile range 9-21 months), a total of 1,689 episodes 
were transmitted to the CareLink network system (Table 2). There were 538 (32%) patient-activated 
episodes and 1,151 (68%) automatically detected episodes. The majority of patient-activated episodes 
(88%) comprised sinus rhythm with or without ectopy, thus, only 12% of patient-activated episodes 
comprised a significant arrhythmia (Table 2).
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Table 2. Overview ICM-detected arrhythmia episodes 
Total episodes
(n=1689)
Symptom episode* 538 (32%)
-    Sinus rhythm 473 (88%)
without ectopy 314 (58%)
with PACs 19 (4%)
with PVCs 140 (26%)
-    Atrial fibrillation 33 (6%)
-    Regular small complex tachycardia 12 (2%)
-    Regular broad complex tachycardia 20 (4%)
Tachy episode* 666 (39%)
-    Sinus rhythm 510 (77%)
without ectopy 268 (40%)
with PACs 20 (3%)
with PVCs 214 (32%)
with noise 8 (1%)
-    Atrial fibrillation 8 (1%)
-    Regular small complex tachycardia 118 (18%)
-    Regular broad complex tachycardia 30 (5%)
AF episode* 213 (13%)
-    Sinus rhythm 18 (9%)
with PACs 2 (<1%)
with PVCs 16 (8%)
-    Atrial fibrillation 180 (85%)
-    Small complex tachycardia 15 (7%)
with intermittent AV-block 15 (7%)
Brady episode* 147 (9%)
-    Sinus rhythm 41(28%)
with undersensing of PVCs 41(28%)
-    Sinus bradycardia 103 (70%)
-    AV block 3 (2%)
Pause episode* 108 (6%)
-    Sinus rhythm 63 (58%)
with sudden drop of R-wave 28 (26%)
with small R-waves 17 (16%)
with undersensing of PVCs 15 (14%)
with loss of contact 3 (3%)
-    Sinus bradycardia 29 (27%)
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-    AV block 3 (3%)
-    Sinus arrest or SA block 13 (12%)
AT episodes* 17 (1%)
-    Atrial fibrillation 10 (59%)
-    Sinus tachycardia 5 (29%)
-    Regular small complex tachycardia 2 (12%)
Data is presented as n (%). * Episode classification by ICM. Abbreviations: ICM, insertable cardiac monitor; PAC, 
premature atrial complex; AF, atrial fibrillation; AV, atrioventricular; SA, sinoatrial; AT, atrial tachycardia; other 
abbreviations as defined by Table 1.    
Primary and secondary endpoints
During follow-up, 8 patients (27%) developed nonsustained VA. Four of 8 patients (50%) had a history 
of nonsustained VA, thus 4 patients (13%) had a de novo nonsustained VA and 4 patients (13%) had 
recurrent nonsustained VA. In 7 of 8 patients (88%) the VA episodes were detected by patient-activated 
episodes. Most patients had monomorphic VA episodes and 1 patient experienced polymorphic VA 
episodes. Of the 8 patients with VA, 3 patients had an impaired systemic ventricular function. Of the 8 
patients with VA, 3 patients received a prophylactic ICD after consultation with their treating physician 
and 3 patients had a change in their antiarrhythmic drug therapy. The remaining 2 patients did not have 
a change in their clinical management. 
 A 19-year-old man with surgical corrected Shone’s complex (coarctation resection, 
subvalvular aortic membrane resection, mitral valve and aortic valve replacement) received a dual-
chamber ICD after detection of recurrent symptomatic nonsustained fast polymorphic VA (mean CL 
240-270 ms, maximal 7 beats) 3 months post-ICM implantation. He received an ICM due to combination 
of palpitations, exercise-induced ventricular ectopy, signs of inferior wall infarction and mild impaired 
systemic ventricular function. After ICD implantation, he experienced two episodes of nonsustained fast 
polymorphic VA without ICD therapy during a follow-up of 17 months.
 The second patient who received a dual-chamber ICD was a 42-year-old woman with surgical 
corrected TOF who experienced recurrent symptomatic nonsustained monomorphic VA (mean CL 490-
520 ms, maximal 11 beats) 3 months post-ICM implantation. She received an ICM for the combination of 
palpitations and near-syncope. She did not experience VA post-ICD implantation during a follow-up of 
27 months. 
 The last patient who received a dual-chamber ICD was a 44-year-old man with congenital 
corrected transposition of the great arteries and tricuspid valvuloplasty who developed an asymptomatic 
nonsustained fast monomorphic VA (mean CL 280 ms, 27 beats) 18 months post-ICM implantation (Figure 
1A). He received an ICM for a combination of syncope and dilated systemic ventricle with moderate-
to-severe systolic ventricular dysfunction. During a follow-up of 12 months post-ICD implantation he 
experienced one episode of nonsustained fast monomorphic VA without ICD therapy.  
 Any significant arrhythmia was detected in 22 patients (73%). Figure 2 shows the proportion 
of patients with a specific arrhythmia and Appendix A provides an overview of detected arrhythmias per 
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patient. In 16 patients (53%) the detected arrhythmia was considered an actionable event. Management 
included initiation or change of antiarrhythmic drug therapy (n=10, 33%), electrophysiology study (n=6, 
20%), ICD implantation (n=3, 10%), electrical cardioversion (n=2, 7%), and pacemaker implantation (n=1, 
3%).
   
Figure 2. Proportion of patients with an ICM-detected arrhythmia.
Discussion
The incidence of ICM-detected VA in a selected CHD population was relatively high (27%). The ICM-
detected VA contributed to the decision to implant a prophylactic ICD in 10% of the study population. 
Furthermore, the detection of other arrhythmias by the ICM resulted in a signifi cant change in clinical 
management in a majority of patients. The present study is the fi rst prospective study focusing specifi cally 
on the use of an ICM for risk stratifi cation in adults with CHD. 
Risk of sudden death
Although the risk of SCD is higher in patients with CHD than in the general population, the absolute 
risk is still relatively low (approximately 0.1% per year)3. This has stimulated the search for risk factors 
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which may help identify patients at risk for SCD, who may benefit from a prophylactic ICD implantation. 
Important risk factors for SCD include among others (recurrent) (non)sustained VA, inducible VA, atrial 
tachyarrhythmias, prolonged QRS duration, systemic ventricular dysfunction, and subpulmonary 
ventricular dysfunction4, 14-17.  Despite the multitude of identified risk factors, the indication for ICD 
implantation remains challenging in clinical practice, especially regarding the potential downside of ICD 
therapy9-11. Furthermore, risk stratification is not uniform for the CHD population. For example, inducible 
sustained VA during programmed ventricular stimulation is useful for risk stratification in patients with 
TOF7, 8, but has not been demonstrated to predict VA/SCD in other CHD populations18. 
Risk stratification using ICM
In patients with certain high-risk features presenting with symptoms (i.e., syncope, near-syncope, 
palpitations), it is of importance for both patients and caregivers to rule out VA. This can be attempted 
using short-term monitoring, however, when symptoms are infrequent longer arrhythmia monitoring is 
necessary. For this purpose, an ICM is a valuable diagnostic tool for detecting paroxysmal arrhythmias as 
well as establishing a symptom-rhythm correlation. We provide data on the diagnostic yield of an ICM in 
a selected adult CHD population deemed at risk for VA. The incidence of VA was high in this population 
and resulted in implantation of an ICD for primary prevention in 10% of the study population. This is 
slightly higher than previous retrospective studies in patients with CHD who received an ICM19, 20. These 
studies focused on the overall diagnostic yield of an ICM and not specifically on the role of an ICM for risk 
stratification. Kenny et al. described the diagnostic outcome of an ICM (Reveal or Reveal Plus, Medtronic 
Inc., Minneapolis, MN, USA) in a predominantly pediatric CHD population (median age 15 years)20. In this 
study, 1 of 18 patients (6%) received an ICD during a median follow-up of 19 months. The patient who 
received an ICD was known with Ebstein’s anomaly and developed monomorphic VA at the age of 16 
years. A more recent retrospective study from Boston Children’s Hospital included 34 patients with CHD 
and an ICM (Reveal LINQ, Medtronic Inc., Minneapolis, MN, USA)19. In this study, 1 of 34 patients (3%) 
received an ICD during a median duration of follow-up of 11.8 months. The patient who received an ICD 
was a patient with Fontan circulation who received an ICM at the age of 32 years. Other series reporting 
the use of ICM in patients with CDH are smaller and mostly performed in a pediatric population21-28. 
 
Cost-benefit of ICMs for risk stratification
Besides the use of an ICM for risk stratification, the ICM detected a significant arrhythmia in 73% of the 
population and this led to a change in clinical management in 53% of patients. Therefore, an ICM can be 
used to titrate medication and identify candidates for an electrophysiologic procedure (i.e., pacemaker, 
ICD or electrophysiological study). An important aspect is the ability to differentiate between benign 
(near)syncope and arrhythmogenic (near)syncope. Providing reassurance to a symptomatic patient is 
valuable in daily clinical practice. 
 Although the use of ICMs for risk stratification seems promising, there are some factors which 
should be considered such as device costs, data overload, clinical relevance of device-detected VA 
and medical overuse. The issue of data overload is exemplified by the recording of more than 1,600 
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episodes in 30 patients in a relatively short follow-up period in our study population. This requires a 
proper logistic organization with a dedicated telemonitoring staff. There is some controversy with regard 
to the clinical relevance of device-detected arrhythmias, especially for atrial fibrillation12. With regard to 
the clinical relevance of device-detected VA, it is important to stress that in our population the majority 
of VA episodes were detected as patient-activated episodes, indicating that the patient experienced 
symptoms. Koyak et al. previously identified that symptomatic but not asymptomatic nonsustained VA 
was associated with appropriate ICD therapy in TOF patients who receive an ICD for primary prevention29. 
Study limitations
A limitation of the present study is the small size and lack of a control group. Therefore, no conclusion 
can be made regarding the incremental value of an ICM compared to standard clinical practice with 
intermittent Holter monitoring. Ideally, a randomized clinical trial would be conducted where patients are 
randomized to an ICM or conventional follow-up. Obstacles for such a clinical trial are the heterogeneity 
of the population and challenges in defining appropriate endpoints. In this regard, it is important to 
stress that our study population was a highly selected population. The usefulness of an ICM may not 
apply to an unselected CHD population. Finally, the classification of broad complex tachycardia as either 
VA or SVT can be challenging considering that only a single surface EGM is available. To reduce the risk 
of misclassification, difficult EGMs were reevaluated by an electrophysiologist.    
Conclusion
There was a high incidence of ICM-detected VA in adults with CHD who were deemed at risk of VA. ICM 
results led to implantation of an ICD in 10% of the study population. The detection of arrhythmias by 
the ICM led to important changes in the clinical management of patients. Our prospective pilot study 
suggests that the use of ICMs for risk stratification in selected adults with CHD is helpful.  
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Aims: The aim of the present study was to compare the rate of actionable arrhythmic events between 
patients with hypertrophic cardiomyopathy (HCM) who are monitored with an insertable cardiac 
monitor (ICM) or Holter monitoring.
Methods: We studied 50 patients (mean age 52 years, 72% men) with HCM at low or intermediate 
risk for SCD of whom 25 patients received an ICM between November 2014 and February 2019. We 
retrospectively identified a control group of 25 patients who were matched on age, sex and HCM Risk-
SCD score category. The mean HCM Risk SCD-score was 3.41±1.31 and 3.31±1.43 for the ICM group 
and Holter group, respectively. The primary endpoint was an actionable event which was defined as 
an arrhythmic event resulting in a change in patient management. The secondary endpoint was the 
occurrence of ventricular tachycardia (VT). 
 
Results: The cumulative actionable event rate at 30 months was higher in the ICM group (51% versus 
27%, log-rank P-value <0.01). De novo atrial fibrillation requiring oral anticoagulation occurred only in the 
ICM group (N=3). Overall, 4 implantable cardioverter defibrillators were implanted for primary prevention 
(N=2 in each group). The cumulative rate of VT episodes at 30 months was similar between groups (23% 
[ICM group] versus 42% [Holter group], log-rank P-value=0.71). Furthermore, the characteristics of the VT 
were similar between groups with regard to the number of beats and rate. 
Conclusions: In adults with HCM, an ICM will detect more arrhythmic events requiring an intervention 
than a conventional Holter strategy. In contrast, the diagnostic yield of detecting VT seems similar for 
both groups.




Insertable cardiac monitors (ICMs) provide continuous rhythm monitoring and are useful for the 
detection of infrequent arrhythmias, especially in patients with recurrent unexplained syncope1. The 
exact role of ICMs in patients with hypertrophic cardiomyopathy (HCM) is less clear. The current ESC 
guidelines recommend that HCM patients with recurrent episodes of unexplained syncope, who are at 
low risk of sudden cardiac death (SCD), should be considered for an ICM1, 2. Furthermore, an ICM may be 
considered for HCM patients with frequent unexplained palpitations2. However, these recommendations 
are based on scarce data and there is no comparative data with ambulatory Holter monitoring3-5. 
The 2014 ESC HCM guidelines recommend the use of ambulatory Holter monitoring to detect atrial 
and ventricular arrhythmias every 12-24 months or more often in the case of symptoms or left atrial 
dilatation2. Theoretically, the diagnostic yield for the detection of arrhythmias is higher for an ICM in 
comparison to intermittent Holter monitoring. This higher diagnostic yield may be clinically relevant in 
this patient population. For example, the detection of ventricular tachycardia (VT) may have an impact 
on risk stratification for SCD and the decision to implant an implantable cardioverter-defibrillator (ICD)2, 
6, 7. Furthermore, HCM patients with documented AF should receive oral anticoagulation to prevent 
stroke2. In the past 5 years, we adopted a strategy to use an ICM in HCM patients at low to intermediate 
risk of SCD for the detection of subclinical arrhythmias, with a particular emphasis on the detection of VT. 
The aim of the present study was to evaluate the incremental value of ICMs compared to a conventional 
strategy (i.e., Holter monitoring) in adults with HCM and a low- or intermediate HCM Risk-SCD score.
Methods
Study population
This was a prospective observational study which included all consecutive adults with HCM who received 
a Reveal LINQ (Medtronic Inc., Minneapolis, MN, USA) between November 2014 and February 2019. All 
patients had an HCM Risk-SCD score <6%. The reason for an ICM was a combination of symptoms (e.g., 
recurrent (near)syncope, palpitations), presence of myocardial fibrosis (determined by the presence of 
late gadolinium enhancement [LGE] on cardiac MRI [CMR]) and/or an intermediate risk for SCD (5-year 
risk of SCD ≥4 to <6%). The decision to implant an ICM was made during a Heart Team consisting of a 
cardiac electrophysiologist and a cardiologist specialized in HCM. 
 The control group was retrospectively identified from our prospective HCM registry and 
consisted of a matched cohort who received conventional follow-up (intermittent Holter monitoring 
every 6-24 months based on treating physician’s discretion). Matching was based on age (with a margin 
of 5 years), sex and HCM Risk-SCD score category (<4% or ≥4 to <6%). Patients in the control group 
required a minimum of 1 Holter study during follow-up and at least a clinical follow-up of 1 year. The 




All ICMs were implanted subcutaneously as recommended by the manufacturer using the incision and 
insertion tool. Furthermore, all patients received a handheld activator to indicate their symptoms when 
necessary. The ICM was routinely programmed with the following settings: tachycardia-detection was 
set to 176 bpm for 16 beats; bradycardia-setting to 30 bpm for 8 beats; pause-setting to 4.5 sec; and atrial 
fibrillation (AF) setting to ‘AF only’. Based on the implanting physician’s preferences other settings could 
be programmed. All devices were connected to the Medtronic CareLink network for remote monitoring.
Clinical follow-up of ICM group
ICM patients were discharged on the day of implantation. Ten days after implantation the patients were 
seen at the out-patient clinic to check the implantation site and to interrogate the ICM. Afterwards, the 
patients were seen regularly at the outpatient clinic according to routine patient care. ICM check-ups 
were performed at the outpatient clinic every 6 months or earlier when necessary based on symptoms 
or transmitted episodes. Remote monitoring was performed on a daily basis during weekdays. All patient 
activated episodes and automatically detected episodes were classified. In case of an inappropriate 
automatically detected episode, the cause of inappropriate detection was specified, if possible. Multiple 
actionable events could occur in 1 patient.
Study endpoints
The primary endpoint of the study was the occurrence of an actionable event which was defined as an 
arrhythmic event resulting in any change in patient management (e.g., start or increase of medication, 
implantation of pacemaker or ICD, catheter ablation, etc.). The secondary endpoint was the occurrence of 
any VT (at least 3 beats), irrespective if this resulted in an actionable event or not. A regular wide complex 
tachycardia was considered a VT if there was a sudden onset and a change in the QRS morphology in 
comparison to the baseline rhythm. An irregular wide complex tachycardia was considered a VT if there 
was a sudden onset and a polymorphic QRS morphology. A regular wide or narrow complex tachycardia 
was considered a supraventricular tachycardia (SVT) if there was a sudden onset and no change in QRS 
morphology. In case of doubt, a second electrophysiologist was consulted for the final diagnosis. For 
both endpoints, the cumulative event rate was determined at 30 months considering the estimated 
battery lifetime of the ICM.
Statistical analysis
Continuous data are presented as mean ± standard deviation or as median with interquartile range 
(IQR) (25th and 75th percentile), as appropriate. Categorical variables are presented by frequencies and 
percentages. Differences of continuous variables between groups were analyzed with the unpaired 
Student’s t test or the Kruskal-Wallis test, as appropriate. Differences between categorical variables were 
evaluated using the chi-square test. Cumulative event rates were estimated with the Kaplan-Meier 
method and differences were compared by log-rank test. Statistical analyses were performed using SPSS 
version 25 (IBM Corp., Somers, NY).




A total of 25 HCM patients received an ICM between 2014 and 2019. We identified 25 matched controls 
with HCM who were seen at the outpatient clinic in the same study period. Baseline characteristics of 
the study population are presented in Table 1. The ICM group more often had a history of syncope (32% 
versus 4%, P=0.01). Other baseline characteristics, including a history of nonsustained VT (NSVT), were 
similar between groups.






Age, years 51 ± 16 52 ± 16 0.94
Sex, man 18 (72%) 18 (72%) 1.00
NYHA functional class ≥II 7 (28%) 7 (28%) 1.00
History of myectomy 2 (8%) 3 (12%) 0.64
Left ventricular systolic function 1.00
-    Normal (EF ≥50%) 25 (100%) 24 (96%)
-    Mildly impaired (EF 45-49%) 0 1 (4%)
Genetic testing 21 (84%) 23 (92%) 0.67
Pathogenic mutation 12 (48%) 14 (56%) 0.57
-    MYBPC3 8 (32%) 11 (44%) 0.38
-    MYH7 3 (12%) 1 (4%) 0.30
-    TPM1 1 (4%) 0 1.00
-    TNNI3 0 2 (8%) 0.49
History of NSVT 13 (52%) 8 (32%) 0.15
History of unexplained syncope 8 (32%) 1 (4%) 0.01
Peak LVOT gradient 6 (5-17) 12 (6-82) 0.19
Family history of SCD 3 (12%) 3 (12%) 1.00
Left atrial size 43 ± 9 45 ± 7 0.23
Maximum left ventricular wall thickness 18 ± 5 18 ± 5 0.49
HCM Risk-SCD score 3.41 ± 1.31 3.31 ± 1.43 0.79
-    <4% 13 (52%) 13 (52%) 1.00
-    ≥4 to ≤6% 12 (48%) 12 (48%) 1.00
Electrocardiography 25 (100%) 25 (100%) 1.00
-    Sinus rhythm 24 (96%) 25 (100%) 1.00
-    Atrial fibrillation 1 (4%) 0 1.00
-    PR interval, if sinus rhythm 164 ± 25 182 ± 25 0.85
-    QRS duration, ms 105 ± 18 102 ± 28 0.56
-    QTc duration, ms 426 ± 25 416 ± 28 0.61
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Holter monitoring 25 (100%) 25 (100%) 1.00
-    <1% PVCs 23 (92%) 25 (100%) 0.49
-    1-10% PVCs 2 (8%) 0 0.49
-    NSVT 11 (44%) 6 (24%) 0.14
-    Supraventricular tachycardia 7 (28%) 12 (48%) 0.15
-    Atrial fibrillation 2 (8%) 0 0.49
Cardiac medication 16 (64%) 19 (76%) 0.35
-    Beta blocker 12 (48%) 14 (56%) 0.57
-    Loop diuretics 5 (20%) 0 0.05
-    ACE-inhibitor/ ARB 6 (24%) 3 (12%) 0.27
-    Oral anticoagulants 5 (20%) 5 (20%) 1.00
-    Calcium channel blocker 3 (16%) 4 (16%) 0.68
-    Amiodarone/Sotalol 2 (8%) 2 (8%) 1.00
Data are presented as n (%), mean ± SD or median with interquartile range. Abbreviations: ACE, angiotensin converting 
enzyme; ARB, angiotensin receptor blocker; CAD, coronary artery disease; EF, ejection fraction; HCM, hypertrophic 
cardiomyopathy; LVOT, left ventricular outflow tract; NSVT, nonsustained ventricular tachycardia; NYHA, New York 
Heart Association; PVC, premature ventricular complex; SCD, sudden cardiac death.
ICM-detected arrhythmias and Holter follow-up
During a mean follow-up of 17±10 months with the ICM, a total of 1,015 episodes were transmitted to the 
CareLink network system. There were 270 (27%) patient-activated episodes and 745 (73%) automatically 
detected episodes. The majority of patient-activated episodes (93%) comprised of sinus rhythm with 
or without ectopy. In the control group, 48 Holter recordings were performed during follow-up. The 
median number of Holter recordings per patient was 2 (IQR, 1-3). The median interval between Holter 
recordings was 12 (IQR, 5-23) months. 
Primary end-point
The cumulative event rate for an actionable event was higher in the ICM group (51% versus 27% at 30 
months, log-rank P-value <0.01) (Figure 1). In the ICM group the following actionable events occurred: 
antiarrhythmic drug therapy (or change in dose) for documented arrhythmias (n=6, 24%), start of non-
vitamin K antagonist oral anticoagulation for documented AF (n=3, 12%), electrophysiology study 
for symptomatic SVT (n=2, 8%), implantation of ICD for primary prevention (n=2, 8%), pacemaker 
implantation for sinus node dysfunction (n=1, 4%) and external electrical cardioversion for AF (n=1, 
4%). In the control group the following actionable events occurred: antiarrhythmic drug therapy (or 
change in dose) for documented arrhythmias (n=6, 24%), implantation of ICD for primary prevention 
(n=2, 8%) and electrophysiology study for symptomatic SVT (n=1, 4%). De novo AF only occurred in 
Table 1. continued
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the ICM group. Of the 3 patients with de novo AF, only 1 patient experienced symptoms required an 
electrical cardioversion for persistent AF. 
Figure 1. Cumulative event rate for actionable events
 Overall, 4 patients received an ICD for primary prevention (2 in each group). A patient in the 
ICM group had an ICM-detected NSVT (7 beats, 171 bpm, patient-activated) which increased his HCM 
Risk-SCD score from 3.6% to 8.0%. He received a prophylactic ICD 15 months after his ICM implantation. 
The other patient in the ICM group had a history of NSVT, HCM Risk-SCD score of 4.44% and patchy LGE 
anterior wall and interventricular septum on his CMR. He experienced an episode of fast monomorphic 
NSVT (32 beats, 200 bpm, automatically detected) 12 months post-ICM implantation. This did not 
increase his HCM Risk-SCD score, but based on his clinical profi le and the malignant character of the VT, 
the patient received an ICD. In the control group, a patient received a prophylactic ICD after a Holter-
detected monomorphic VT episode (3 beats, 135 bpm) increased his HCM Risk-SCD score from 4.4% 
to 9.6% at 27 months after initial risk evaluation. The second patient in the control group who received 
a prophylactic ICD had an HCM Risk-SCD score of 4.2% and had a history of NSVT. The combination of 
Holter-detected recurrent VT and recurrent near-syncope was the indication for an ICD 26 months after 
initial risk evaluation.
Secondary end-point
The cumulative event rate for VT was 23% in the ICM group and 42% in the control group at 30 months 
(log-rank P-value = 0.71) (Figure 2). Most VT episodes (4 of 5, 80%) in the ICM group were patient-activated 
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episodes, thus, were detected while patients experienced symptoms. One patient of the ICM group had 
a VT episode which was automatically detected (32 beats, 200 bpm). The characteristics of documented 
VT episodes were similar between groups with regard to the median number of documented beats (5 
[IQR, 5-7] versus 6 [IQR, 4-11], for ICM group and control group, respectively, P=1.00) and median rate 
(150 bpm [IQR, 145-155 bpm] versus 136 bpm [IQR, 125-168 bpm], for ICM group and control group, 
respectively, P=0.21).
Figure 2. Cumulative event rate for ventricular arrhythmias
Discussion
The present study is the fi rst study comparing the value of an ICM to conventional Holter monitoring 
in HCM patients with a low or intermediate HCM Risk-SCD score. The main fi nding is that actionable 
arrhythmic events occurred more frequently in the ICM group in comparison to the Holter group. In 
contrast, the cumulative rate of detected VT was similar between both groups. 
It is well-known that prolonged arrhythmia monitoring increases the yield of arrhythmia 
detection. The indications for an ICM has expanded over the years and its use is currently not only limited 
to patients with recurrent unexplained syncope1, 8. Other important indications include the detection of 
subclinical AF, risk stratifi cation in patients with inheritable heart disease by the detection of VT and 
establishing a symptom-rhythm correlation in symptomatic patients9. In patients with HCM who are 
at low risk for SCD according to the HCM Risk-SCD score, the current ESC guidelines recommends that 
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an ICM should be considered in patients with recurrent unexplained syncope and may be considered 
in those with unexplained palpitations1, 2. However, limited data exists on the clinical impact of ICMs in 
HCM patients and most studies comprised less than 10 patients3-5. 
 The present study is the first to provide insight in the incremental value of an ICM in patients 
with HCM. The rate of actionable arrhythmic events was higher in the ICM group in comparison to 
a matched group who had intermittent Holter monitoring. Interestingly, de novo AF requiring oral 
anticoagulation only occurred in the ICM group. It is known that AF occurs in approximately 20% of 
patients with HCM and is associated with impaired quality of life, thromboembolism and mortality10-15. 
To prevent thromboembolic complications, the guidelines recommend the use of lifelong oral 
anticoagulation, irrespective of the CHADS-VASc score, when AF occurs in patients with HCM2. Several 
studies in HCM patients with a cardiac implantable electronic device have demonstrated a high 
incidence of clinically silent AF episodes which may have important implications13, 16. In our study, 3 
patients (12%) were started on oral anticoagulation after the detection of de novo AF detected by the 
ICM. Thus, an ICM may play a role in the detection of subclinical AF in this specific population. 
 SCD is the most feared consequence of HCM, which has led to meticulous efforts to identify 
those patients who may benefit from a prophylactic ICD. Since 2014, the HCM Risk-SCD model provides 
guidance to physicians to identify patients deemed to be at high risk for SCD, and thus eligible for 
a prophylactic ICD17, 18. In clinical practice however, we are confronted with patients with a low or 
intermediate risk who have additional risk factors which are not incorporated in the HCM Risk-SCD 
model, such as extensive LGE on CMR19, LV apical aneurysms, multiple pathogenic sarcomere protein 
variants, and LV dysfunction. The presence of NSVT is an important risk factor, especially in those 
patients younger than 30 years of age20, 21. In the American guidelines there is class IIa indication for 
an ICD in patients with NSVT who have additional SCD modifiers (i.e, age <30 years, LGE on CMR, LVOT 
obstruction, LV aneurysm, syncope >5 years ago)6. Considering the clinical relevance of documenting VT 
in this population, routine ambulatory Holter monitoring is recommended2, 6, 7. 
  We expected that continuous monitoring with an ICM would improve VT detection. 
Interestingly, in our study the diagnostic yield for detecting VT was similar between the ICM and the 
Holter group. This apparent paradox can be partly explained by the ICM settings. Only longer and faster 
runs of VT (≥16 beats at a rate of >176 bpm) or symptomatic VT (patient-activated episodes) will be 
detected by the ICM, while with Holter monitoring a VT of ≥3 beats at a rate of >120 bpm will suffice. 
The Reveal LINQ can be programmed to detect a tachycardia of 5 beats at a rate of >120 bpm. However, 
this sensitive programming setting will result in a suboptimal signal-to-noise ratio, as many tachycardia 
episodes will be due to sinus tachycardia.
 There is some inconsistency in the literature with regard to the prognostic significance of 
specific characteristics of documented VT. Studies in unselected HCM cohorts have shown no association 
between characteristics of the detected VT on ambulatory Holter monitoring and the occurrence of 
SCD21. However, several HCM cohorts with ICDs (higher-risk cohorts) demonstrated that longer-lasting 
and faster VT were more predictive of the occurrence of appropriate ICD therapy22-24. For example, in 160 
HCM patients with ICDs, Wang et al. reported the independent association of fast (>200 bpm), long (>7 
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beats) and repetitive runs of VT with the occurrence of ICD therapy, whereas this association was not 
shown for slower, shorter and single-run of VT24. These data are important and support the use of ICMs 
as these devices are able to capture the more predictive longer and faster VT. 
 Finally, there are some factors that need to be considered when using ICMs in this patient 
population, including device costs, data overload, the clinical relevance of detected arrhythmias and 
medical overuse. A dedicated telemonitoring staff is a requirement before providing such a service to 
patients.
Study limitations
Although we used a matched control group, the present study is a nonrandomized study and selection 
bias is possible. The control group had a lower proportion of patients with a history of syncope. It is 
important to stress that the ICM population was not a general HCM population, but a selected cohort 
of HCM patients with symptoms or additional risk factors for SCD. Finally, the classification of wide 
complex tachycardia as either VT or SVT can be challenging considering that only a single surface 
electrogram is available. To reduce the risk of misclassification, difficult electrograms were reevaluated 
by an electrophysiologist.
Conclusions
In patients with HCM, the use of an ICM resulted in more actionable arrhythmic events if compared 
to intermittent Holter monitoring. Interestingly, de novo AF was only detected in the ICM group. The 
diagnostic yield of detecting VT appeared similar between both rhythm detection strategies, which may 
be explained by the ICM not detecting short runs of VT.
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Introduction: There is limited data on the experience with insertable cardiac monitors (ICMs) in patients 
with Brugada syndrome. 
Objective: To evaluate the outcome of ICM in symptomatic patients with Brugada syndrome who are 
at suspected low risk of sudden cardiac death (SCD).
Methods: We conducted a prospective single-center cohort study including all symptomatic patients 
with Brugada syndrome who received an ICM (Reveal LINQ) between July 2014 and October 2019. The 
main indication for monitoring was to exclude ventricular arrhythmias as the cause of symptoms and to 
establish a symptom-rhythm relationship.
Results: A total of 20 patients (mean age, 39 ± 12 years; 55% male) received an ICM during the study 
period. Nine patients (45%) had a history of syncope (presumed nonarrhythmogenic) and 5 patients 
had a recent syncope (<6 months). During a median follow-up of 32 months (interquartile range, 11-36 
months), 3 patients (15%) experienced an episode of nonsustained ventricular arrhythmia. No patient 
died suddenly, nor experienced a sustained ventricular arrhythmia, and no patient had a recurrence of 
syncope. Overall, 17 patients (85%) experienced symptoms during follow-up, of whom 10 patients had 
an ICM-detected arrhythmia. In 4 patients (20%) the ICM-detected arrhythmia was an actionable event. 
ICM-guided management included antiarrhythmic drug therapy for symptomatic ectopic beats (n=3), 
pulmonary vein isolation and oral anticoagulation for atrial fibrillation (n=1), electrophysiological study 
for risk stratification (n=1), and pacemaker implantation for atrioventricular block (n=1).
Conclusions: An ICM can be used to exclude ventricular arrhythmias in symptomatic patients with 
Brugada syndrome at low risk of SCD. Furthermore, an ICM-detected arrhythmia changed clinical 
management in 20% of patients. 




Risk stratification in patients with Brugada syndrome is challenging1-3. Several risk factors for arrhythmic 
events (sustained ventricular arrhythmia or sudden cardiac death [SCD]) have been identified but 
the most robust predictors are a spontaneous type 1 Brugada electrocardiogram (ECG) pattern and 
presumed arrhythmogenic syncope1-3. There is controversy over the predictive role of inducible 
sustained ventricular arrhythmia during electrophysiological study (EPS), but it seems to be informative 
for predicting arrhythmic risk in moderate-risk patients when using less aggressive stimulation protocols 
(up to double extrastimuli)1-5. 
 The current guidelines recommend an implantable cardioverter-defibrillator (ICD) in patients with 
Brugada syndrome with aborted cardiac arrest, documented spontaneous sustained ventricular arrhythmias 
or a combination of spontaneous type 1 Brugada ECG pattern and a history of syncope6, 7. The downside of 
ICD therapy is the risk of late complications, inappropriate ICD shocks and psychological burden8. 
 In clinical practice, physicians are confronted with patients with Brugada syndrome who 
have symptoms such as palpitations, near-syncope, or nonarrhythmic syncope5, 9. Some symptoms 
are caused by anxiety for arrhythmic events, but it may be difficult to differentiate this from clinically 
relevant arrhythmias. Insertable cardiac monitors (ICM) are increasingly being used in doubtful cases to 
exclude ventricular arrhythmias as the cause of symptoms5, 10, 11.  The recent ESC guidelines and expert 
consensus conference report support the use of ICMs in patients with Brugada syndrome and recurrent 
unexplained syncope12, 13. The aim of the present study is to evaluate the use of ICMs in symptomatic 
patients with Brugada syndrome who are presumed to be at low risk of SCD. 
Methods
 
Study design and population
The present study is a prospective single-center cohort study which included all symptomatic adults 
with Brugada syndrome who received an ICM between July 2014 and October 2019.The main indication 
for arrhythmia monitoring was to exclude ventricular arrhythmias as the cause of symptoms. Most 
patients have received a 24-hour Holter monitoring prior to ICM implantation. Patients with high risk 
features, such as a spontaneous sustained ventricular arrhythmia, a combination of spontaneous type 
1 Brugada ECG pattern and arrhythmic syncope, or positive EPS, were not considered for an ICM but 
were recommended an ICD6, 14. Until 2014, we recommended EPS to all patients with spontaneous or 
drug-induced Brugada ECG pattern. Thereafter, EPS was only proposed to doubtful cases. The study was 
approved by the institutional review board of the Erasmus MC.
Device programming and follow-up
All ICMs (Reveal LINQ, Medtronic) were implanted subcutaneously using the incision and insertion tool. 
Furthermore, all patients received a handheld activator to indicate their symptoms when necessary. 
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The ICM was programmed according to local settings: tachycardia-detection was set to 176 bpm for 16 
beats (nominal setting); bradycardia-setting to 30 bpm for 8 beats (nominal 4 beats); pause-setting to 4.5 
sec (nominal 3.0 sec); and atrial fibrillation (AF) setting to ‘AF only’. These settings were chosen to improve 
the signal-to-noise ratio. All devices were connected to the CareLink network (Medtronic) for remote 
monitoring. Patients were discharged on the same day of implantation. Ten days after implantation the 
patients were seen at the out-patient clinic to check their wound and to interrogate the ICM. Afterwards, 
the patients were seen regularly at the outpatient clinic according to routine patient care. ICM check-ups 
were performed at the outpatient clinic every 6 months or earlier when necessary based on symptoms 
or transmitted episodes. Remote monitoring was performed on a daily basis during weekdays. Remote 
monitoring involves automatic unscheduled transmission of alert events. 
Classification of episodes and endpoints
All patient activated episodes and automatically detected episodes were classified. In the case of an 
inappropriate automatically detected episode, the cause of inappropriate detection was specified, if 
possible. A regular broad complex tachycardia (BCT) was considered a ventricular arrhythmia if there 
was a sudden onset and a change in the QRS morphology in comparison to the baseline rhythm. An 
irregular BCT was considered a ventricular arrhythmia if there was a sudden onset and a polymorphic 
QRS morphology. A regular broad or small complex tachycardia was considered a supraventricular 
tachycardia if there was a sudden onset and no change in QRS morphology. In the case of doubt, a 
second electrophysiologist was consulted for the final diagnosis. Finally, it was established whether a 
detected arrhythmia resulted in a change in patient management (‘actionable event’). 
Statistical analysis
Data are presented as mean ± standard deviation or as median with corresponding 25th and 75th 
percentile, as appropriate. Categorical variables are presented by frequencies and percentages. Statistical 
analyses were performed using SPSS version 21.
Results 
Study population
A total of 20 patients with Brugada syndrome (mean age, 39 ± 12 years; 55% male) received an ICM 
during the study period. Baseline characteristics of the study population are listed in Table 1 and 2. 
Symptoms before ICM implantation consisted of syncope suggestive of a non-arrhythmogenic cause 
(n=9, 45%), palpitations (n=7, 35%) or a combination of near-syncope and palpitations (n=4, 20%). Of 
the 9 patients with syncope, 7 patients (78%) had only 1 syncopal event and 5 patients (56%) had a 
recent syncope (<6 months before ICM implantation). A detailed patient-level description of patient 
characteristics is presented in Table 2. There were no ICM- or procedure-related complications.
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Table 1. Clinical baseline characteristics. 
Total group
(n=20)
Age, years 39 ± 12
Gender, male 11 (55%)
Family history of SCD in first-degree relatives 8 (40%)
History of atrial flutter at age <35 years 1 (5%)
Symptoms
-    Palpitations 11 (55%) 
-    Syncope  9 (45%)
-    Near syncope 4 (20%)
Systemic systolic ventricular function
-    Normal left ventricular ejection fraction (≥55%) 20 (100%)
Genetic variance
-    No (likely) pathogenic SCN5A variant 14 (70%)
-    No genetic testing 4 (20%)
-    Pathogenic SCN5A variant 2 (10%)
Clinical presentation
-    Ajmaline induced Brugada ECG 14 (70%)
-    Fever induced Brugada ECG 4 (20%)
-    Spontaneous Brugada ECG 2 (10%)
Electrocardiography
-    Sinus rhythm 20 (100%)
-    PR interval, ms 169 ± 28
-    QRS duration, ms 103 ± 18
-    QTc duration, ms 391 ± 22
-    Fragmented QRS 4 (20%)
EP-study 7 (35%)
-    No inducible sustained VA 7 (35%)
-    VERP <200ms 2 (10%)
Holter monitoring 16 (80%)
-    No PVCs 10 (50%)
-    ≤1% PVCs 6 (30%)
-    Supraventricular tachycardia 0
-    Ventricular tachycardia 0
SA-ECG 16 (80%)
-    Late potentials 10 (50%)
Data are presented as n (%) or mean with standard deviation. Abbreviations: ECG, electrocardiogram; EP, 
electrophysiology; PVC, premature ventricular arrhythmia; SCD, sudden cardiac death; VA, ventricular arrhythmia; 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































During a median follow-up of 32 months (IQR, 11-36 months), a total of 1,912 episodes were transmitted 
to the CareLink network system (Appendix A). There were 904 (47%) patient-activated episodes and 1,008 
(53%) automatically detected episodes. The majority of patient-activated episodes (98%) comprised 
sinus rhythm with or without ectopy, thus, only a minority of patient-activated episodes comprised a 
significant arrhythmia.
Detection of ventricular arrhythmias episodes
During follow-up, 3 patients (15%) experienced an episode of nonsustained ventricular arrhythmia 
(Table 2, Figure 1). 
 The first patient was a 23-year-old male with ajmaline-induced Brugada syndrome and an 
anxiety disorder (treated by psychiatrist) who received an ICM due to recurrent unexplained symptoms 
(i.e. near-syncope and palpitations). During follow-up, he experienced 6 episodes of symptomatic regular 
slow monomorphic nonsustained ventricular arrhythmia (4-8 beats, patient-activated). It is important 
to note, that the majority of his patient-activated episodes did not show any arrhythmia. The patient 
underwent an EPS which was negative and based on the negative EPS he was treated conservatively.
 The second patient was a 41-year-old female with ajmaline-induced Brugada syndrome and 
a positive family history of SCD who received an ICM for a history of presumed nonarrhythmogenic 
syncope. She experienced one symptomatic episode of irregular nonsustained ventricular arrhythmia 
(9 beats, patient-activated) with palpitations five months post ICM-implantation. It was decided to 
continue arrhythmia monitoring and to perform an EPS if there was a recurrent ventricular arrhythmia 
episode. 
 The third patient was a 42-year-old male with fever-induced Brugada syndrome, fragmented 
QRS and a negative EPS who received an ICM for palpitations. He experienced a symptomatic regular 
monomorphic nonsustained ventricular arrhythmia (7 beats, patient-activated) 16 months post ICM-
implantation. Because he also had symptomatic ventricular ectopic beats, he was treated successfully 
with quinidine sulphate. No ventricular arrhythmia was seen thereafter. His ICM was explanted 3.5 years 
after implantation. 
 No patient died suddenly or experienced a sustained ventricular arrhythmia.
Symptom-rhythm correlation
No patient experienced syncope during a median follow-up of 32 months (IQR, 11-36 months). Overall, 
17 patients (85%) experienced any symptom during follow-up (Figure 1, Table 2). Ten of 17 (59%) 
symptomatic patients had an ICM-detected arrhythmia. In 4 patients (20%) the ICM-detected arrhythmia 
was considered an actionable event. ICM-guided management included antiarrhythmic drug therapy 
for symptomatic ectopic beats (n=3), pulmonary vein isolation and oral anticoagulation for atrial 
fibrillation (n=1), electrophysiological study for risk stratification (n=1), and pacemaker implantation for 
high-degree atrioventricular block (n=1).


































































































































































































 Two patients with ventricular arrhythmia episodes and actionable events have been described 
previously. Furthermore, a 35-year-old male with ajmaline-induced Brugada syndrome experienced 
symptomatic paroxysmal AF detected by the ICM. He was started on oral anticoagulation and sotalol. In 
addition, he was scheduled for a pulmonary vein isolation.
 A 50-year-old female with recurrent syncope, fever-induced Brugada syndrome and a positive 
family history of SCD at young age (third-degree relative) received a dual-chamber pacemaker after her 
ICM detected a 10-seconds pause due to high-degree AV block. During a follow-up of 18 months after 
pacemaker implantation, no episode of ventricular arrhythmia was documented by her pacemaker. 
 Overall, in 10 patients (45%) the ICM was explanted. In 9 patients the ICM was explanted due 
to end of battery life. 
Discussion
The present study is one of the largest case series evaluating the outcome of continuous monitoring 
in adults with Brugada syndrome with low risk of SCD. During almost 3 years of follow-up, there was 
a low risk of nonsustained ventricular arrhythmia and an absence of sustained ventricular arrhythmia. 
In 4 patients (20%), an ICM-guided diagnosis resulted in a change of patient management. No patient 
required an ICD during follow-up. Thus, an ICM may provide reassurance to a symptomatic patient with 
Brugada syndrome.  
Risk stratification
Brugada syndrome is characterized by an increased risk of SCD. Several risk factors for SCD have been 
identified including among others spontaneous type 1 Brugada ECG pattern, history of arrhythmogenic 
syncope, positive EPS, family history of SCD <35 years, fractionated QRS, early repolarization in 
the peripheral leads, increased Tpeak-Tend interval, sinus node dysfunction, first-degree AV block 
and nonsustained ventricular arrhythmia1-4. The role of EPS in patients with Brugada syndrome is 
controversial. A recent meta-analysis demonstrated that ventricular arrhythmia induction using single 
or double extrastimuli was associated with a 2- to 3-fold increased risk of arrhythmic events4. However, it 
is important to note that a negative EPS alone is not sufficient to preclude arrhythmia risk, especially in 
patients with clinical high-risk features. Using a recently developed risk score (published in 2017) based 
on clinical parameters, the risk score in our study population ranged from 0 to 3 points corresponding 
to an estimated 5-year event rate ranging from 1.6% to 16.6%1. The arrhythmic event rate in our study 
population was 0% during a median follow-up of almost 3 years, supporting the clinical judgment not 
to implant a prophylactic ICD in our study population. 
Role of ICM in Brugada syndrome
An ICM is a sensitive tool to detect paroxysmal arrhythmias and is particularly useful for establishing a 
symptom-rhythm correlation. In the general population, there is a clear indication for an ICM in patients 
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with recurrent unexplained syncope12, 15. Interestingly, the recent ESC guidelines give a class IIa indication 
(level of evidence C) for an ICM (instead of an ICD) in Brugada patients with recurrent unexplained 
syncope who are at low risk of SCD12. Currently, there is limited published data on the use of ICM in 
patients with Brugada syndrome5, 10, 11, 16-18. A few case reports in Brugada patients with presumed non-
arrhythmogenic syncope have demonstrated the detection of self-terminating sustained ventricular 
arrhythmia by the ICM16, 17. These patients received a prophylactic ICD. Until now, there are 2 reported 
case series with >10 patients. In 2012, Kubala et al. reported a retrospective analysis of 11 patients (mean 
age 44 years) with Brugada syndrome and ICM (Reveal DX, Medtronic)10. Most patients were symptomatic 
and had a previous EPS, furthermore, half of the study population had a spontaneous type 1 Brugada 
ECG pattern. During a mean follow-up of 33 months, no ventricular arrhythmic event was documented 
in patients with recurrence of symptoms. In 2017, Giustetto et al. reported the experience with ICMs 
in the Piedmont Brugada registry5. In this study, 13 patients with neurally mediated syncope and 14 
patients with unexplained, suspected arrhythmia-related syncope received an ICM. During follow-up, no 
patient had an arrhythmic event (defined as ventricular fibrillation, sustained ventricular arrhythmia or 
SCD). Our study expands the experience with ICM in symptomatic patients with Brugada syndrome and 
is in line with previous studies by demonstrating no sustained ventricular arrhythmias during follow-up. 
In contrast to previous studies, we reported all ICM-detected arrhythmic events independent of initial 
symptoms. 
Considerations
There seems to be a role to use ICM in selected symptomatic Brugada patients. Patients who are recently 
diagnosed with Brugada syndrome usually experience increased anxiety considering the increased risk 
of SCD. The heightened awareness of palpitations or near-syncope may be troublesome for patients, and 
in this respect an ICM with remote monitoring may provide reassurance by excluding clinically relevant 
arrhythmias during symptoms. 
 On the other hand, when using an ICM there are some limiting factors which should be 
considered such as device costs, data overload, clinical relevance of device-detected ventricular 
arrhythmia and medical overuse. The issue of data overload is highlighted by the recording of almost 
2,000 episodes in 20 patients in our study population. A dedicated telemonitoring staff with a proper 
infrastructure is advised before providing such a service to patients
Study limitations
Although this is one of the largest reported series on the use of ICM in Brugada patients, the sample 
size is still relatively small. This may impact on the external validity of the study results. Furthermore, a 
longer follow-up duration may potentially increase the likelihood of detecting ventricular arrhythmias. 
However, the average battery life time of the Reveal LINQ is 3 years. A longer follow-up would thus 
require replacement of the ICM. Finally, asymptomatic ventricular arrhythmia episodes which are shorter 
(<16 beats) or slower (<176 bpm) than the programmed cutoff values will be missed. Therefore, the true 




An ICM can be used to exclude ventricular arrhythmias in symptomatic patients with Brugada syndrome 
at presumed low risk of SCD and thereby providing reassurance. Furthermore, an ICM-detected 
arrhythmia changed clinical management in 20% of patients. 




Appendix A. Overview of ICM-detected arrhythmias
Total episodes
(n=1912)
Symptom episodes* 904 (47%)




-    Regular broad complex tachycardia 8 (<1%)
-    Regular small complex tachycardia 4 (<1%)
-    Atrial fibrillation 4 (<1%)
Brady episodes* 822 (43%)
-    Sinus bradycardia 818 (99%)
-    Sinus rhythm 2  
with undersensing of PVCs 2
-    Sinus arrest 2 (<1%)
Tachycardia episodes* 121 (6%)





Pause episodes* 53 (3%)
-    Sinus rhythm 48 (91%)
with sudden drop of R-wave 41
with small R-waves 6
with undersensing of PVCs 1
-    Sinus arrest 4 (8%)
-    AV-block 1 (2%)
Atrial tachycardia* 11 (<1%) 
Sinus rhythm 11 (100%)
Atrial fibrillation* 1 (<1%)
Sinus rhythm with PACs 1 (100%)
Data are presented as n (%). * Episode classification by ICM. Abbreviations: AV-block, atrio-ventricular block; PAC, 
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Background: A chronic total occlusion (CTO) is common in out-of-hospital cardiac arrest (OHCA) 
survivors with coronary artery disease. It is unclear whether a CTO contributes to ventricular arrhythmias 
in this population. 
Objective: This study sought to evaluate the impact of unrevascularized CTO’s on the occurrence 
of appropriate implantable cardioverter-defibrillator (ICD) therapy and all-cause mortality in OHCA 
survivors with coronary artery disease.
Methods: This was a retrospective study that included all consecutive OHCA survivors with coronary 
artery disease who received an ICD from 1999 until 2015. Study endpoints were appropriate ICD therapy 
and all-cause mortality. 
Results: We identified 217 OHCA survivors (mean age 63±10 years, 86% man) with coronary artery 
disease. An unrevascularized CTO was present in 71 of 217 patients (33%) at the time of ICD implantation. 
During a median follow-up of 61 months (interquartile range, 28-97 months), 57 of 217 patients (26%) 
experienced an appropriate ICD therapy. CTO patients had a higher incidence of appropriate ICD therapy 
in comparison to non-CTO patients (logrank P=0.002). Multivariate Cox regression analysis identified 
CTO (hazard ratio, 2.07; 95% confidence interval, 1.23-3.50; P=0.007) as an independent predictor of 
appropriate ICD therapy. The presence of a CTO was not associated with a higher mortality rate (logrank 
P=0.18).
Conclusions: In OHCA survivors with coronary artery disease receiving an ICD for secondary prevention, 
a CTO was an independent predictor for the occurrence of ventricular arrhythmias but not for mortality.




The exact role of a chronic total occlusion (CTO) in causing a life-threatening ventricular arrhythmias (VA) 
is not clear. In clinical practice we encounter out-of-hospital cardiac arrest (OHCA) survivors with a CTO 
who have a relatively preserved left ventricular function and no significant rise in cardiac enzymes. One 
may speculate that the presence of a CTO may contribute to the VA event by a complex interplay of scar 
and ischemia. A previous nonrandomized study showed that failed or unattempted CTO recanalization 
in stable coronary artery disease patients was associated with increased risk of sudden cardiac death in 
comparison to those with revascularized CTO1. Furthermore, several studies in patients with ischemic 
cardiomyopathy and severe LV dysfunction who receive an ICD for primary prevention have shown that 
a CTO is an independent predictor of VA2, 3. Currently, there is limited data on the prognostic implications 
of a CTO in patients with coronary artery disease who present with OHCA due to VA. The aim of the 
present study was to evaluate the impact of a CTO on the occurrence of VA and all-cause mortality in 
survivors of OHCA with coronary artery disease. 
Methods
Study Population
The study population was identified using the prospective ICD registry of the department of cardiology 
of the Erasmus Medical Center in Rotterdam, the Netherlands. Baseline clinical and echocardiography 
data, characteristics of the implant procedure, and data for all follow-up visits were prospectively 
recorded in a dedicated database. We identified all consecutive patients with coronary artery disease 
who received an ICD for secondary prevention after OHCA due to VA between December 1999 and June 
2015. Coronary artery disease was defined as the presence of significant coronary artery stenosis (>50%) 
or a history of percutaneous or surgical revascularization. 
 For analysis of the association between CTO and VA, 2 researchers (S.C.Y. and E.Y.) analyzed 
every patient in our cohort for the presence of a CTO at the time of ICD implantation by evaluating the 
coronary angiograms and catheterization reports before ICD implantation. This study was approved by 
the institutional review board of the Erasmus Medical Center. 
Definition of study variables
Chronic total occlusion was defined as complete vessel occlusion with TIMI 0 flow within the occluded 
segment and an estimated occlusion duration of ≥3 months4, 5. Occluded vessels that were surgically 
or percutaneously revascularized and secondary occluded vessels (i.e., diagonal branch, posterior 
descending artery, and posterolateral branches) were not classified as CTO in this study. Multivessel 
disease was defined as the presence of 2 or more coronary arteries with significant non-revascularized 




Devices were programmed with 2-3 consecutive zones (monitor zone, ventricular tachycardia zone and 
ventricular fibrillation zone, usually 2 zones) with limits slightly varying per manufacturer. The cut-off 
rate for the VT zone was usually set at 171-182 bpm and the cut-off rate for the VF zone was usually set 
at 222-230 bpm. In the VT zone, arrhythmias were initially treated with a series of antitachycardia pacing 
(ATP) bursts followed by shocks. In the VF zone, device shocks were the initial therapy or, when available, 
“ATP during charging”. If a patient had a VA with cycle length lower than the initially programmed cut-
off, another detection zone for slow VT was added. Conventional programming was used for detection 
duration. Detection in the VF zone was usually programmed at 18 of 24 intervals or a 2.5-second delay 
depending on manufacturer. Detection in the VT zone was usually programmed at 16-20 intervals or a 
5-second delay depending on manufacturer.
Follow-up and endpoints
Patients were usually followed every 3-6 months. The follow-up visits included clinical assessment 
and device interrogation. Unscheduled device interrogations were performed in case of symptomatic 
episodes of arrhythmia and during unplanned hospitalization. All spontaneous VA episodes were 
prospectively reviewed and classified (D.A.M.J.T). The primary endpoint was appropriate ICD therapy 
defined as the delivery of ATP or shock for VA (either ventricular tachycardia or ventricular fibrillation). 
The secondary endpoint was all-cause mortality. 
Statistical Analysis
Continuous data are presented as mean ± standard deviation if the data were normally distributed, or as 
median with interquartile range (25th and 75th percentile) otherwise. Categorical variables are presented 
by frequencies and percentages. Differences of continuous variables between the two groups were 
analyzed with the unpaired Student’s t-test or the Mann-Whitney U-test, as appropriate.  Differences 
between categorical variables were evaluated using the Chi-square test or the Fisher’s exact test in case 
of small expected cell frequencies. 
 The cumulative event rate of appropriate ICD therapy was calculated using the Kaplan-Meier 
method. Predictors of appropriate ICD therapy were determined using univariable and multivariable 
Cox regression analysis. Potential predictors were presence of CTO, left ventricular ejection fraction 
(LVEF) <35%, coronary artery bypass graft, multivessel disease, age >70 years, NYHA class III and renal 
dysfunction (GFR <60 mL/min). Any variable with a P value <0.10 and CTO status were entered in 
the multivariable model. Data are presented as hazard ratios (HR) and 95% confidence intervals (CI). 
A subgroup analysis was also performed where patients with unrevascularized CTO were compared 
to patients with recent (i.e., between OHCA and ICD implantation) successful CTO revascularization 
(surgical or percutaneous). Statistical analyses were performed using SPSS V.21.0. All statistical tests were 
two-sided. P values <0.05 were considered statistically significant. 





A total of 217 patients received an ICD as secondary prevention after experiencing OHCA for VA during 
the study period. The CTO group consisted of 71 patients (33%) with an unrevascularized CTO before 
ICD implantation. Baseline characteristics are depicted in Table 1. The CTO group was older, had more 
multivessel disease and had less coronary artery bypass grafts (CABG). Of the 71 CTO patients, 23 
patients (32%) underwent myocardial perfusion scintigraphy. Of the patients who underwent imaging 
stress testing, the majority (21 of 23 patients, 91%) demonstrated no or limited myocardial ischemia.








Age (years), mean±SD 63±10 62±11 65±9 0.03
Male gender 187 (86) 123 (84) 64 (90) 0.24
Medical history
-    Diabetes mellitus 39 (18) 26 (18) 13 (18) 0.93
-    Renal dysfunction (GFR <60 mL/min) 50 (23) 31 (21) 19 (27) 0.36
-    Previous CABG 66 (30) 55 (38) 11 (16) 0.001
-    Previous PCI 121 (56) 81 (56) 40 (56) 0.91
-    NYHA class ≥II 144 (66) 95 (65) 49 (69) 0.56
-    Multivessel disease 40 (18) 7 (5) 33 (47) <0.001
-    LVEF <35% 112 (52) 71 (49) 41 (58) 0.21
-    QRS ≥130 ms 55 (25) 33 (23) 22 (31) 0.18
Medication at ICD implantation
-    ACE inhibitor 177 (82) 120 (82) 57 (80) 0.73
-    Beta-blocker 177 (82) 121 (83) 56 (79) 0.48
-    Statin 171 (79) 115 (79) 56 (79) 0.99
-    Diuretic 106 (49) 71 (49) 35 (49) 0.93
-    Amiodarone 39 (18) 29 (20) 10 (14) 0.30
-    Digoxin 20 (9) 14 (10) 6 (9) 0.79
ICD type 0.81
-    Single-chamber 135 (62) 93 (64) 42 (59)
-    Dual-chamber 59 (27) 38 (26) 21 (30)
-    CRT-D 23 (11) 15 (10) 8 (11)
Data are presented as n (%), unless stated otherwise. ACE indicates angiotensin-converting-enzyme; CABG, coronary 
artery bypass graft; CRT-D, cardiac resynchronization therapy with defibrillator; GFR, glomerular filtration rate; ICD, 
implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PCI, 




During a median follow-up of 61 months (28-97 months), 57 of 217 patients (26%) of the total group 
experienced an appropriate ICD therapy. The incid ence of appropriate ICD therapy was higher in the 
CTO group in comparison to the non-CTO group (logrank P=0.002, Figure 1). The cumulat ive event rates 
for appropriate ICD therapy (ATP and ICD shock) in the CTO group were 19.7%, 37.3% and 37.3% at 1, 3 
and 5 years, respectively. The cumulative event rates for appropriate ICD therapy in the non-CTO group 
were 9.4%, 21.9% and 24.8% at 1, 3 and 5 years, respectively. Using univariate Cox regression analysis, 
the presence of a CTO was associated with an increased risk of appropriate ICD therapy (HR 2.20; 95% 
CI 1.31-3.72; P=0.003) (Table 2). Multivariate Cox regression analysis demonstrated that CTO and LVEF 
<35% were independent predictors of appropriate ICD therapy (Table 2). The cumulative event rate for 
appropriate ICD therapy in the CTO and non-CTO group stratifi ed by left ventricular function is depicted 
in Figure 2. 
 When restri cting the outcome data to appropriate ICD therapy in the VF zone, the CTO group 
only showed a trend towards a higher rate of appropriate ICD therapy in comparison to the non-CTO 
cohort (logrank P=0.08). The 5-year event rate of appropriate ICD therapy in the VF zone was 20.6% and 
15.8% in the CTO and non-CTO group, respectively. 
Figure 1. Cumulative event rate for appropriate ICD therapy in CTO and non-CTO populations - CTO indicates 
chronic total occlusion; ICD, implantable cardioverter-defi brillator.
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Table 2. Predictors of appropriate ICD therapy
Univariable Multivariable
HR (95%CI) P-value HR (95%CI) P-value
CTO 2.20 (1.31-3.72) 0.003 2.07 (1.23-3.50) 0.007
LVEF <35% 2.07 (1.19-3.59) 0.01 1.94 (1.11-3.38) 0.02
Multivessel disease 1.64 (0.89-3.03) 0.11
CABG 1.35 (0.79-2.31) 0.27
Age >70 years 1.11 (0.62-1.98) 0.73
NYHA class III 1.06 (0.33-3.39) 0.92
Renal dysfunction 0.80 (0.42-1.51) 0.49
CABG indicates coronary artery bypass graft; CTO, chronic total occlusion; LVEF, left ventricular ejection fraction; 
NYHA, New York Heart Association.
Figure 2. Cumulative event rate for appropriate ICD therapy in patients with CTO and non-CTO stratifi ed by LV 
ejection fraction below and above 35%. Abbreviations: CTO indicates chronic total occlusion; ICD, implantable 
cardioverter-defi brillator; LVEF, left ventricular ejection fraction.
Mortality
A total of 58 patients (27%) died during follow-up. The surviva l rate was similar between the CTO and 
non-CTO group (logrank P=0 .18, Figure 3). The cumulat ive survival rates in the CTO group were 94.2%, 
83.9% and 81.6% at 1, 3 and 5 years, respectively. The cumulative survival rates in the non-CTO group 
were 99.2%, 85.9% and 82.2% at 1, 3 and 5 years, respectively. Univariate and multivariate Cox regression 
analysis demonstrated that the presence of a CTO was not a predictor of all-cause mortality (Table 
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3). Univariate Cox regression analysis showed that LVEF <35%, age >70 years and renal dysfunction 
were associated with increased all-cause mortality. However, multivariate Cox regression analysis 
demonstrated that LVEF <35% and age >70 years were independent predictors of all-cause mortality. 
Figure 3. Cumulative survival rate in CTO and non-CTO populations. Abbreviations: CTO indicates chronic total 
occlusion.
Table 3. Predictors of all-cause mortality
Univariable Multivariable
HR (95%CI) P-value HR (95%CI) P-value
CTO 1.44 (0.85-2.45) 0.18 0.97 (0.51-1.87) 0.93
Age >70 years 3.19 (1.90-5.38) <0.001 2.84 (1.64-4.92) <0.001
LVEF <35% 2.20 (1.23-3.92) 0.008 2.07 (1.15-3.73) 0.02
Renal dysfunction 2.19 (1.29-3.72) 0.004 1.63 (0.94-2.81) 0.08
Multivessel disease 1.76 (0.97-3.19) 0.06 1.35 (0.65-2.80) 0.42
NYHA class III 1.75 (0.70-4.39) 0.24
CABG 1.23 (0.72-2.09) 0.45
CABG indicates coronary artery bypass graft; CTO, chronic total occlusion; LVEF, left ventricular ejection fraction; 
NYHA, New York Heart Association.
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Recent CTO revascularization and appropriate ICD therapy
There was a subgroup of patients (n=25) who underwent successful CTO revascularization in the period 
between OHCA and ICD implantation. The cumulative event rate of appropriate ICD therapy within this 
group was similar to the unrevascularized CTO group (n=71) (logrank P=0.48). 
Discussion
The present study demonstrates that a CTO was an independent predictor of appropriate ICD therapy, 
but was not associated with all-cause mortality. This work also found that LVEF<35% was an independent 
predictor of both appropriate ICD therapy and all-cause mortality. 
Chronic total occlusion and ventricular arrhythmias
CTO is a very common condition among patients with coronary artery disease, with a reported 
prevalence between 30% to 50% in patients with ischemia referred to the catheterization laboratory6, 
7. Therefore, it is not surprisingly that there was a high prevalence of CTO in our population of out-of-
hospital cardiac survivors with coronary artery disease who received an ICD. The exact role of a CTO in 
causing or triggering the initial ventricular fibrillation episode is not fully understood. However, there 
are several observations that may suggest that the presence of a CTO play an important role in the 
development of VA in patients with coronary artery disease. 
 A recent study showed that patients with previously failed or not attempted CTO recanalization 
had a higher incidence of sudden cardiac death (2.7% versus 0.5% at 4-years of follow-up) in comparison 
to those with successful CTO recanalization1. These observations may imply that ischemia associated 
with a CTO renders a patient vulnerable for VA. This is strengthened by the observation that CTO’s 
are an independent predictor of VA in patients with ischemic cardiomyopathy and ICDs for primary 
prevention2, 3. Our study is, to the best of our knowledge, the first study which shows that a CTO is also 
an independent predictor of VA in survivors of OHCA with coronary artery disease who receive an ICD. 
 There are several explanations for the increased risk of VA in CTO patients. The substrate of VA 
in patients with ischemic cardiomyopathy is usually a myocardial scar8. Channels of slow conduction, a 
pre-requisite for reentry, can be found within the scar or, more commonly, in the scar-border zone8-10.  It 
is known that the presence of a CTO is associated with ischemia, as measured by fractional flow reserve, 
even in the presence of well-developed collaterals11, 12. Ischemia around the post-infarction necrotic core 
may increase electrical instability and the development of VA. 
Chronic total occlusion and all-cause mortality in ICD recipients
Prior studies in ischemic cardiomyopathy patients who received an ICD as primary prevention have 
shown conflicting results of the effect of a CTO on all-cause mortality2, 13. It is important to realize that 
primary prevention patients have a low ejection fraction, which is a strong predictor of all-cause mortality. 
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In our study cohort of patients who received an ICD for secondary prevention, of which approximately 
half (52%) had a LVEF<35%, the presence of CTO was not associated with a higher mortality rate. 
 The lack of a clear adverse effect of a CTO on all-cause mortality in ICD recipients (either 
primary or secondary prevention) is in contrast to data from non-ICD carriers. A recent meta-analysis, 
not specifically including ICD recipients, showed that failed CTO recanalization is associated with a 
higher risk of all-cause mortality in comparison to those with successful CTO recanalization (odds ratio 
1.92; 95% CI 1.59-2.33)14. This discrepancy in the effect of a CTO on all-cause mortality may be partially 
explained by the prevention of SCD due to VA in ICD recipients. 
Clinical implications and future directions
The results of the present study may have several implications. First, due to technical advances in 
percutaneous coronary intervention techniques, CTO recanalization can be achieved with high success 
rates and low complication rates15. At this moment, there is no compelling evidence that successful CTO 
recanalization during initial hospitalization may reduce VA burden in survivors of OHCA. In the small 
substudy in our cohort, there was no reduction in appropriate ICD therapy in patients who underwent 
recent CTO revascularization before ICD implantation. However, this analysis is hampered by the small 
sample size (n=25, underpowered) and the observational nature of the study design. Appropriately 
designed prospective randomized trials can elucidate this issue. 
 Second, our study supports the causative role of a CTO in the development of VA irrespective 
of the left ventricular function. Interestingly, CTO patients with a LVEF>35% had a similar incidence 
of VA in comparison to non-CTO patients with severe LV dysfunction (LVEF<35%). Previous studies 
have shown that severe LV dysfunction is an important predictor of sudden cardiac death and ICDs 
are indicated as primary prevention in ischemic cardiomyopathy patients with severe LV dysfunction 
primarily based on the results of the MADIT II and SCD-HeFT trials (median LVEF 23-24%)16-18. Previous 
CTO studies demonstrated a higher risk of all-cause mortality and sudden cardiac death rate in patients 
with failed CTO recanalization despite the fact that only a minority (7-11%) had severe LV dysfunction1, 
19. In our study, the presence of a CTO had a similar predictive power as severe LV dysfunction. More 
research is needed to investigate the incidence of VA and the role of a prophylactic ICD in patients with 
failed CTO recanalization and preserved LV function.   
Study limitations
There are several limitations. The current guidelines recommend prolonged detection settings and 
higher tachycardia therapy zone limits to reduce ICD therapy primarily based on the MADIT-RIT trial20. 
These guidelines were published in 2015 and we changed our clinical practice in 2016 (these patients 
are not included in this study). We do not know whether these new settings will change the conclusions 
of our study as they will probably lower the incidence of appropriate ICD therapy both in the CTO 
and non-CTO groups. In addition, we have no complete data on the extent of ischemia in the CTO 
population and thus cannot make a distinction between those with small or moderate/large ischemic 
burden. One can imagine that patients with moderate or large ischemic burden are more prone to VA. 
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Finally, the single-center design may limit generalizability of the data. However, the 3-year mortality rate 
in our study (15%) was similar to the ICD arms of secondary prevention randomized controlled trials21-23.
Conclusion
In OHCA survivors with coronary artery disease, the presence of a CTO is common and is an independent 
predictor of future VA. A CTO was not associated with a higher mortality rate in this secondary prevention 
ICD group. The data support the causative role of a CTO in the development of VA. Further studies are 




1. Godino C, Bassanelli G, Economou FI, Takagi K, Ancona M, Galaverna S, Mangieri A, Magni V, Latib A, Chieffo A, 
Carlino M, Montorfano M, Cappelletti A, Margonato A and Colombo A. Predictors of cardiac death in patients 
with coronary chronic total occlusion not revascularized by PCI. Int J Cardiol. 2013;168:1402-9.
2. Nombela-Franco L, Mitroi CD, Fernandez-Lozano I, Garcia-Touchard A, Toquero J, Castro-Urda V, Fernandez-
Diaz JA, Perez-Pereira E, Beltran-Correas P, Segovia J, Werner GS, Javier G and Luis AP. Ventricular arrhythmias 
among implantable cardioverter-defibrillator recipients for primary prevention: impact of chronic total coronary 
occlusion (VACTO Primary Study). Circulation Arrhythmia and electrophysiology. 2012;5:147-54.
3. Di Marco A, Anguera I, Teruel L, Dallaglio P, Gonzalez-Costello J, Leon V, Nunez E, Manito N, Gomez-Hospital 
JA, Sabate X and Cequier A. Chronic total occlusion of an infarct-related artery: a new predictor of ventricular 
arrhythmias in primary prevention implantable cardioverter defibrillator patients. Europace. 2016.
4. Di Mario C, Werner GS, Sianos G, Galassi AR, Buttner J, Dudek D, Chevalier B, Lefevre T, Schofer J, Koolen J, 
Sievert H, Reimers B, Fajadet J, Colombo A, Gershlick A, Serruys PW and Reifart N. European perspective in the 
recanalisation of Chronic Total Occlusions (CTO): consensus document from the EuroCTO Club. EuroIntervention. 
2007;3:30-43.
5. Authors/Task Force m, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, 
Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa 
Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W and Witkowski A. 2014 ESC/EACTS Guidelines 
on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of 
Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special 
contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European heart 
journal. 2014;35:2541-619.
6. Christofferson RD, Lehmann KG, Martin GV, Every N, Caldwell JH and Kapadia SR. Effect of chronic total coronary 
occlusion on treatment strategy. The American journal of cardiology. 2005;95:1088-91.
7. Werner GS, Gitt AK, Zeymer U, Juenger C, Towae F, Wienbergen H and Senges J. Chronic total coronary occlusions 
in patients with stable angina pectoris: impact on therapy and outcome in present day clinical practice. Clin Res 
Cardiol. 2009;98:435-41.
8. Horowitz LN, Josephson ME and Harken AH. Epicardial and endocardial activation during sustained ventricular 
tachycardia in man. Circulation. 1980;61:1227-38.
9. Arenal A, del Castillo S, Gonzalez-Torrecilla E, Atienza F, Ortiz M, Jimenez J, Puchol A, Garcia J and Almendral J. 
Tachycardia-related channel in the scar tissue in patients with sustained monomorphic ventricular tachycardias: 
influence of the voltage scar definition. Circulation. 2004;110:2568-74.
10. de Bakker JM, van Capelle FJ, Janse MJ, Wilde AA, Coronel R, Becker AE, Dingemans KP, van Hemel NM and 
Hauer RN. Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: 
electrophysiologic and anatomic correlation. Circulation. 1988;77:589-606.
11. Sachdeva R, Agrawal M, Flynn SE, Werner GS and Uretsky BF. The myocardium supplied by a chronic total 
occlusion is a persistently ischemic zone. Catheterization and cardiovascular interventions : official journal of the 
Society for Cardiac Angiography & Interventions. 2014;83:9-16.
CTO AND VENTRICULAR ARRHYTHMIA
119
7
12. Werner GS, Surber R, Ferrari M, Fritzenwanger M and Figulla HR. The functional reserve of collaterals supplying 
long-term chronic total coronary occlusions in patients without prior myocardial infarction. European heart 
journal. 2006;27:2406-12.
13. Raja V, Wiegn P, Obel O, Christakopoulos G, Christopoulos G, Rangan BV, Roesle M, Abdullah SM, Luna M, Addo 
T, Ayers C, Garcia S, de Lemos JA, Banerjee S and Brilakis ES. Impact of Chronic Total Occlusions and Coronary 
Revascularization on All-Cause Mortality and the Incidence of Ventricular Arrhythmias in Patients With Ischemic 
Cardiomyopathy. The American journal of cardiology. 2015;116:1358-62.
14. Christakopoulos GE, Christopoulos G, Carlino M, Jeroudi OM, Roesle M, Rangan BV, Abdullah S, Grodin J, 
Kumbhani DJ, Vo M, Luna M, Alaswad K, Karmpaliotis D, Rinfret S, Garcia S, Banerjee S and Brilakis ES. Meta-
analysis of clinical outcomes of patients who underwent percutaneous coronary interventions for chronic total 
occlusions. The American journal of cardiology. 2015;115:1367-75.
15. Patel VG, Brayton KM, Tamayo A, Mogabgab O, Michael TT, Lo N, Alomar M, Shorrock D, Cipher D, Abdullah 
S, Banerjee S and Brilakis ES. Angiographic success and procedural complications in patients undergoing 
percutaneous coronary chronic total occlusion interventions: a weighted meta-analysis of 18,061 patients from 
65 studies. JACC Cardiovascular interventions. 2013;6:128-36.
16. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, 
McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH and Sudden Cardiac 
Death in Heart Failure Trial I. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. 
The New England journal of medicine. 2005;352:225-37.
17. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML and 
Multicenter Automatic Defibrillator Implantation Trial III. Prophylactic implantation of a defibrillator in patients 
with myocardial infarction and reduced ejection fraction. The New England journal of medicine. 2002;346:877-83.
18. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, 
Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van 
Veldhuisen DJ, Authors/Task Force M and Document R. 2015 ESC Guidelines for the management of patients 
with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management 
of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of 
Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). European 
heart journal. 2015;36:2793-867.
19. Jones DA, Weerackody R, Rathod K, Behar J, Gallagher S, Knight CJ, Kapur A, Jain AK, Rothman MT, Thompson 
CA, Mathur A, Wragg A and Smith EJ. Successful recanalization of chronic total occlusions is associated with 
improved long-term survival. JACC Cardiovascular interventions. 2012;5:380-8.
20. Wilkoff BL, Fauchier L, Stiles MK, Morillo CA, Al-Khatib SM, Almendral J, Aguinaga L, Berger RD, Cuesta A, Daubert 
JP, Dubner S, Ellenbogen KA, Mark Estes NA, 3rd, Fenelon G, Garcia FC, Gasparini M, Haines DE, Healey JS, Hurtwitz 
JL, Keegan R, Kolb C, Kuck KH, Marinskis G, Martinelli M, McGuire M, Molina LG, Okumura K, Proclemer A, Russo 
AM, Singh JP, Swerdlow CD, Teo WS, Uribe W, Viskin S, Wang CC and Zhang S. 2015 HRS/EHRA/APHRS/SOLAECE 
expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart 
rhythm : the official journal of the Heart Rhythm Society. 2016;13:e50-86.
CHAPTER 7
120
21. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, Mitchell LB, Green MS, Klein GJ and O’Brien B. 
Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator 
against amiodarone. Circulation. 2000;101:1297-302.
22. Kuck KH, Cappato R, Siebels J and Ruppel R. Randomized comparison of antiarrhythmic drug therapy with 
implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). 
Circulation. 2000;102:748-54.
23. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-
fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. The New 
England journal of medicine. 1997;337:1576-83.









Frequency of Need for Antitachycardia or 
Antibradycardia Pacing or Cardiac Resynchronization 
Therapy in Patients with a Single-Chamber Implantable 
Cardioverter-Defi brillator
Mireille C. Melles, MSc, Sing-Chien Yap, MD, PhD, Rohit E. Bhagwandien, MD, Rafi  Sakhi, MD; 
Tamas Szili-Torok, MD, PhD, Dominic A.M.J. Theuns, PhD
Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, 
Rotterdam, the Netherlands.




The subcutaneous implantable cardioverter-defibrillator (S-ICD) is unable to deliver antitachycardia 
pacing (ATP), bradycardia pacing, and cardiac resynchronization therapy (CRT). However, little is known 
about the proportion of patients that develop the need for one of these features. We evaluated the 
potential suitability for a S-ICD at the time of first replacement in a cohort of patients with a transvenous 
single-chamber device who did not need bradycardia pacing at the time of implantation. The study 
cohort consisted of patients who received a transvenous single-chamber ICD between 1998 and 
September 2017. The primary endpoint was a combined endpoint of the need for atrial or ventricular 
pacing, development of a CRT indication, or termination of ventricular arrhythmias by ATP delivery. 
During a mean follow-up of 5.6 ± 1.9 years, 78 out of 254 (31%) patients reached the primary endpoint. 
The 7-years cumulative S-ICD suitability rate was 65.6% (95% CI 58.5% – 71.7%). Event rates were 9.5% 
(95% CI 6.5% – 13.9%) at 1-year follow-up, and 28.0% (95% CI 22.8% – 34.2%) at 5-years follow-up. For 
individual endpoints incidence rates were 1.8 (95% CI 1.2 – 2.6) per 100-patient-years for CRT, 0.3 (95% 
CI 0.1 – 0.8) per 100-patient-years for pacing-dependency, and 4.9 (95% CI 3.8 – 6.3) per 100-patient-
years for appropriate ATP therapy. No baseline variables for predicting S-ICD unsuitability were found. In 
conclusion, at the time of the first replacement, 69% of the patients with a single-chamber device would 
have been clinically eligible for the S-ICD. Incidence rates of developing a bradycardia pacing and CRT 
indication are low. 




The implantable cardioverter defibrillator (ICD) has proven to be effective both in primary and secondary 
prevention of sudden cardiac death1-4. However, the transvenous ICD (TV-ICD) has been associated with 
acute and chronic complications due to the use of endovascular leads5-7. Lead failure and infection 
might require extraction, which is associated with a risk of severe complications, reported up to 1.7%8,9. 
Based on this, an entirely subcutaneous implantable defibrillator (S-ICD) has been developed as an 
alternative to the TV-ICD system10. The S-ICD has proven to be competent in terminating ventricular 
arrhythmias with defibrillation11-14. However, a trade-off of the S-ICD is the inability to deliver bradycardia 
pacing, cardiac resynchronization therapy (CRT) and antitachycardia pacing (ATP). Therefore, patients 
who qualify for a single-chamber TV-ICD without an indication for bradycardia pacing or ATP can be 
considered clinically eligible for a S-ICD. When considering these patients, many physicians are still 
reluctant to implant the S-ICD due to potential need for pacing or ATP. However, there is limited data 
on the proportion of patients who actually develop an indication for bradycardia pacing or CRT during 
follow-up. The aim of the study is to determine the need for pacing or ATP at the time of elective device 
replacement in a cohort of patients with a single-chamber TV-ICD who were theoretical eligible for 
a S-ICD at baseline. Predictors of development of an indication for bradycardia pacing or CRT, and 
predictors of monomorphic ventricular arrhythmias which can be terminated by ATP were identified. 
Methods
Patients for this retrospective observational cohort study were obtained from the prospectively collected 
registry of all patients who underwent ICD implantation at the Erasmus Medical Centre, Rotterdam, 
the Netherlands. All patients who received a transvenous single-chamber ICD were identified. Patients 
who were pacemaker dependent or had another indication for bradycardia pacing and those who 
had a secondary prevention indication based on sustained monomorphic ventricular tachycardia 
(VT) were excluded from analysis. For the purpose of the study, the cohort comprised of those who 
underwent generator replacement or upgrade. The study period for inclusion was from November 
1998 to September 2017. The administrative censoring date for analyses was September 2017 for all 
patients alive until that date. The study protocol was approved by the IRB of the Erasmus MC. The ethics 
committee waived the need for written informed consent, since the present study was a retrospective 
cohort analysis of patients with a clinical indication for ICD implantation.
 Data on baseline clinical characteristics, implantation procedures, and scheduled or 
unscheduled follow-up visits were prospectively collected in the Erasmus Medical Center ICD registry. 




 The endpoint of the current study was the inappropriateness for an S-ICD system, which 
was defined as the occurrence of one of the following individual endpoints which ever occurred first: 
The development of an indication for bradycardia therapy, defined as the need for atrial and/or right 
ventricular pacing. If the bradycardia settings of the ICD required reprogramming to a higher lower rate or 
rate adaptive pacing mode, this was also considered an indication for bradycardia therapy. If the patient 
required reprogramming of bradycardia settings or required an upgrade to a dual-chamber device, the 
date of replacement or upgrade was considered the date of endpoint. The development of an indication 
for CRT. If the patient required an upgrade to a CRT-D, the date of upgrade was considered the date of 
endpoint. Termination of ventricular arrhythmias by ATP delivery was considered an endpoint. The date 
of first successful termination of VT by ATP was considered the endpoint. If a patient did not reach one 
of the above endpoints, the patient was censored at the date of elective generator replacement. 
Statistical analysis 
Normality of distribution was assessed by using the Shapiro-Wilk test. Continuous variables are 
presented as mean ± SD or as median with 25th and 75th percentiles, where appropriate. Data were 
compared by the Student t or Mann-Whitney U test, as appropriate. Categorical data are expressed 
as percentages and compared with Fisher’s exact test. The event-free rate of unsuitability for an S-ICD 
system was calculated using the Kaplan-Meier method. The incidence rates of the endpoints upgrade 
(dual-chamber ICD/CRT-D) and ATP delivery were calculated and expressed per 100-patient-years with 
a 2-sided 95% confidence interval (CI). Univariate logistic regression analyses were used to determine 
potential clinical baseline predictors for unsuitability for a S-ICD, with the calculation of ORs with 95% CIs. 
Any variable with a P value < 0.10 was analyzed in a multivariate model. A P value < 0.05 was considered 
significant. All statistical analyses were performed using SPSS, version 24 (IBM Corp, Armonk, NY, USA) 
and STATA, version 12 (Statacorp, College Station, TX, USA. 
Results
During the study period, a total of 1174 patients received a single-chamber TV-ICD. Excluding patients 
that had a secondary prevention indication based on sustained monomorphic VT, 977 patients 
remained. Of these, 269 patients received at least 1 replacement or upgrade. Nine patients were pacing-
dependent at baseline, 5 patients received a re-implantation shortly after the first implantation due to 
an infection, and 1 patient received a replacement in another hospital. Consequently, these patients 
were excluded (Figure 1). The remaining 254 patients were considered the study cohort, with a mean 
age of 53 ± 14 years, majority were male (72%), and structural heart disease was present in 78% of 
patients. Most patients were in sinus rhythm at baseline (91%), with a mean heart rate of 69 ± 13 bpm. 
Other baseline characteristics are presented in Table 1. Beta-blockers were used in 187 (74%) of the 
patients, most of them used bisoprolol (24%), carvedilol (15%), or metoprolol (34%). 
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Table 1. Baseline clinical characteristics
Total group
(n=254)
Age (years) 53 ± 14
Men 183 (72%)
Indication ICD therapy
-    Primary prevention 160 (63%)
-   Secondary prevention 94 (37%)
Coronary artery disease 144 (57%)
-   Myocardial infarction 127 (50%)
Atrial fibrillation 50 (20%)
Inherited primary arrhythmia syndrome 13 (5%)
-   Cardiomyopathy 121 (48%)
-   Dilated 35 (14%)
-   Ischemic 59 (24%)
-   Hypertrophic 14 (6%)
-   Non compaction 11 (4%)
Left ventricular ejection fraction (%) 31 (25, 40)
New York Heart Association class
-   1 99 (39%)
-   2 135 (53%)
-   3 18 (7%)
Diabetes mellitus 41 (16%)
Creatinine (μmol/L) 80 (70, 95)
Electrocardiographic parameters
Rhythm
-   Sinus 232 (91%)
-   Atrium fibrillation 22 (9%)
Heart rate (bpm) 69 ± 13
PR interval (ms) 171 ± 29
QRS duration (ms) 108 (98, 125)
QRS morphology
-   Normal 160 (63%)
-   Left bundle branch block 34 (13%)
-   Right bundle branch block 22 (9%)
-   Intraventricular conduction delay 23 (9%)
Atrioventricular conduction disorder 28 (11%)




Antiarrhythmic medication 214 (84%)
-   Sodium channel blocker* 2 (1%)
-   β-blocker* 187 (74%)
-   Sotalol* 10 (4%)
-   Amiodarone* 30 (12%)
-   Digoxin* 30 (12%)
Calcium antagonists 27 (11%)
ACE inhibitors / ARBs 193 (76%)
Diuretics 126 (50%)
Statins 147 (58%)
Normally distributed continuous data is presented as mean ±SD, non-Gaussian distributed continuous data as 
median (IQR), and categorical data as count (%). *Patients could be using more than 1 antiarrhythmic drug.
Figure 1. Flowchart describing the study population selection. Abbreviation: VT = Ventricular Tachycardia
Table 1. continued
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 The mean interval from fi rst implantation to fi rst elective replacement or upgrade was 5.6 ± 1.9 
years. During follow-up, 78 patients (31%) developed an indication for bradycardia pacing, CRT, and/or 
received ATP for termination of ventricular arrhythmias. These patients are considered non-eligible for the 
S-ICD. In Figure 2, the eligibility rate for S-ICD over time is shown. At 7 years follow-up, S-ICD eligibility rate 
was 66% (95% CI 59% – 72%). Event-rates for unsuitability were 10% (95% CI 7% – 14%) at 1-year follow-up, 
28% (95% CI 23% – 34%) at 5-years follow-up, and 34% (95% CI 28% – 41%) at 7-years follow-up.
Figure 2. Cumulative eligibility rate for the S-ICD over time
 Eight (3.1%) patients developed a bradycardia pacing indication; of which 3 (1.2%) received 
a dual-chamber ICD, 3 received a CRT-D, and 2 patients retained their single-chamber device. In total, 
25 (10%) patients received a CRT-D. The total follow-up period until the fi rst re-implantation was 1358.1 
years, which yields a total upgrade and bradycardia pacing indication rate of 2.1 (95% CI 1.4 – 3.0) per 
100-patient-years, 1.8 (95% CI 1.2 – 2.6) per 100-patient-years in case of CRT-D, and 0.3 (95% CI 0.1 – 
0.8) per 100-patient-years in case of dual-chamber ICD and bradycardia pacing. The indications for 
an upgrade to a dual-chamber ICD were symptomatic bradycardia in 2 patients and the presence of 
supraventricular tachycardia’s in 1 patient. Thirteen patients received a CRT-D upgrade based a class I 
recommendation, 1 based on a class IIa recommendation, and 2 based on a class IIb recommendation.15
The remaining 9 patients (36%) received a CRT-D at the discretion of the physician. Monomorphic VT 
terminated by ATP was observed in 57 patients (22%), yielding an incidence rate of 4.9 (95% CI 3.8 – 6.3) 
CHAPTER 8
132
per 100-patient-years. The mean cycle length of the VT was 315 ± 36 ms. In Figure 3, the cumulative 
event-rates for individual and combined endpoints are presented.
 Univariate regression analysis was performed in order to establish baseline predictors of 
unsuitability for a S-ICD (Table 2). Multivariate logistic regression analysis controlling for variables with 
a univariate P-value < 0.1 revealed that none were signifi cant predictive variables. A regression analysis 
specifi cally to predict ATP therapy identifi ed no variables. An analysis to predict bradycardia pacing and/
or CRT indication was not possible due to small sample size.
Figure 3. Cumulative event rates for the individual endpoints and combined endpoint. Solid line – combined 
endpoint; long dashed line – ATP therapy; squared dotted line – bradycardia pacing and CRT indication. Abbreviations: 
ATP = Antitachycardia Pacing; CRT = Cardiac Resynchronization Therapy.
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Table 2. Univariate and multivariate regression analysis for the occurrence of the primary endpoint
Logistic regression analysis Univariate analysis
Multivariate analysis
Variables OR 95% CI P-value P-value
IPAS 0.17 (0.02 - 1.36) 0.10 1.00
Cardiomyopathy 1.60 (0.94 - 2.73) 0.09 0.59
LVEF (%) 0.97 (0.94 - 0.99) 0.01 0.08
Creatinine (μmol/L) 1.01 (0.99 - 1.02) 0.10 0.90
PR duration (ms) 1.01 (1.00 - 1.02) 0.02 0.05
QRS duration (ms) 1.01 (1.00 - 1.02) 0.03 0.36
Non-normal QRS morphology 1.97 (1.14 - 3.39) 0.02 0.05
Amiodarone therapy 2.50 (1.16 - 5.41) 0.02 0.71
Abbreviations: IPAS = Inherited Primary Arrhythmia Syndromes; LVEF = left ventricular ejection fraction.
 The mean interval until re-implantation was significantly different between elective 
replacement and upgrade for bradycardia pacing and CRT indication group, respectively 5.8 ± 1.7 years 
vs. 3.6 ± 2.2 years (P < 0.001). Differences in ECG parameters between groups are presented in Table 3. 
No difference in heart rate was seen in the upgrade group over time. Beta-blocker therapy is presented 
in Table 4. In total, 187 (74%) at baseline vs. 191 patients (75%) at the time of the first replacement were 
taking beta-blockers (P = 0.52). For the replacement and upgrade group respectively, 166 (74%) vs. 168 
(75%) (P = 0.64), and 21 (70%) vs. 23 (77%) (P = 0.56). Pearson correlation showed no correlation between 
difference in heart rate over time and difference in daily dosage of bisoprolol over time (r = -0.21, P = 
0.16), carvedilol over time (r = -0.17, P = 0.95), and metoprolol over time (r =-0.08, P = 0.56. 
Table 3. Electrocardiographic parameters at baseline and follow-up 
Baseline (t0) Replacement (t1) P-value
Heart rate (bpm)
-    Total 69 ± 13 65 ± 12 <0.001*
-    Replacement 69 ± 13 65 ± 12 <0.001*
-    Bradycardia/CRT 68 ± 14 68 ± 16 0.88
PR interval (ms)
-    Total 171 ± 26 182 ± 33 <0.001*
-    Replacement 168 ± 25 179 ± 31 <0.001*
-    Bradycardia/CRT 192 ± 30 208 ± 40 0.003*
QRS duration (ms)
-    Total 114 ± 24 125 ± 31 <0.001*
-    Replacement 112 ± 22 121 ± 28 <0.001*
-    Bradycardia/CRT 129 ± 29 156 ± 33 <0.001*
Data are presented as mean ± SD. P-values are computed by (paired) Student T test. * P-value < 0.05 was considered 
significant. Abbreviation: CRT = Cardiac Resynchronization Therapy.
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Table 4. Beta-blocker therapy at baseline and follow-up
Baseline (t0) Replacement (t1) P-value
Daily dose bisoprolol (mg)
-    Total 4.3 ± 3.7 5.4 ± 3.7 0.07
-    Replacement 4.4 ± 3.8 5.6 ± 3.8 0.09
-    Bradycardia/CRT 3.3 ± 2.4 4.0 ± 2.9 0.58
Daily dose carvedilol (mg)
-    Total 26.5 ± 20.7 33.2 ± 23.5 0.20
-    Replacement 27.6 ± 20.7 33.5 ± 24.5 0.30
-    Bradycardia/CRT 6.25, 6.25* 31.3 ± 12.5 0.06
Daily dose metoprolol (mg)
-    Total 90.5 ± 59.7 80.4 ± 48.3 0.25
-    Replacement 89.6 ± 59.0 77.6 ± 46.5 0.18
-    Bradycardia/CRT 96.6 ± 67.1 107 ± 60.7 0.74
Data are presented as mean ± SD. P-values are computed by Student T test. * Only two patients, daily dose carvedilol 
in both patients 6.25 mg
Discussion
We found that the majority of the patients (69%) implanted with a transvenous single-chamber ICD 
would still have been theoretical eligible for the S-ICD, retrospectively, at time of replacement of the 
device. Non-eligibility was caused more often by appropriate ATP therapy (4.9 per 100-patient-years), 
than by the development of bradycardia pacing or CRT indication (2.1 per 100-patients-years). We did 
not find any baseline determinants that could be used to predict if a patient is unsuitable for a S-ICD.
 So far little was known about the proportion of patients that develop a bradycardia pacing 
indication and the need for CRT. It is difficult to place our findings in relation to those of other studies, 
due to differences in sample size, study design, definitions and follow-up duration. Analysis of the IDE trial 
and the EFFORTLESS S-ICD registry showed very low explantation rates of the S-ICD for both the need 
for bradycardia pacing and CRT (0.1 – 0.4%)13,14. Other studies described a higher need for bradycardia 
pacing. Namely, De Bie et al.16 evaluated in a comparable study that the S-ICD eligibility was 55% after 
5-years follow-up, compared to 72% after 5-years follow-up in our study. It is striking that they found that 
11% had developed a bradycardia pacing indication. However, this might be an overestimation, as a 20% 
ventricular pacing burden was used as a cut-off for pacing-dependency. Besides, they included patients 
with a dual-chamber ICD with a DDI 40 non-tracking backup mode at baseline. The development of a 
CRT indication is comparable, given follow-up duration. Also, the DAVID trial17 mentioned in 2002 that 
3.9% of the VVI patients crossed over to a dual-chamber device in a median follow-up of only 8.4 (0 – 23.6) 
months. Finally, Grett et al.18 found in a retrospective study that in 2.2 years of follow-up 15% developed 
a pacemaker indication, and 0.8% developed the need for CRT. However, the indication for a pacemaker 
NEED FOR PACING IN SINGLE-CHAMBER ICDs
135
8
may be overestimated, as some patients (7.4%) already had a high risk of pacemaker dependency at 
baseline. Thus, it seems that event-rates for both indications are low, as seen in our results.
 One of the most important disadvantage of the S-ICD is the incapability to deliver ATP therapy, 
since painful ICD shocks are associated with a reduced quality of life19. We found that 22% of the patients 
experienced appropriate ATP therapy. A median of 4 (1;8) VT episodes per patient were treated with 
ATP during 5.6 ± 1.9 years of follow-up. Grett et al.18 found a comparable amount of ATP therapy, given 
follow-up duration. De Bie et al.16 found that 27% have had ATP therapy, but in a shorter follow-up 
period. Yet, Auricchio et al.20 found, during a follow-up of 22 ± 9 months, an 1-year incidence rate of 
4.3% for appropriate ATP therapy in patients with a single-chamber ICD, and a 2-years incidence rate of 
7.2%. However, these studies did not assess the number of ATP treatments per person, so no statements 
can be made about grading how much a patient would have benefitted from ATP therapy. In addition, 
Burke et al.13 found that after a mean follow-up of 1.8 ± 0.9 years only 0.1% of the S-ICDs were explanted 
because of the need for ATP, and 0.1% because of VT storms attempted to suppress with overdrive 
pacing. In the long-term follow-up of the EFFORTLESS registry, Boersma et al.14 showed that 5.8% of 
patients experienced a shock for at least 1 sustained monomorphic VT episode in 3.1 years; 2.2% of 
patients experienced shocks for more than 1 monomorphic VT episodes. Only 0.5% had their S-ICD 
removed for perceived need for ATP over a follow-up of 3.1 ± 1.5 years. Therefore, the actual rate of 
patients that would benefit ATP therapy, once implanted with the S-ICD, is probably lower than seen in 
our results. Unfortunately, our study did not find any baseline characteristics that could predict the need 
for ATP in the future.
 The differences in ECG parameters between patients that develop the need for bradycardia 
pacing or CRT and patients with an elective replacement, may be due to worsening of the heart 
function mainly in the CRT group at time of the upgrade. The association between beta-blockers and the 
proportion of patients that develop a pacing indication was not objectified before. Our results suggest 
that the association between increasing of the dosage beta-blockers and lowering of the heart rate is 
not clinically relevant. For those who received an upgrade no increase in daily dosage beta-blocker has 
been observed between baseline and the time of upgrade. 
 Although we did not find any predictive variables for unsuitability for the S-ICD, QRS duration 
had a P-value below 0.05 in the univariate regression. De Bie et al.16 found QRS duration as a significant 
predictive variable in the multivariate analysis. Possibly, patients with a wider QRS complex at baseline 
will benefit less from a S-ICD, due to a larger chance of needing CRT in the future. Given the outcome 
that only a small amount of patients develop the need for pacing and/or CRT, the inability to give ATP 
still remains the biggest disadvantage of the S-ICD. Future studies should investigate if patients with 
a S-ICD receive more appropriate shocks, because ATP therapy is not possible. A randomized clinical 
trial like PRAETORIAN is needed to assess the superiority or non-inferiority of the S-ICD compared to 
the contemporary TV-ICD21. Also, a new subcutaneous device should be generated, with the same 
advantages of the current S-ICD, only with the ability to give ATP therapy.
 Since this was a retrospective study, potential limitations regarding uniformity of data 
collection, clinical missing data and ascertainment bias could not be excluded. Based on the inclusion 
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criteria of the study, potential selection bias could not be excluded. Also, some subgroups have a small 
sample size. Finally, all patients who did not reach the endpoint of this study were considered potential 
candidates for the S-ICD, however, other factors that determine eligibility for the S-ICD, like QRS and 
T-wave morphology and vector screening, and patients’ preference were not assessed. 
 At time of the first replacement of the device, 69% of the patients implanted with a single-
chamber TV-ICD would still have been potentially eligible for the S-ICD. Only a small amount of patients 
that are suitable for a S-ICD at baseline developed an indication for bradycardia pacing and/or CRT. 
Distinguishing patients at baseline that would be ineligible for the S-ICD during follow-up is not possible 
on the basis of our study. 
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Background: The manufacturer has developed a new ECG screening tool to determine eligibility for 
the subcutaneous ICD (S-ICD), the “automatic screening tool” (AST), which may render manual ECG-
screening unnecessary. The aim of the study was to determine the eligibility for the S-ICD using two 
methods (manual ECG-screening versus AST) in different patient categories including patients with 
cardiomyopathy, congenital heart disease and inherited primary arrhythmia syndrome.
Methods: We prospectively evaluated the ECG suitability for an S-ICD in consecutive patients at our 
outpatient clinic between February and June 2017. The primary endpoint of the study was ECG eligibility 
defined as at least 1 successful vector in both supine and sitting postures.
Results: A total of 254 patients (167 men; mean age 45 ± 16 years) were screened using both methods. 
Overall, there was a high ECG eligibility using either method (93% versus 92%, P=0.45). Overall agreement 
between both methods was 94%. Patients with hypertrophic cardiomyopathy (HCM) more often had 
a failed screening test using either test in comparison to the patients without HCM (manual: odds ratio 
[OR] 3.3, 95% confidence interval [CI] 1.2-9.3, P=0.02; AST: OR 3.0, 95% CI 1.2-7.6, P=0.02). 
Conclusion: AST showed a high agreement with manual ECG-screening for S-ICD. Overall there was a 
high ECG eligibility for S-ICD, although patients with HCM had a lower passing rate irrespective of the 
screening method.




Implantable cardiac defibrillators (ICD) are highly effective in preventing sudden cardiac death (SCD) 
due to malignant ventricular arrhythmias1-4. Conventional transvenous ICD (TV-ICD) systems are 
often associated with short- and long-term complications due to placement of endovascular leads5, 
6. Therefore, an entirely subcutaneous implantable defibrillator (S-ICD) system has been developed 
as an alternative to TV-ICD7. Previous studies have proven the efficacy and safety of S-ICD therapy in 
primary and secondary prevention of SCD8-10. However, the advantage of the S-ICD is partially offset 
by the presence of inappropriate shocks due to QRS/T-wave oversensing11-13. In order to prevent S-ICD 
implantation in patients susceptible for sensing problems, a pre-implantation ECG screening has been 
developed to identify patients that are likely to have an unsuitable subcutaneous ECG. Conventionally, 
the eligibility for S-ICD is mainly based on template ECG morphology screening, in which QRS-complex 
and T-wave morphology are manually evaluated (manual ECG-screening). Approximately 7% to 11% 
of patients are considered not eligible for S-ICD implantation based on manual ECG screening 14-16. 
Recently, the manufacturer (Boston Scientific, Natick, MA, USA) developed an automatic screening tool 
(AST), which aims to automatically identify the eligibility for S-ICD. The performance of AST has not been 
assessed.
 The aim the study was to determine the difference between manual ECG-screening and AST, 
and to determine the eligibility of patients with structural heart disease (SHD) or an inherited primary 
arrhythmia syndrome (IPAS) for an S-ICD using both screening methods.
Methods
Study population
This single center, prospective study evaluates the eligibility for S-ICD by using the conventional manual 
ECG-screening and the novel AST. From February 2017 to June 2017, all consecutive patients with SHD 
or IPAS were screened during their routine visit at the outpatient clinic. Exclusion criteria were ≥ 3% 
ventricular pacing, cardiac resynchronization therapy and patients with paced QRS-complex during 
screening. All included patients provided informed consent to participate in the study, and the study 
was approved by the institutional review board of the Erasmus Medical Center, MEC-2017-035.
ECG data collection
The S-ICD system (Boston Scientific, Natick, MA, USA) utilizes 3 sensing electrodes to monitor the cardiac 
electrical activity (A, distal from the sternal defibrillation coil; B, proximal from the sternal defibrillation 
coil; C, pulse generator (CAN) implanted at the left-lateral midaxillary line). These electrodes represent 
3 vector projections of cardiac electrical conduction (secondary: A-to-CAN, primary: B-to-CAN, and 
alternate: A-to-B). In order to mimic the S-ICD sensing vectors, 3 bipolar limb lead electrodes were placed 
in the same configuration as advised by the manufacturer. The left arm (LA) electrode was placed one cm 
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left lateral of the xiphoid, the right arm (RA) electrode was placed 14 cm cranial to the LA-electrode and 
the left leg (LL) electrode was placed at the 5th intercostal space along the mid-axillary line representing 
the proximal, distal sensing electrode and pulse generator of the S-ICD system, respectively. The ground 
electrode (RL) was placed on the lower torso to ensure that other leads positions were undisturbed. The 
derived bipolar leads represent the S-ICD sense vectors (Alternate = Lead I, Secondary = Lead II, and 
Primary = Lead III) (Figure 1A).
Figure 1. Panel A. Diagram of S-ICD sensing vectors and the exact placements limb-lead electrodes; Panel B. Diagram 
of S-ICD sensing vectors and placements limp-lead electrodes.
Manual ECG screening
A 3-lead ECG was obtained by a standard ECG-recorder at a paper speed of 25mm/s for a period of 10 
seconds. This process was repeated in both supine and sitting posture at three diff erent ECG-gains (5, 10 
and 20 mm/mV). The recorded ECGs were evaluated by using the standard manual ECG-screening tool 
provided by Boston Scientifi c. This tool consists of six colored profi les that corresponds to the automatic 
gain settings of the S-ICD. Based on current recommendation, a patient is considered eligible for S-ICD 
if all complexes in 10-second strip of at least one sense vector pass the screening process in at least 2 
postures. The manual ECG screening tool rejects complexes in which the QRS amplitude is too large, 
too small, or the ratio of QRS amplitude to T-wave amplitude is insuffi  cient. The availability of a second 
appropriate sensing vector may reduce the chance of cardiac signal oversensing by reprogramming a 
diff erent sensing vector. In order to allow both the physician and the device to optimize the sensing 
vector after implantation, multiple appropriate (≥2 vector) sensing vector was evaluated.
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 In order to assess the inter-observer variability of the manual ECG-screening, the surface ECGs 
of 50 randomly selected patients were reevaluated. This was performed independently in a blind fashion 
by two investigators (SCY and DAMJT). 
Automatic screening tool
The automatic screening tool (AST, Model 2889, EMBLEM S-ICD) is a new application that automatically 
determines the eligibility for S-ICD. This novel application is available on the Boston Scientific Zoom 
programmer (3120 zoom LATITUDE) and is a proposed alternative to the manual ECG-screening. Using 
the Boston Scientific Zoom programmer, a 3-lead surface ECG, with the same configuration as for the 
manual ECG-screening, was recorded for at least 10 seconds in both supine and sitting postures (Figure 
1B). Subsequently, AST summarized the eligibility for S-ICD per sense vector for both postures and 
provided for each vector-posture combination the ECG data that were used during the screening. A 
patient was considered eligible for S-ICD if at least 1 vector passed the screening process in both supine 
and sitting postures.
 AST uses the measured QRS amplitude and QRS/T-wave ratio to determine the appropriateness 
of the sensing vectors just like the Vector SelectTM algorithm when the S-ICD system is implanted. In fact, 
AST resembles the S-ICD sensing scheme which reduces subjectivity associated with the manual ECG 
screening.
Statistical analysis
Continuous data are presented as mean ± standard deviation if the data were normally distributed, or 
as median with interquartile range (25th and 75th percentile), where appropriate. Categorical variables 
are presented by frequencies and percentages. Differences of continuous variables between groups 
were analyzed with the unpaired Student’s t-test. Differences between unpaired categorical variables 
were evaluated using the Chi-square test or the Fisher’s exact test, as appropriate. Paired nominal data 
were compared with the McNemar Chi-square test. In the absence of a gold standard, the manual ECG-
screening method was considered the reference method. Inter-observer agreement was evaluated 
using the Cohen’s Kappa statistics. A P-value <0.05 was considered statistically significant. Statistical 
analyses were performed using SPSS version 21.
Results
Study population
The study cohort consisted 254 patients who underwent both manual ECG-screening and AST in both 
supine and sitting postures at the same day. The population was predominantly male (66%) with a mean 
age of 45 ± 16 years. SHD was present in 194 patients (76%); cardiomyopathies (n=126) and congenital 
heart disease (CHD, n=68), and IPAS was present in 60 patients (24%). Further baseline characteristics 
are presented in Table 1. Seventy-five patients already had a transvenous ICD system, single-chamber in 
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61 patients and dual-chamber in 14. For all patients, the percentage right ventricular pacing was < 3%. 
Twenty-five patients already carried an S-ICD, while 10 received a subcutaneous system after screening.








Male gender 167 (66%) 154 (65%) 13 (76%) 0.34
Age, years 45 ± 16 45 ± 16 44 ± 16 0.70
Body mass index, kg/m2 26.1 ± 4.5 26.2 ± 4.5 25.0 ± 5.0 0.39
Implantable cardioverter-defibrillator 110 (43%) 104 (44%) 6 (35%) 0.49
-    Primary prevention indication 70 (28%) 67 (28%) 3 (18%) 0.67
-    Secondary prevention indication 40 (16%) 37 (16%) 3 (18%) 0.74
Cardiac diagnosis
Structural heart disease 194 (76%) 180 (76%) 14 (82%) 0.77
-    Cardiomyopathy 126 (50%) 117 (49%) 9 (53%) 0.78
Hypertrophic cardiomyopathy 48 (19%) 41 (17%) 7 (41%) 0.02
Ischemic cardiomyopathy 31 (12%) 29 (12%) 2 (12%) 1.00
Non-ischemic cardiomyopathy 22 (9%) 22 (9%) 0 0.38
Non-compaction cardiomyopathy 11 (4%) 11 (5%) 0 1.00
Arrhythmogenic right ventricular cardiomyopathy 14 (6%) 14 (6%) 0 0.61
-    Congenital heart disease 68 (27%) 63 (27%) 5 (29%) 0.80
Tetralogy of Fallot 25 (10%) 22 (9%) 3 (18%) 0.23
TGA-arterial switch 15 (6%) 14 (6%) 1 (6%) 1.00
TGA-Mustard/Senning 18 (7%) 18 (8%) 0 0.62
Fontan circulation 10 (4%) 9 (4%) 1 (6%) 0.51
Inherited primary arrhythmia syndrome 60 (24%) 57 (24%) 3 (18%) 0.77
-    Brugada syndrome 37 (15%) 35 (15%) 2 (12%) 1.00
Ajmaline induced type 1 ECG 27 (11%) 26 (11%) 1 (6%) 1.00
Spontaneous type 1 ECG 10 (4%) 9 (4%) 1 (6%) 0.51
-    Idiopathic VF 13 (5%) 12 (5%) 1 (6%) 0.60
-    Long QT syndrome 10 (4%) 10 (4%) 0 1.00
Data are presented as mean ± SD, categorical data as n(%). Abbreviations: TGA = transposition of the great arteries; 
VF = ventricular fibrillation
S-ICD eligibility rate
Overall, 237 patients (93%) were eligible for S-ICD implantation and 17 (7%) ineligible using the ≥ 1 
vector pass criterion (manual ECG-screening). Baseline characteristics stratified by S-ICD eligibility 
are presented in Table 1. There were no differences in demographics, ICD indication, and underlying 
etiology between patients who passed and those who failed manual ECG screening (Table 1). However, 
hypertrophic cardiomyopathy (HCM) was more prevalent in patients who were ineligible for S-ICD 
implantation compared to those who were eligible (41% vs. 17%; P = 0.02).
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 When using AST, 233 patients (92%) were eligible for S-ICD. Similar to manual ECG-screening, 
no differences in baseline characteristics were found between patients who passed and those who 
failed screening by AST, except for HCM. Proportionally, HCM patients who were ineligible for S-ICD 
implantation were higher compared to those who were eligible (38% vs. 17%; P = 0.02). Taken together, 
HCM patients had a higher risk to fail ECG screening test using either method in comparison to the 
total population (manual ECG-screening: odds ratio [OR] 3.3, 95% confidence interval [CI] 1.2 - 9.3, P 
= 0.02; AST: OR 3.0, 95% CI 1.2 - 7.6, P = 0.02). When using the stringent ≥ 2 vector pass criterion, the 
S-ICD eligibility rate was 80% for manual ECG-screening and 83% for AST. Considering inter-observer 
agreement, manual ECG-screening proved to be reproducible, with a Cohen’s Kappa of 0.88 and 0.79, for 
≥ 1 and ≥ 2 vector pass criterion, respectively.
Overall vector eligibility
In order for a vector to pass, that vector had to satisfy the ECG screening template (at any gain) in both 
the erect and supine position. In manual ECG-screening the highest pass rate was observed for the 
primary sensing vector (78%), followed by the secondary sensing vector (75%). The alternate sensing 
vector had the lowest pass rate (57%). Similar pass rates were found when using AST; 80%, 77%, and 
59%, for primary, secondary, and alternate sensing vector respectively. Overall, pass rates were higher 
for the primary and secondary sensing vector compared to the alternate sensing vector in both manual 
ECG-screening and AST (P < 0.001).
 Comparison manual and automatic ECG-screening 
The S-ICD eligibility rates for both screening methods are presented in Table 2. Overall, the S-ICD 
eligibility rate was not different between manual ECG-screening and AST (93%, 95% CI [90%-96%] vs. 
92%, 95% CI [88% - 95%]; P = 0.45). The overall agreement for the patient population between manual 
ECG-screening and AST was 94%. Discrepancy between the two screening methods was observed in 
16 patients (6%). In 4% of the patients  manual ECG-screening showed at least 1 suitable vector while 
AST demonstrated no suitable vector. In contrast, in 2% of patients AST showed at least 1 suitable vector 




Table 2. Eligibility for subcutaneous ICD implantation based on ≥ 1 vector passing
Manual AST P-value
Structural heart disease (n=194) 180 (93) 175 (90) 0.30
-    Cardiomyopathy (n=126) 117 (93) 115 (91) 0.75
Hypertrophic cardiomyopathy (n=48) 41 (85) 40 (83) 1.00
Ischemic cardiomyopathy (n=31) 29 (94) 29 (94) 1.00
Non-ischemic dilated cardiomyopathy (n=22) 22 (100) 21 (96) 1.00
Non-compaction cardiomyopathy (n=11) 11 (100) 11 (100) 1.00
Arrhythmogenic right ventricular cardiomyopathy (n=14) 14 (100) 14 (100) 1.00
-    Congenital heart disease (n=68) 63 (93) 60 (88) 0.76
Tetralogy of Fallot (n=25) 22 (88) 22 (88) 1.00
TGA-arterial switch (n=15) 14 (93) 13 (87) 1.00
TGA-Mustard/Senning (n=18) 18 (100) 17 (94) 1.00
Fontan circulation (n=10) 9 (90) 8 (80) 1.00
Inherited primary arrhythmia syndrome (n=60) 57 (95) 58 (97) 1.00
-    Brugada syndrome (n=37) 35 (95) 36 (97) 1.00
Ajmaline induced type 1 ECG (n=27) 26 (96) 26 (96) 1.00
Spontaneous type 1 ECG (n=10) 9 (90) 10 (100) 1.00
-    Idiopathic VF (n=13) 12 (92) 12 (92) 1.00
-    Long QT syndrome (n=10) 10 (100) 10 (100) 1.00
Total (n=254) 237 (93) 233 (92) 0.45
Data are presented as categorical data as n(%).  Abbreviations: TGA = transposition of the great arteries; VF = 
ventricular fibrillation 
Considering a vector-based analysis, the frequency of pass and failure per vector for both screening 
methods are presented in Table 3. Discordance between manual ECG-screening and AST was highest 
in the alternate sensing vector (24%), followed by primary (16%) and secondary sensing vector (15%). 
When comparing both screening methods per sensing vector, no significant difference in agreement/
discordance was observed. 
Follow-up of S-ICD patients
The median follow-up of the S-ICD patients was 34 months (interquartile range: 11 to 62 months). 
Inappropriate ICD therapy was observed in 4 patients. Of these, one patient experienced an 
inappropriate shock due to QRS/T-wave oversensing caused by attenuation of the QRS complex. Two 
patients experienced an inappropriate due to a supraventricular arrhythmia detected in the shock zone. 
One patient received an inappropriate shock immediately post-implantation due to oversensing of low-
amplitude signals and artefacts. These signals were caused by air entrapment at the proximal sensing 
electrode. All patients with inappropriate shocks had ≥ 2 suitable vectors with either screening method.
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Table 3. Eligibility for S-ICD implantation per vector for manual and automatic ECG screening
Automatic Screening Tool
Primary vector Secondary vector Alternate vector
Manual ECG-screening Fail Pass Fail Pass Fail Pass
Primary vector Fail 33 23 - - - -
Pass 17 181 - - - -
Secondary vector Fail - - 42 22 - -
Pass - - 16 174 --
Alternate vector Fail - - - - 75 34
Pass - - - - 28 117
Data are presented as frequencies
Discussion
In the present study, we compared the eligibility for the S-ICD system in a large cohort of patients using 
the conventional (manual ECG-screening) and novel (AST) ECG-screening system. The main finding of 
the study was that AST had a similar performance as manual ECG-screening. In addition, we provide 
an overview of the passing rates in different patient categories using the both screening methods. In 
comparison to other structural or electrical heart diseases, patients with HCM demonstrated a lower 
passing rate.
Advantages of AST
The manual ECG-screening for S-ICD was developed by the manufacturer to identify patients who might 
be susceptible to QRS-T-wave oversensing and, therefore, are at higher risk for inappropriate shocks. 
According to the current literature, the overall eligibility rate for S-ICD, based on manual ECG-screening, 
range from 85% to 93% for ≥ 1 successful vector in an unselected cardiac patient cohort14, 15. This is in line 
with the results of the present study (93% passing rate for manual ECG-screening).
 Despite the high inter-observer and inter-test agreement, manual ECG-screening system is 
time consuming and is subject to the clinicians observation and interpretations. Investigators should 
also be briefly trained before using the manual ECG-screening system. In contrast to the manual 
ECG-screening, AST eliminates the inter- and intra-observer variability. In our study, AST has a similar 
performance as manual ECG-screening with a low proportion of disagreement. This result is in line with 
2 recent published studies evaluating the performance of AST compared to manual ECG-screening. 
The study by Francia et al.17 reported similar eligibility rates, 91% with manual ECG-screening and 94% 
with AST in 235 patients with an indication for ICD. More recently, Bogeholz et al.18 found that eligibility 




S-ICD eligibility in different patient populations
There are limited studies addressing the eligibility for S-ICD in patients with SHD and IPAS. Only three 
studies have assessed the eligibility for S-ICD in patients with cardiomyopathy, however, these studies 
specifically addressed patients with HCM19-21. The 1-vector passing rate using manual ECG-screening 
in our HCM population was 85% which is in agreement with the data of 2 previous papersa19, 20. 
However, the study by Srinivasan et al.21 reported a much lower passing rate of 62%. This may be to the 
requirement of a suitable vector during exercise testing in the last study, which we did not perform. 
However, the present study followed the pre-implant screening method for S-ICD, as recommended by 
the manufacturer, which does not require exercise testing.
 Despite the promising advantages of the S-ICD in patients with CHD, there are limited data 
available whether the sensing algorithm of the S-ICD is appropriate in these patients. According to the 
study of Zeb et al.22, which evaluated the eligibility of patients with CHD for S-ICD based on ≥ 1 successful 
vector, 88% of the patients with CHD were considered eligible for S-ICD. Our study reported a similar 
passing rate for both screenings methods (manual ECG-screening 93% and AST 88%). The screening 
tools were developed using data from normal heart orientation. However, in line with the latter study, 
there were no differences in the eligibility for S-ICD between the different CHD diagnosis. We recognize 
that some patients with CHD may require a personalized position of their subcutaneous electrode 
due to unusual cardiac anatomy and atypical ECG characteristics. The use of right-sided parasternal 
lead position has been shown to achieve appropriate S-ICD sensing vector in selected patients with 
transposition of the great arteries, tetralogy of Fallot and Fontan circulation23-25.
 Limited studies investigated the eligibility for S-ICD in patients with IPAS, most studies involved 
patients with Brugada syndrome. In the study of Conte et al.26, 87% of the patients with IPAS passed the 
screening for S-ICD based on ≥1 successful vector, which was similar to the results of both manual ECG-
screening and AST of the present study. Previous studies demonstrated a lower passing rate (81%-82%) 
for Brugada patients, especially in those with spontaneous type 1 Brugada syndrome26-28. In our study, 
the passing rate was high (95%). Patients with spontaneous type 1 Brugada syndrome had numerically 
a lower passing rate (90%), but this was not statistically different from patients with ajmalin-induced 
Brugada syndrome (P=0.47 manual ECG-screening and P=0.73 AST). This discrepancy in passing rate 
with previous publication may be explained by the lower proportion of patients with spontaneous 
Brugada pattern in our cohort.
 The eligibility for S-ICD based on ≥ 2 successful vectors has been investigated in only two 
studies16, 20. In line with the study of Randles et al.16, which reported an overall passing rate of 85% for ≥2 
successful vectors in an unselected cardiac patient cohort, the overall passing rate of the present study 
was 80% for the manual ECG-screening and 83% for AST.
Clinical implications
The manual ECG-screening method has been developed to identify patients that are likely to have an 
unsuitable subcutaneous ECG. Zeb et al.29 investigated the performance of the manual ECG-screening 
tool and reported a sensitivity of 95% and specificity of 79%. Despite the high sensitivity of manual 
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ECG screening, inappropriate shocks are still mainly caused by QRS/T-wave oversensing30. The current 
study evaluated the performance of AST compared to manual ECG-screening and no differences in 
S-ICD eligibility rate were observed. During follow-up, one patient experienced an inappropriate shock 
due to QRS/T-wave oversensing caused by attenuation of the QRS complex. The question arises how 
to increase specificity in order to decrease the number of patients experiencing inappropriate shocks? 
Brouwer et al. investigated algorithm-based screening by using an external S-ICD31. This method may 
improve the identification of eligible S-ICD candidates but needs further investigation. Despite the fact 
that AST resembles the Vector SelectTM algorithm of the S-ICD, a mismatch between the selected sensing 
vector by the S-ICD and AST in a considerable fraction of patients18. Of note, one has to keep in mind that 
transient causes of QRS/T-wave oversensing due to attenuation of the QRS complex or air entrapment 
cannot be detected by ECG screening methods.
Study limitations
The present study addressed the eligibility for S-ICD in a large cohort of patients with SHD and IPAS using 
both manual ECG-screening and AST, certain limitations are present. Since the ECGs were collected from 
awake individuals at rest, the passing rate for an S-ICD might be overestimated due to ECG changes 
under certain conditions such as enhanced vagal tone during sleeping or exercise. Application of S-ICD 
screening test during exercise is suggested to identify T-wave oversensing and would likely result in a 
greater failure rate. Another limitation might be that the study cohort consisted of patients with and 
without an ICD indication. However, when comparing the S-ICD eligibility rate between patients with 
and without an ICD indication, no difference was found (P = 0.61).
Conclusion
The present study shows that AST is an appropriate alternative to the manual ECG-screening for S-ICD 
systems. The eligibility for S-ICD implantation is high in patients with SHD and IPAS, although patients 
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The avoidance of transvenous leads is the key innovation of the Subcutaneous ICD (S-ICD) carrying the 
benefits of preventing long-term vascular complications & lead issues requiring potentially hazardous 
interventions especially extraction. However, this brings the challenge of ensuring optimal sensing of 
ventricular arrhythmias in the absence of intracardiac electrograms. By utilizing the 3 sensing vectors 
to differentiate the R wave from the T wave, very effective sensing is possible avoiding unnecessary 
shocks for SVT outperforming transvenous device algorithms for the latter1. However, there are two 
major sources of concern: Surface ECG screening could “rule out” potentially eligible patients and the risk 
of T wave oversensing causing inappropriate shocks. 
 The risk of unnecessary exclusion relates to the possibility of human error with manual 
screening using a “ruler and paper”. Also, the printed ECG does not fully represent the signal the device 
actually sees because it is derived between 2 skin electrodes rather than between the subcutaneous 
lead & generator, it is also processed by a VectorSelectTM sensing algorithm in the implanted S-ICD. 
 Manual screening has a positive predictive value of only 59% and negative predictive value 
of 98% when compared to the S-ICD’s sensing2. This has resulted in a drive to standardize the screening 
process and ideally match the signals & processing to the in-situ S-ICD. The introduction of the Automated 
Screening Tool (AST) is the first step in this direction. In this issue, Sakhi et al. & Theuns compared 256 
patients with the manual (MST) versus the AST3. They demonstrate no significant difference in overall 
eligibility between the 2 techniques reflecting the findings of two other groups who have undertaken 
similar studies4,5. However, there are important differences in the details of the findings. Francia et al.4, 
showed that there were significant much larger differences in the vector selection: At least two vectors 
were appropriate in 69% patients with MST and 80% patients with AST (p = 0.008) as opposed to only a 
6% difference between the tools. This is important as having at least one vector gives increased room for 
maneuvers if subsequent oversensing issues arise and raises confidence in prescribing 
 S-ICD over transvenous devices even though only 1 vector is required. The most frequent 
reason for screening failure with MST was a high- amplitude T-wave (31% of failures)4. With AST, 23% 
of recordings that failed with MST for high-amplitude T-wave were acceptable. This can be partially 
addressed by using right sided or sternal lead positions. Bogeholz et al., showed similar rule out rates 
between the MST: 3.0% and AST: 6.1% but the implanted S-ICD worked flawlessly in all these patients5. 
Furthermore, the AST did not predict the finally selected sensing vector better than MST with a clear 
mismatch between AST and MST for the predicted eligibility of single vectors- only 49% of patients have 
identical single vectors selected by both approaches. These data highlight the discrepancies between 
the S-ICD VectorSelectTM sensing algorithm and the AST/MST parameters that are tested and raise 
some controversial questions as to the benefits of screening at all-this needs to be fully determined in a 
large S-ICD implanted cohort. 
 The populations screened also differ: Francia 90% cardiomyopathies, Bogeholtz 27% versus 
50% in Sakhi et al. which has implications in dissecting the details of the screening differences. The 
overall single vector pass rates for both the techniques at a level of N90% are certainly higher than in 
inherited cardiac conditions such as HCM with manual screening where 38% patients were ineligible for 
S-ICD with a single vector on the left side: 10% failed on exercise with large R waves being an important 
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factor6. No studies have systematically compared left, sternal & right sided screening with both AST and 
MST. Generally, the main determinants of likelihood of screening failure in the overall S-ICD population 
using the AST are QRS widening/bundle branch block, decreased R/T-wave ratio in lead I and T-wave 
inversion in I, II, or aVF5. 
 Sakhi et al.’s study is an important step to standardize screening. It is vital to ensure a rigorous 
screening approach to maximize eligibility using all available lead positions, maximize the number of 
sensing vectors & avoid inappropriate therapies or undersensing especially if patients have dynamic 
T wave changes on exercise e.g. Long QT Syndrome and Cardiomyopathy cases: these are the main 
reasons to justify pre-operative screening. 
 The key problem of T wave oversensing has been effectively addressed with the SMARTPASS 
filter. The SMARTPASS filter applies a high pass filter to remove low frequency T waves enabling only R 
waves to be detected by the device. This was initially tested on a retrospective dataset of inappropriate 
shock signals demonstrating a 40% re- duction in T wave oversensing7. Subsequent clinical testing by 
Theuns et al. in the LATTITUDE Remote Monitoring Registry has vindicated these findings: 1984 patients 
S-ICD were compared with the filter enabled or off- inappropriate shocks were reduced to just 4.3% vs 
9.7% matching that seen with transvenous systems without compromising appropriate therapies8. 
 Can the vectors that are sensed be further improved to reduce patient exclusion? Refinement 
could come from a more detailed vector analysis of the signal between the S-ICD lead configurations 
to provide a reconstructed ECG for sensing. This concept is well established in the literature and was 
recently tested in a series of S-ICD recipients where 3 ECG vectors can be utilized to reconstruct the 
QRS-T wave morphology of an 8 lead ECG9,10. Therefore, every patient could have a personalized ideal 
ECG vector to enable optimal sensing with a maximum R:T wave ratio difference & the 8 lead ECG could 
be reconstructed after an event from the S-ICD signals to provide diagnostic information and potentially 
guide VT ablation. Indeed, discrimination algorithms could combine vectors to optimize discrimination 
further. 
In conclusion, Theuns and his co-authors work to enhance S-ICD screening and sensing is to be 
commended3,8. Automatic screening should enable standardization of S-ICD patient selection and with 
suit- able software and hardware enhancements we will see further refinements in sensing and event 
data. Leadless pacing for ATP and bradycardia may also enable hybrid S-ICD systems to further reduce T 
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Background: Currently, the eligibility for a subcutaneous implantable defibrillator (S-ICD) system relies 
on a pre-implant vector screening based on the automated screening tool (AST). We investigated which 
12-lead ECG characteristics are associated with eligibility for an S-ICD in a heterogeneous population 
at risk for sudden cardiac death (SCD). The goal is to determine patient eligibility for S-ICD using the 
standard 12-lead ECG, thereby avoiding additional AST screening. 
Methods: We evaluated the eligibility for an S-ICD in 254 consecutive patients at risk for SCD. We 
identified 12-lead ECG parameters which were independently associated with AST passing (≥1 vector) 
using multivariable logistical regression analysis in our derivation cohort. The final model was tested in 
a separate validation cohort.
Results: The overall passing rate was 92% in our derivation cohort. Independent 12-lead ECG 
characteristics associated with AST passing were QRS≤130 ms, absence of QRS/T discordance in lead 
II and R/T-ratio ≥3.5 in lead II. Eighty-three of 254 patients (33%) fulfilled these three criteria and had a 
passing rate of 100%. Of the validation cohort, 37 of 60 patients (62%) fulfilled all three criteria and also 
had a passing rate of 100%. The interobserver agreement for applying the ECG model was 90% (Cohen’s 
Kappa= 0.80).
Conclusion: Using the standard 12-lead ECG, we developed a simple screening model with a high 
specificity for S-ICD eligibility. Our results suggest that patients who fulfill the three ECG criteria do not 
need additional AST-screening. 




The efficacy and safety of the subcutaneous implantable defibrillator (S-ICD) has been demonstrated 
in both primary and secondary prevention of sudden cardiac death (SCD)1. However, the advantage of 
the S-ICD is partially offset by the presence of inappropriate shocks that is mainly attributed to T-wave 
oversensing1-4. Therefore, it is recommended that every S-ICD candidate needs to be screened before 
S-ICD implantation to reduce the likelihood of T-wave oversensing. In current practice, the eligibility 
for a subcutaneous implantable defibrillator system relies on a pre-implant vector screening based on 
the automated screening tool (AST). Several studies have investigated the feasibility of AST for S-ICD 
eligibility screening5-7. 
 Previous studies demonstrated several standard 12-lead ECG characteristics associated with 
the eligibility for an S-ICD. However, these associations were based on the manual ECG screening 
tool8-10. We investigated which 12-lead ECG characteristics are associated with eligibility for an S-ICD 
in a heterogeneous population at risk for sudden cardiac death (SCD). The goal is to determine patient 
eligibility for S-ICD using the standard 12-lead ECG, thereby avoiding additional AST screening. Quick 
assessment of eligibility for a S-ICD based on a standard 12-lead ECG may be useful as the healthcare 
provider immediately knows if a patient is eligible for a S-ICD.
Methods
Study design
This was a retrospective study evaluating 12-lead ECG characteristics associated with AST passing in 
consecutive patients with cardiomyopathy, congenital heart disease, and inherited primary heart 
disease. The purpose of the present study was to develop a 12-lead ECG screening model which can 
identify patients who are eligible for an S-ICD, thereby omitting additional AST screening. The standard 
12-lead ECG was acquired directly after the AST-screening. A patient was considered eligible for S-ICD 
if at least one sensing vector passed the AST in both supine and sitting posture. The screening model 
was developed using a derivation cohort. This derivation cohort consisted of 254 patients which 
was previously described by our group.7 In this study we investigated the eligibility for S-ICD using 
both AST and manual ECG screening. In brief, all consecutive patients at risk for SCD were screened 
for their eligibility for S-ICD during their routine outpatient clinic using both AST and manual ECG 
screening between February and June 2017. Exclusion criteria were ≥3% ventricular pacing, cardiac 
resynchronization therapy and patients with paced QRS-complex during screening. 
 Finally, the derived 12-lead ECG screening model was tested in an independent validation 
cohort consisting of implantable cardioverter defibrillator (ICD) candidates who underwent AST-
screening in a clinical setting after June 2017. All included patients provided informed consent to 
participate in the study, and the study was approved by the institutional review board of the Erasmus 




Standard 12-lead ECG characteristics, such as PR interval, QRS duration, presence of interventricular 
conduction delay and QT(c) interval (as determined by Fridericia formula), JTc (JTc= QTc - QRS duration) 
were extracted from the baseline standard 12-lead ECG. Furthermore, maximum QRS and T-wave 
amplitude (absolute maximum deflection from the isoelectric line), absence of T-wave inversion 
(TWI) and QRS/T-wave discordance, and R/T-ratio were manually determined using E-scribe software 
(E-scribeTM ECG Workstation version 8.16.1). The characteristics were specifically analyzed in lead I, II 
and aVF, since these leads have a vector direction which are comparable to the primary, secondary 
and alternate sensing vector of the S-ICD, respectively. T-wave was considered inverted when the 
highest amplitude had a negative polarity and QRS/T-wave discordance was noticed when the T-wave 
had an opposite direction as the QRS complex. For the purpose of determining TWI and QRS/T-wave 
discordance the T-wave should be ≥0.1 mV.
 ECG characteristics of the patients who passed the AST were compared to the patients 
who failed. Furthermore, a specific vector-based analysis was performed to investigate which ECG 
characteristics were associated with eligibility for S-ICD at the corresponding vector level.
Statistical analysis
Continuous data are presented as mean ± standard deviation or as median with interquartile range 
(25th and 75th percentile), where appropriate. Categorical variables are presented by frequencies and 
percentages. Differences between groups were analyzed with the unpaired Student’s t-test, Chi-square 
test or the Fisher’s exact test, as appropriate. Univariable and multivariable logistic regression analysis 
were performed to identify factors associated with AST passing. Any univariable variable with a P-value 
<0.05 was entered in a multivariable forward conditional model. Inter-observer agreement between 2 
observers (RS and SCY) was evaluated using Cohen’s Kappa statistics. A P-value <0.05 was considered 
statistically significant. Statistical analyses were performed using SPSS version 24.
Results 
Baseline characteristics 
A total of 254 consecutive patients were screened for their S-ICD eligibility using the AST. Among them 
167 (66%) patients were males and the mean age of the study population was of 51±16 years. The 
majority of the patients had structural heart disease (SHD; n=194, 76%). Inherited primary arrhythmia 
syndrome (IPAS) was present in 60 (24%) patients. Hundred and ten (43%) patients had an ICD at the 
time of enrollment. The majority (64%) of the indications were for primary prevention.
 Comparative demographic and clinical characteristics of those who passed (n=233, 92%) 
and those who failed (n=21, 8%) the AST are listed in Table 1. The passing rate varied from 83% for 
hypertrophic cardiomyopathy (HCM) to 100% for long QT syndrome (LQTS). There were no statistically 
significant differences in demographics, ICD indication, and underlying etiology between patients who 
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passed and those who failed the screening. Detailed overview of the baseline characteristics has been 
previously reported by Sakhi et al.7
Table 1. Demographics and clinical characteristics
Total 
(n=254)
Pass (n=233) Fail 
(n=21)
P-value
Male gender (%) 167 (66) 154 (66) 13 (62) 0.70
Age, years, ±SD 51 ± 16 51 ± 16 56 ± 16 0.17
BMI, kg/m2, ± SD 26.1 ± 4.5 26.0 ± 4.5 26.5 ± 5.0 0.68
Implantable cardioverter-defibrillator 110 (43) 103 (44) 7 (33) 0.36
Primary prevention 70 (28) 65 (28) 5 (24) 0.69
Secondary prevention 40 (16) 38 (16) 2 (10) 0.41
Cardiac diagnosis*
Structural heart disease (%) 194 (76) 175 (75) 19 (90) 0.11
-    Cardiomyopathy 126 (50) 115 (49) 11 (52) 0.79
-    Congenital heart disease 68 (27) 60 (26) 8 (38) 0.22
Inherited primary arrhythmia syndrome (%) 60 (24) 58 (25) 2 (10) 0.11
Data are presented as mean ± SD, categorical data as n (%). BMI: body-mass index. 
Patient based ECG analysis 
ECG characteristics stratified by S-ICD eligibility are listed in Table 2. Patients who passed the screening 
had a higher proportion of QRS≤130 ms and QTc≤450 ms in comparison to those who failed the 
screening. When looking at specific leads, the patients who passed the screening had less TWI in lead II; 
less QRS/T-wave discordance in lead II and aVF; and a higher R/T-ratio in lead II and aVF in comparison 
to those who failed the screening. 
Vector-based ECG analysis
The primary, secondary and alternate sensing vectors of 254 patients, both supine and sitting postures, 
were analyzed separately, resulting in 762 vectors. The primary sensing vector was the most appropriate 
(80%, n=204), followed by the secondary vector (77%, n=196) and the alternate vector (59%, n=151). 
Results of the absolute QRS amplitude and R/T-ratio of lead I, lead II and lead aVF with the corresponding 
vectors are demonstrated in Figure 1. Patients who passed the secondary or alternate vector had a 
higher absolute QRS amplitude in their corresponding leads (lead II and aVF, respectively) in comparison 
to those who failed (lead II: 0.92 mV versus 0.66 mV, P<0.01; lead aVF: 0.81 mV versus 0.53 mV, P<0.01). 
Furthermore, they also had a higher R/T-ratio in leads II and aVF (lead II: 3.88 versus 2.50, P<0.01; lead 
aVF: 4.77 versus 2.82, P<0.01). A R/T-ratio of ≥3.5 was deemed as the optimal cutoff based on the highest 
sensitivity and specificity for the specific leads (Figure 1). A more detailed overview of ECG characteristics 
with the matching screening vectors are provided in supplementary material (Appendix A). Patients 
who passed the screening had a higher proportion of R/T-ratio ≥3.5 in lead II and aVF (Table 2).
CHAPTER 10
166








Sinus rhythm (%) 229 (90) 209 (90) 20 (95) 0.41
PR interval (IQR)* 169 (152-189) 168 (151-187) 188 (161-193) 0.06
QRS≤130 ms 200 (79) 193 (83) 7 (33) <0.01
QT≤450 ms 227 (89) 210 (90) 17 (81) 0.19
QTc≤450 ms 223 (88) 208 (89) 15 (71) 0.02
JTc duration 294 (275-316) 295 (275-316) 289 (273-322) 0.36

























Absence of T-wave inversion (%)
- lead I 211 (83) 197 (85) 14 (67) 0.04
- lead II 225 (89) 210 (90) 15 (71) 0.02
- lead aVF 215 (85) 200 (86) 15 (71) 0.09
Absence of QRS/T-wave discordance (%) 
- lead I 179 (70) 167 (72) 12 (57) 0.16
- lead II 198 (78) 188 (81) 10 (48) <0.01
- lead aVF 163 (64) 156 (67) 7 (33) <0.01
R/T-ratio per lead (IQR)
























R/T-ratio of ≥3.5 per lead (%) 
- lead I 149 (59) 139 (60) 10 (48) 0.28
- lead II 128 (50) 123 (53) 5 (24) 0.02
- lead aVF 136 (54) 130 (56) 6 (29) 0.02
* Only in patients with sinus rhythm, IQR= interquartile range.
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Figure 1. Eligibility for S-ICD of the different screening vectors based on the QRS-amplitude and R/T-ratio of the 
corresponding leads. NS= no significant p-value.
ECG characteristics associated with S-ICD eligibility
Univariable and multivariable analysis for S-ICD eligibility are presented in Table 3. Univariable analysis 
demonstrated that QRS duration ≤130 ms, QTc duration ≤450 ms, absence of TWI in lead I and lead II, 
absence of QRS/T-wave discordance in lead II and aVF, and R/T-ratio ≥3.5 in II and aVF were associated 
with AST passing based on ≥1-vector pass rule. Independent ECG characteristics associated with AST 
passing were QRS≤130 ms, absence of QRS/T-wave discordance in lead II and R/T-ratio ≥3.5 in lead II. 
 When applying the ECG criteria in the derivation cohort, 83 patients (33%) fulfilled all three 
ECG criteria. In these patients, the eligibility for S-ICD based on ≥1 vector passing rate was 100%, When 




Table 3. ECG characteristics associated with S-ICD eligibility
Variables Univariable Multivariable
OR (95% CI) P-value OR (95% CI) P-value
QRS≤130 ms 9.65 (3.66-25.43) <0.01 8.09 (2.88-22.77) <0.01
QTc≤450 ms 3.33 (1.18-9.54) 0.02
Absence of T-wave inversion in lead I 2.74 (1.03-7.25) 0.04
Absence of T-wave inversion in lead II 3.65 (1.29-10.33) 0.02
Absence of QRS/T-wave discordance in lead II 5.05 (1.98-12.92) <0.01 4.19 (1.49-11.74) <0.01
Absence of QRS/T-wave discordance in lead aVF 3.95 (1.53-10.19) <0.01
R/T-ratio ≥3.5 in lead II 3.58 (1.27-10.01) 0.02 4.21 (1.27-13.95) 0.02
R/T-ratio ≥3.5 in lead aVF 3.16 (1.18-8.42) 0.02
Abbreviations: OR= odds ratio; CI= confidence interval. 
Validation analysis
The 12-lead ECG screening model was evaluated in a validation cohort consisting of 60 ICD candidates 
who underwent AST-screening as part of their clinical workup for ICD implantation. The mean age of 
the validation cohort was 49 ± 17 years and the majority of the patients were male (76%). In total, 50 
patients had SHD (83%) and IPAS was present in 10 (17%) patients. The ≥1 vector pass rate was 90% 
for this cohort, 6 patients (10%) failed the AST screening. When applying the derived screening model, 
37 of 60 patients (62%) fulfilled all three 12-lead ECG criteria. The ≥1 vector pass rate was 100% for this 
selected cohort, thus all patients who fulfilled the three ECG criteria were eligible for S-ICD. Furthermore, 
when using the stringent criteria for S-ICD eligibility (≥2 vector pass rule) the eligibility increased from 
78% to 89% in patients. The interobserver agreement of the screening model was good with a Cohen’s 
Kappa of 0.80 and an overall agreement of 90%. 
Follow- up of S-ICD patients
Of the patients who fulfilled all the three ECG criteria in the derivation cohort, 18 of 83 patients (22%) 
had an S-ICD. During a median follow-up of 66 months (interquartile range: 35-85 months), two patients 
experienced an inappropriate shock. One patient received an inappropriate shock due to R-wave 
attenuation and the other patient due to a supraventricular tachyarrhythmia detected in the shock zone. 
In the validation cohort, 28 of the 37 patients (76%) who fulfilled the three ECG criteria received an S-ICD 
and during a median follow-up of 11 months (interquartile range: 3-15 months) none of the patients 
experienced an inappropriate shock. 




The present study demonstrated that QRS duration ≤130 ms, absence of QRS/T-wave discordance in 
lead II and R/T-ratio ≥3.5 in lead II were independently associated with eligibility for S-ICD based on AST-
screening. Interestingly, the eligibility for S-ICD was 100% in patients who fulfilled all three criteria in both 
the derivation and validation cohort.
 Using the AST as a pre-implant screening tool, eligibility rates from 92% to 96% have been 
reported5-7. The study by Francia et al., reported eligibility rates of 94% and 80% when using ≥1-vector and 
≥2-vector pass rule, respectively5. This is in line with the results of the present study (92% for ≥1-vector 
pass and ≥ 80% 2-vector pass). More recently, Bogeholz et al., found a ≥1-vector AST passing rate of 
94% in 33 consecutive patients who already had an S-ICD system implanted6. Comparable results were 
demonstrated by Sakhi et al., in S-ICD patients in whom eligibility for S-ICD had already been determined 
with manual ECG screening (n=35, 100% ≥1-vector pass rule)7. 
ECG characteristics associated with S-ICD eligibility
Previous studies have identified 12-lead ECG characteristics associated with S-ICD ineligibility based on 
manual ECG screening, such as prolonged QRS duration, low R/T-ratio, T-wave inversion and QRS/T-wave 
discordance8-10. Considering the high agreement between manual ECG screening and AST on a patient 
level, one would expect the same factors to be associated with S-ICD ineligibility based on AST7. We 
identified similar factors associated with S-ICD ineligibility: prolonged QRS duration, presence of QRS/T-
wave discordance in lead II, and low R/T-ratio in lead II. Bogeholz et al. also demonstrated that prolonged 
QRS duration, presence of T-wave inversion and a low R/T-ratio were more common in patients who 
failed AST-screening. 
 The purpose of AST screening is to select patients who are at low risk of T-wave oversensing. 
Our proposed screening model achieves the same result albeit at the cost of sensitivity (patients who 
fail our screening model, may still be suitable based on AST). The identified ECG factors are probably 
associated with a normal repolarization with a good signal-to-noise ratio. It is known that prolonged QRS 
duration and QRS/T-wave discordance are associated with repolarization abnormalities. By excluding 
patients with repolarization abnormalities and a low R/T-ratio, it seems logical that the chance of T-wave 
oversensing is low.
Clinical implications
When a patient is a potential ICD candidate and does not have an indication for pacing, biventricular 
pacing or ATP then the patient is a potential candidate for an S-ICD. In clinical practice, a potential S-ICD 
candidate undergoes vector screening using AST and when at least 1 vector is suitable then we will 
discuss the pros and cons of transvenous and subcutaneous ICDs. Based on previous studies it is known 
that the S-ICD eligibility rate based on AST is relatively high (>90%). Some implanters have argued to 
abolish vector screening considering this high passing rate. Unfortunately, inappropriate shocks due to 
T-wave oversensing do occur and this should be prevented. We developed a simple screening model 
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using the standard 12-lead ECG which can identify patients who have a very high likelihood to pass the 
vector screening based on AST. When patients fulfill all three ECG criteria, it seems safe to omit vector 
screening considering the 100% ≥1 vector passing rate and even 96% ≥2 vector passing rate. Despite 
the excellent specificity (100%), the sensitivity of the proposed screening model varied between 36-
67%. This means that a substantial proportion of ICD candidates still requires AST screening. Based on 
the results of the present study, we propose a simple flowchart to determine eligibility for an S-ICD that 
can be easily implemented in daily clinical practice (Figure 2). 
Figure 2. Proposed screening procedure for S-ICD screening in daily clinical practice. CRT= cardiac resynchronization 
therapy; VT= ventricular tachycardia; TV-ICD= transvenous implantable cardioverter defibrillator.




Several limitations are important to highlight. It has been previously shown that S-ICD screening 
during exercise can identify T-wave oversensing and results in a greater failure rate, especially in certain 
patients with HCM3, 11, 12. We did not test our study population during exercise, therefore we cannot draw 
conclusions on the validity of our model in patients undergoing exercise testing as part of the screening. 
Furthermore, the combination of the small number of patients in the validation cohort and high passing 
rate may affect the accuracy of the specificity of our model. Therefore, the 12-lead ECG screening model 
should be validated in a larger population before widespread clinical adoption. Finally, the safety of 
the proposed algorithm can be evaluated when comparing the inappropriate shock rates of patient 
populations screened with the proposed algorithm versus AST only. 
Conclusion
Using the standard 12-lead ECG we developed a simple screening model with a high specificity for S-ICD 
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Epilogue
Tali sono tutte le cose vere, dopo che son trovate; 
ma il punto sta nel saperle trovare.
(All truths are easy to understand once they are discovered; 
the point is to discover them) 
Galileo Galilei 
(Dialogo sopra i due massimi sistemi del mondo, 1632)
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Prolonged rhythm monitoring using a subcutaneous insertable cardiac monitor (ICM) has proven to be 
of incremental diagnostic value for a wide spectrum of indications, especially in patients with recurrent 
unexplained syncope1, 2. The aim of the present thesis (Part I) was to investigate the clinical value of 
ICMs as part of risk stratification in different patients with inherited and/or structural heart disease who 
are susceptible to sudden cardiac death (SCD) but who do not have a clear indication for an implantable 
cardioverter-defibrillator (ICD) for primary prevention. Furthermore, given the fact that the majority of 
patients with inherited and/or structural heart disease are young and do not require bradycardia pacing 
or resynchronization therapy, we wanted to investigate their suitability for a completely subcutaneous 
ICD system (Part II). The following summary addresses the main findings of the studies included in this 
thesis and discuss their clinical features and future perspectives.
Part I – Summary 
In Part I of the present thesis we focus on the clinical usefulness of ICMs as diagnostic tool for risk 
stratification in patients who are at low to moderate risk of SCD. First, we provide a review in Chapter 
2, in which we discuss the current indications for ICMs and give an overview of the latest generation of 
commercially available ICMs. According to the current guidelines and expert consensus, the indications 
for ICMs are expanding to patients with primary cardiomyopathy (e.g., hypertrophic cardiomyopathy, 
arrhythmogenic right ventricular cardiomyopathy), inherited primary arrhythmia syndrome (e.g., 
long-QT syndrome, Brugada syndrome), suspected unproven epilepsy, and unexplained falls1-5. 
The current generation ICMs are smaller, easier to implant, have better diagnostics, and are capable 
of remote monitoring. Figure 1 provide an overview of the current ICMs on the market. The Reveal 
LINQ (Medtronic) is the smallest ICM and has the most extensive performance and clinical data. The 
BioMonitor 2 (Biotronik) is the largest ICM but has excellent R-wave amplitudes, longest longevity, and 
reliable remote monitoring. The Confirm Rx (Abbott) is capable of providing mobile data transmission 
enabled by a smartphone app. 
 Considering the expanding role for ICMs for risk stratification in patients with primary 
cardiomyopathy or inherited arrhythmia syndrome, we performed a pilot study in which we described 
our initial experience with the current generation of ICM (Reveal LINQ) (Chapter 3). We hypothesized 
that patients with structural or electrical heart disease would have a higher incidence of ventricular 
arrhythmia (VA) compared to those without underlying heart disease. We found that in comparison 
to patients without heart disease, the diagnostic yield of an ICM was lower in patients with inherited 
arrhythmia syndrome and the incidence of ICM-diagnosed nonsustained VA was higher in patients with 
structural heart disease Interestingly, 4 patients (4%) received an ICD based on the findings of the ICM. 
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Figure 1. Overview of current generation ICMs. Reveal LINQ (Medtronic), Confi rm Rx (Abbott/St. Jude medical), and 
BioMonitor 2 (Biotronik), respectively.
 Based on the results of our pilot study, we specifi cally evaluated the value of ICMs in specifi c 
patient categories at low to moderate risk of SCD. The occurrence of syncope in patients who are 
potentially susceptible to SCD could be the result of a self-terminating VA and is considered a risk factor 
for SCD in certain heart conditions. Furthermore, symptoms like palpitations and near-syncope may 
also be associated with other signifi cant arrhythmias. Considering the potential adverse eff ects of ICD 
therapy, the decision to implant an ICD is not easy, especially in young patients. In this regard, an ICM 
can be used to exclude VA as the cause of symptoms. Furthermore, continuous arrhythmia monitoring 
will also provide the physician the assurance that any VA, also those that are asymptomatic, will be 
documented. The strategy of using an ICM for this purpose in diff erent patient population is described 
in Chapter 4-6. 
 An important mode of death in adults with congenital heart disease (CHD) is SCD and is mainly 
driven by VA. In current practice, the decision to implant an ICD in patients with CHD is challenging 
and is largely based on the physician’s clinical judgement6-9. In Chapter 4 (EDVA-CHD study), we 
prospectively evaluated the usefulness of ICMs in adults with CHD who deemed at risk of SCD. The 
EDVA-CHD study demonstrated that long-term arrhythmia monitoring by an ICM seems valuable for 
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risk stratification in adults with CHD resulting in an ICD for 10% of the study population. Furthermore, 
ICM-detected arrhythmias leading to changes in clinical management occurred in 73% of patients. 
 The ESC guidelines recommend the use of the HCM Risk-SCD model to identify ICD candidates 
in patients with hypertrophic cardiomyopathy (HCM). One important risk factor in this model is the 
occurrence of (non)sustained VA3, 5, 10. In Chapter 5, we compared the diagnostic yield of ICMs in the 
detection of VA with conventional Holter monitoring. The study was performed in patients with HCM 
who are deemed to be at low to moderate risk of SCD based on the HCM Risk-SCD model. This study 
demonstrated that in adults with HCM, the diagnostic yield of detecting a VA is similar for ICMs and 
conventional Holter monitoring. However, compared to conventional strategy, ICMs detected more 
arrhythmic events requiring a therapeutic intervention.
 Brugada syndrome is an inherited syndrome associated with a risk of SCD due to VA11, 12. Risk 
stratification in patients with Brugada syndrome is challenging and there is debate on the prognostic 
role of an electrophysiology study13-15. In clinical practice, physicians are confronted with patients with 
Brugada syndrome who have symptoms such as palpitations, near-syncope, or nonarrhythmogenic 
syncope16, 17. Some symptoms are caused by anxiety for arrhythmic events, but it may be difficult to 
differentiate this from clinically relevant arrhythmias. The purpose of the study in Chapter 6 was to 
evaluate the value of ICMs in symptomatic patients with Brugada syndrome who are at low risk of SCD. 
The main reason for arrhythmia monitoring was to exclude VA as the cause of symptoms and to establish 
a symptom-rhythm relationship. Half of the population had a history of syncope. There was no sustained 
VA during follow-up of almost 3 years. The majority of patients had symptoms during follow-up, and 20% 
required a change in clinical management based on an ICM-detected arrhythmia. 
 Finally, chronic coronary total occlusion (CTO) has been identified as a risk factor for VA in 
primary prevention ICD recipients with LV dysfunction. CTO is a very common condition among patients 
with coronary artery disease, with a reported prevalence between 30 to 50% in patients with referred to 
catheterization laboratory18, 19. In Chapter 7, we conducted a retrospective single-center study in which 
we evaluated the impact of unrevascularized CTOs on the occurrence of appropriate ICD therapy in out-
of-hospital cardiac arrest survivors with coronary artery disease. A CTO was an independent predictor of 
appropriate ICD therapy, even after correcting for severe LV dysfunction. 
Part I - Discussion
There is a clear indication to use an ICM as a diagnostic tool in patients with recurrent unexplained 
syncope without high-risk features20. A history of syncope in patients with structural heart disease or 
inheritable arrhythmia syndrome is associated with an increased risk of SCD. When the mechanism 
of syncope is nonarrhythmogenic, the management of patients with high-risk features is similar to 
those without syncope. The clinical problem is that the distinction between nonarrhythmogenic and 
arrhythmogenic syncope can be difficult. In this respect, an ICM can be useful. The recent European 
guidelines expand the role of ICM to patients with structural heart disease or inheritable arrhythmia 
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syndrome who have recurrent episodes of unexplained syncope who are at low risk of SCD2. We 
evaluated a strategy of using an ICM in symptomatic patients with congenital heart disease, HCM and 
Brugada syndrome who were at low to moderate risk of SCD. It is good to realize that these patients 
already underwent comprehensive evaluation before ICM implantation which did not lead to a specific 
treatment. The goal of continuous monitoring in these patients was to establish a symptom-rhythm 
correlation and to detect asymptomatic VA. We demonstrated that the incidence of VA was relatively low 
during follow-up, but up to 10% of patients received an ICD, depending on the patient population. In 
addition, ICM-detected arrhythmias led to a change in clinical management in a 20-53% of the patients. 
Finally, it is important to highlight that the exclusion of VA as the cause of symptoms and continuous 
monitoring provides reassurance to patients who have an underlying disease predisposing them to 
malignant arrhythmias.
 Though the use of ICMs in patients with high-risk features seems promising, there are several 
factors that should be considered, including device costs, data overload, clinical relevance of device-
detected VA and medical overuse. The issue of data overload is exemplified by the recording of more 
than 4,600 episodes in 75 patients during the follow-up period of our studies. This requires a proper 
logistic organization with a dedicated telemonitoring staff. Furthermore, since the insertion procedure 
can take place outside the catheterization laboratory in a less resource intensive environment and can 
be performed by trained nurses, we expect that the costs related to ICM implantation will decrease21-24.
 In conclusion, an ICM can be a useful diagnostic tool in symptomatic patients with structural 
heart disease or inheritable arrhythmia syndrome who are at low to moderate risk of SCD when 
comprehensive evaluation has not led to a specific treatment. 
Part I – Future perspective
Since the introduction of the ICMs in 1980, technological improvements have led to miniaturization 
of the device, improved sensing capabilities, atrial fibrillation detection algorithms, and availability of 
remote monitoring25, 26. Recently, the indications for ICMs have expanded to other populations. While 
previously it was mainly used for patients with recurrent unexplained syncope, the ICM can be used 
for risk stratification or to detect atrial fibrillation after cryptogenic stroke or after catheter ablation27. 
ICMs can also be useful for research purposes to clarify the mechanism of clinical events. For example, 
CTO has been identified as a risk factor for VA in patients who received an ICD for primary or secondary 
prevention28-30. Patients with a failed CTO revascularization have a higher mortality rate in comparison 
to those with successful recanalization31. Based on these observations we hypothesize that CTO is an 
important predictor of VA, especially after a failed recanalization. Currently, we are evaluating 3 groups of 
patients with a CTO for the occurrence of VA with an ICM (NCT03475888, VACTOR study). These groups 
are patients with successful percutaneous CTO recanalization, failed percutaneous CTO recanalization 
and untreated CTO. The results are expected in 2023.
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 Currently, ICMs are used for continuous monitoring of the heart rhythm. Considering the remote 
monitoring capabilities, the diagnostic capabilities may expand to other fields. The most promising field 
is to remotely monitor patients with heart failure in order to detect early signs of worsening heart failure. 
The CHAMPION study has demonstrated that patients with NYHA III heart failure who are managed 
with remote monitoring using a wireless implantable hemodynamic monitoring system (CardioMEMS™, 
Abbott) have a reduction in heart-failure-related hospitalizations32. The CardioMEMS™ system monitors 
the pulmonary artery pressure using a small pressure sensor which is permanently implanted in the distal 
pulmonary artery. It is also possible to use physiological trends for detecting early signs of worsening 
heart failure. The MultiSENSE study demonstrated that the HeartLogic™ diagnostic (Boston Scientific) 
can predict future heart failure events33. HeartLogic™ uses multiple sensors in an ICD to track changes 
in heart sounds, intrathoracic impedance, respiration, heart rate and patient activity metrics. When the 
composite index crosses a certain threshold, the clinician is proactively alerted via remote monitoring. It 
is likely that heart failure diagnostics can be incorporated in an ICM providing the possibility to remotely 
monitor patients with heart failure who do not have an ICD. For example, the purpose of the currently 
ongoing LINQ HF study (Medtronic) is to assess the relationship between changes in LINQ derived 
data and other physiologic parameters with subsequent acute decompensated heart failure events 
(NCT02758301). No results have been published yet. In conclusion, we expect that the availability of 
heart failure diagnostics will be an important mile stone in the evolution of ICMs. 
Part II – Summary
In part II of this thesis we evaluated the suitability of different patient categories for a subcutaneous ICD 
(S-ICD, Figure 2). The current guidelines give a class IIa recommendation for an S-ICD as an alternative 
to a transvenous ICD if there is no need for pacing therapy, cardiac resynchronization therapy (CRT) or 
antitachycardia pacing (ATP). Furthermore, to prevent inappropriate shocks due to T-wave oversensing it 
is recommended that every candidate undergo vector screening to check if they qualify for an S-ICD. In 
Chapter 8 we evaluated the potential candidacy for an S-ICD at the time of first replacement in a cohort 
of patients with a transvenous single chamber ICD who did not need pacing at the time of implantation. 
At the time of first ICD replacement, 69% of patients was potentially suitable for an S-ICD. Thus, 31% 
needed either ATP, CRT and/or bradypacing during the first battery-lifetime. For individual end points, 
annual incidence rates were 4.9% appropriate ATP, 1.8% for CRT, and 0.3% for pacing-dependency. No 
baseline variables could predict which patient would potentially be suitable for an S-ICD. 
 If a patient is considered a candidate for an S-ICD (no need for pacing, ATP or CRT), then 
vector screening is performed to check if the patient has a suitable QRS-T morphology. Usually this 
was done manually using a manual ECG-screening tool and a vector electrocardiogram. Recently, an 
Automated Screening Tool (AST) became available, fully automating this process of vector screening. In 
Chapter 9 we prospectively evaluated the eligibility for a S-ICD using the two screening tools (manual 
vector screening versus AST) in different patient categories including patients with cardiomyopathy, 
congenital heart disease and inherited primary arrhythmia syndrome. There was a high vector eligibility 
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using either method (93% versus 92%, P = 0.45). Furthermore, agreement between the two screening 
methods was 94%. Patients with hypertrophic cardiomyopathy more often had a failed screening test in 
comparison to other patients.
Figure 2. The current (second) generation of the S-ICD system (Boston Scientifi c). 
 Previous studies have demonstrated that several standard 12-lead ECG characteristics are 
associated with the eligibility for a S-ICD based on manual vector screening34-36. In Chapter 10, we 
investigated which 12-lead ECG characteristics were associated with eligibility for an S-ICD based on 
AST in a heterogenous population. We found that QRS ≤ 130 ms, absence of QRS/T discordance in lead 
II and R/T-ratio ≥3.5 in lead II were independently associated with S-ICD eligibility based on AST. Patients 
who fulfi lled all three criteria (n=83, 33%) had a passing rate of 100%. Therefore, our results suggest that 
patients who fulfi ll the three 12-lead ECG criteria do not need additional vector screening for S-ICD 
eligibility. 
Part II - Discussion 
There are several advantages of an S-ICD in comparison to a transvenous ICD. These include the reduced 
risk of lead dysfunction, elimination of risk of endocarditis, lower procedural risk and relative ease of 
extraction. Disadvantages of an S-ICD are the inability to provide pacing (including ATP and CRT), 
larger pulse generator size, shorter battery longevity and requirement of a pre-implant ECG screening. 
Although the current guidelines recommend that an S-ICD should be considered as an alternative to 
a transvenous ICD, there is only a modest implementation of this technology in clinical practice37. A 
physician may have the opinion that a patient without immediate need for pacing therapy or ATP may 
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potentially require these therapies in the future, thereby opting for a transvenous ICD to be on the safe 
side. 
 We demonstrated that the majority (69%) of patients who have a transvenous single chamber 
ICD would have qualified for an S-ICD at the time of first replacement. The most important reason 
not to qualify for an S-ICD was the occurrence of ATP (4.9% per year). Interestingly, the risk of pacing 
dependency was low in this population (0.3% per year). Thus, based on our data we can conclude that 
the potential need for future pacing therapy is low in a standard ICD population who do not have a need 
for pacing therapy at implantation. With regard to the development of the need of CRT, it is important 
to realize that a de novo CRT-implantation is easier than an upgrade to CRT in a patient who have a 
transvenous ICD38, 39.
 If a patient is a potential candidate for a S-ICD, then a pre-implant vector screening is 
recommended by the manufacturer to avoid the risk of QRS/T-wave oversensing. Previously, this was 
done using a ruler and printed vector electrocardiogram. To automate this process, the manufacturer 
has developed the Automated Screening Tool (AST). We demonstrated that AST has a good agreement 
with the previous manual vector screening for identifying suitable patients for an S-ICD. Furthermore, we 
demonstrated that the single-vector passing rate was high (92%) in a heterogenous patient population 
including patients with congenital heart disease and inheritable primary arrhythmia syndromes. The 
only exception were patients with hypertrophic cardiomyopathy, who had a lower passing rate (83%) 
based on AST. Importantly, previous studies have demonstrated that the passing rate may further 
decline when testing was done during exercise40-42. Furthermore, we demonstrated that a pre-implant 
vector screening can potentially be omitted if the patient fulfills specific criteria on a standard 12-lead 
ECG (i.e., QRS duration of ≤130ms, R/T-ratio ≥3.5 in lead II and absence of T-wave discordance in lead 
II). Although we tested our model in a validation cohort, external validation in a larger population is 
necessary. Furthermore, we don’t know the risk of inappropriate shocks when patients with an S-ICD are 
screened based on our 12-lead ECG model. 
 Finally, the risk of inappropriate shocks due to cardiac oversensing has been reduced by the 
recent introduction of SMART Pass technology. The SMART Pass feature activates an additional high-pass 
filter thereby reducing the amplitude of lower frequency signals (e.g., T-waves). This feature has resulted 
in reduction of first inappropriate shock by 50%43. Considering this technological improvement, some 
physicians have chosen not to perform pre-implant vector screening. 
Future perspectives
Although the S-ICD has several theoretical advantages in comparison to the traditional transvenous ICD, 
the ongoing PRAETORIAN trial will provide more insight in the advantages and disadvantages of the 
S-ICD44. The primary endpoint is a composite of inappropriate shocks and ICD-related complications. 
 An interesting concept that is being explored is the modular S-ICD system, consisting of a 
combined system including a leadless cardiac pacemaker (LCP) and S-ICD system45, 46. This combined 
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system will be able to provide ATP, which is currently one of the major disadvantages of the current 
S-ICD system. Reliable device-device communication between the EMPOWER™ LCP and EMBLEM™ 
S-ICD, through the use of galvanic coupling, has been confirmed in animal studies45, 46. Furthermore, 
firmware upgrade of the S-ICD to enable the ability to communicate with the LCP can be performed in 
existing S-ICD without replacement or explantation of the device. The advantage of the modular S-ICD 
system is that an S-ICD can be implanted in eligible patients and an EMPOWER™ LCP be implanted later 
when patients develop the need for ATP. Human clinical studies are expected soon. 
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DUTCH SUMMARY | NEDERLANDSE SAMENVATTING
Inleiding
Implanteerbare loop recorders (ILR) zijn effectief voor het detecteren van sporadische 
hartritmestoornissen. In deel I van dit proefschrift hebben wij de klinische waarde van een ILR 
onderzocht bij patiënten met een erfelijke of verworven hartziekte met een potentieel risico op plotse 
hartdood. Aangezien de meerderheid van patiënten met een erfelijke hartziekte jong is, wilden wij in 
deel II van dit proefschrift onderzoeken of deze patiënten geschikt zijn voor een volledig subcutane 
ICD (S-ICD) systeem. De onderstaande samenvatting geeft de belangrijkste bevindingen van de studies 
weer die in dit proefschrift zijn opgenomen. 
Deel I – Nut van een ILR voor risicostratificatie 
In deel I van dit proefschrift richten we ons op de klinisch waarde van een ILR als diagnostisch instrument 
voor risicostratificatie bij patiënten met een laag tot matig risico op plotse hartdood. In hoofdstuk 
2 geven we een overzicht van de huidige indicaties voor een ILR en bespreken we de verschillende 
commercieel verkrijgbare ILR’s. Volgens de huidige richtlijnen kunnen ILR’s ook toegepast worden bij 
patiënten met een erfelijke cardiomyopathie (bijv. hypertrofische cardiomyopathie, aritmogene rechter 
ventriculaire cardiomyopathie) en een erfelijke elektrische hartziekte (bijv. long-QT syndroom, Brugada 
syndroom). De huidige generatie ILR’s zijn kleiner, makkelijker te implanteren, beter in het detecteren van 
ritmestoornissen en in staat om op afstand het hartritme te monitoren (remote monitoring). De Reveal 
LINQ (Medtronic) is de kleinste en meest gebruikte ILR. De BioMonitor 2 (Biotronik) is qua afmetingen de 
grootste ILR, maar heeft wel een goed signaalkwaliteit en de langste batterijlevensduur. De Confirm Rx 
(Abbott) is in staat tot mobiele datatransmissie met behulp van een smartphone app.  
 Met het oog op de uitbreiding van het indicatiegebied van ILR’s tot patiënten met een 
erfelijke cardiomyopathie of een elektrische hartziekte, hebben we een pilotstudie uitgevoerd waarin 
we onze eerste ervaringen met de Reveal LINQ hebben beschreven (hoofdstuk 3). De diagnostische 
opbrengst van de ILR hebben we bij 3 groepen (structurele hartafwijking, erfelijke elektrische hartziekte, 
normaal hart) onderzocht. Opvallend genoeg was de diagnostische opbrengst het laagst bij patiënten 
met een erfelijke elektrische hartziekte. Daarnaast was het risico op kamerritmestoornissen het hoogst 
bij patiënten met een structurele hartafwijking.  Bovendien kreeg 4% van de studiepopulatie een 
implanteerbare cardioverter-defibrillator (ICD) op basis van de bevindingen van de ILR. 
 Het optreden van syncope bij patiënten met een hartziekte kan het gevolg zijn van een 
kamerritmestoornis. Daarom wordt onverklaarbare syncope vaak beschouwd als een risicofactor voor 
plotse hartdood. Ook al is syncope een risicofactor voor plotse hartdood, het besluit om een ICD als 
primaire preventie te geven is niet eenvoudig. Zeker niet bij jonge patiënten met bijvoorbeeld een 
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erfelijke hartziekte. Een ICD heeft namelijk ook nadelige gevolgen zoals onterechte ICD-therapie, 
malfunctie en ICD-gerelateerde infectie. Aan de andere kant kan het optreden van klachten bij een 
patiënt die een risico heeft op plotse hartdood beangstigend zijn. Een ILR kan nuttig zijn om het ritme te 
detecteren tijdens het optreden van klachten. Daarnaast kan continue ritmebewaking middels een ILR 
de behandelend arts de zekerheid te bieden dat elke kamerritmestoornis, ook als deze asymptomatisch 
is, wordt gedocumenteerd. In hoofdstuk 4-6 hebben wij in drie specifieke patiëntencategorieën met 
een laag tot matig risico op plotse hartdood de klinische meerwaarde van een ILR onderzocht. 
 Plotse hartdood is een belangrijke doodsoorzaak bij volwassenen met een aangeboren 
hartafwijking en wordt voornamelijk veroorzaakt door een kamerritmestoornis. In de huidige praktijk is 
de beslissing om een ICD te implanteren bij deze patiënten een uitdaging en dit is grotendeels gebaseerd 
op het klinisch oordeel van de behandelend arts. In hoofdstuk 4 hebben wij prospectief de klinische 
meerwaarde van een ILR onderzocht bij volwassenen met een aangeboren hartafwijking. Dit waren 
voornamelijk symptomatische patiënten met een aantal risicofactoren voor een kamerritmestoornis. 
Gedurende een mediane follow-up van 16 maanden, kreeg 27% een kamerritmestoornis en uiteindelijk 
kreeg 10% een ICD. Bovendien leidde de bevindingen op de ILR tot wijzigingen van het klinisch beleid 
in 73% van de studiepopulatie. 
 In de huidige Europese richtlijnen wordt het gebruik van de risicocalculator (HCM Risk-SCD 
model) aanbevolen bij patiënten met hypertrofische cardiomyopathie om potentiële ICD-kandidaten 
te identificeren. Bij een berekende 5-jaars risico op plotse hartdood van 6% wordt een ICD aanbevolen. 
Een belangrijke risicofactor in deze calculator is het optreden van kortdurende kamerritmestoornissen 
(>120/min, minimaal 3 complexen). In hoofdstuk 5 hebben wij de meerwaarde van een ILR boven een 
conventionele strategie onderzocht bij patiënten met hypertrofische cardiomyopathie. De patiënten 
in deze studie hadden een laag tot matig risico op plotse hartdood volgens de risicocalculator. De 
gekozen controlegroep was vergelijkbaar met de ILR-groep op basis van leeftijd, geslacht en berekende 
risicoscore. Dit onderzoek toonde aan dat de detectie van kamerritmestoornissen vergelijkbaar was 
tussen beide groepen. Echter, in de ILR-groep werden er meer ritmestoornissen gedetecteerd die 
resulteerde in een wijziging van het klinisch beleid. 
 Brugada syndroom is een erfelijke elektrische hartziekte dat geassocieerd is met een verhoogd 
risico op plotse hartdood ten gevolge van een kamerritmestoornis.  Risicostratificatie bij patiënten met 
Brugada syndroom is lastig en er is discussie over de prognostische rol van een elektrofysiologisch 
onderzoek voor risicostratificatie. Indien patiënten zich presenteren met klachten die mogelijk 
gerelateerd zijn aan hartritmestoornissen dan is het wenselijk om te weten of een ritmestoornis hieraan 
ten grondslag ligt. Het doel van onze studie in hoofdstuk 6 is te evalueren wat de opbrengst is van 
een ILR bij symptomatische Brugada patiënten. De belangrijkste reden voor een ILR was het uitsluiten 
van kamerritmestoornis als oorzaak van de symptomen en het documenteren van een symptoom-
ritme correlatie. De helft van de studiepopulatie had een keer syncope gehad voor de ILR-implantatie. 
Gedurende een gemiddelde follow-up van bijna 3 jaar werd er bij 15% van de studiepopulatie een 
kortdurende kamerritmestoornis gedetecteerd. Geen patiënt kreeg een ICD. Daarnaast werd er bij 20% 




 Tot slot, een chronische totale occlusie van een kransslagader komt veel voor bij patiënten met 
coronairlijden. Eerdere studies hebben aangetoond dat een chronische totale occlusie een belangrijke 
risicofactor is voor het krijgen van kamerritmestoornissen bij patiënten die een ICD hebben gekregen 
voor primaire preventie van plotse hartdood. In hoofdstuk 7 hebben we retrospectief onderzocht 
of een chronische totale occlusie een voorspeller was van kamerritmestoornissen bij patiënten die 
een ICD kregen na een hartstilstand (secundaire preventie). Een chronische totale occlusie bleek een 
onafhankelijke voorspeller te zijn van terechte ICD-therapie. Het 5-jaars risico op een terechte ICD-
therapie was 37% in de groep met een chronische totale occlusie en 25% in de groep zonder een 
chronische totale occlusie. Op dit moment onderzoeken wij de incidentie van kamerritmestoornissen 
bij patiënten met een chronische totale occlusie middels een ILR (VACTOR studie, NCT03475888).
Deel II – Subcutane ICD
In deel II van dit proefschrift hebben wij de geschiktheid voor een subcutane ICD onderzocht bij 
verschillende patiënten groepen. De huidige richtlijnen geven aan dat een S-ICD een alternatief is voor 
een transveneuze ICD indien er geen noodzaak is voor bradypacing, cardiale resynchronisatie therapie 
(CRT) of antitachycardie pacing (ATP). De S-ICD maakt gebruik van een oppervlakte vector om de 
hartfrequentie te bepalen. Indien de S-ICD ten onrechte andere signalen oppikt (oversensing) dan kan 
dat leiden tot een onterechte ICD schok. Derhalve wordt aanbevolen om bij elke S-ICD kandidaat de 
vectoren te screenen om te bepalen of hij/zij geschikt is voor een S-ICD. 
 In hoofdstuk 8 hebben wij retrospectief onderzocht of patiënten met een transveneuze ICD 
geschikt waren geweest voor een S-ICD. Dit waren patiënten die op het moment van de implantatie 
geen pacing indicatie hadden. Ten tijde van de eerste ICD-wissel bleek 69% van de patiënten achteraf 
gezien potentieel geschikt voor een S-ICD. Gedurende de eerste levensduur van de ICD had namelijk 
slechts 31% van de patiënten CRT, ATP en/of bradypacing therapie nodig. De jaarlijkse incidentie 
voor ATP, CRT en bradypacing was 4.9%, 1.8% en 0.3%, respectievelijk. Echter, er waren geen klinische 
parameters ten tijde van de initiële ICD-implantatie die voorspelden of iemand geschikt was voor een 
S-ICD. Daarnaast weten we niet bij hoeveel patiënten de vectoren geschikt waren voor een S-ICD. 
 Bij een S-ICD kandidaat wordt standaard een vectorscreening uitgevoerd om te controleren 
of de kandidaat een geschikte QRS-T-morfologie heeft. Voorheen werd dit gedaan middels een 
vectorelektrocardiogram en een vector screening tool waarbij handmatig bekeken werd of de QRS-
T-morfologie geschikt was. In 2016 heeft de fabrikant software ontwikkeld waarmee dit proces 
geautomatiseerd werd, de zogenaamde Automated Screening Tool (AST). In hoofdstuk 9 hebben wij 
prospectief in een heterogene populatie de geschiktheid voor een S-ICD onderzocht met behulp van 
de twee methoden (manuele vectorscreening versus AST). De S-ICD geschiktheid op basis van beide 
screeningsmethoden was vergelijkbaar (93% versus 92%) en de overeenkomst tussen de twee methoden 
was 94%. Patiënten met een hypertrofische cardiomyopathie hadden 3x meer kans op ongeschikte 
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vectoren dan andere patiënten. Dit komt waarschijnlijk door de abnormale T-top morfologie in deze 
populatie.
 Eerdere studies hebben aangetoond dat een 12-afleidingen ECG kan voorspellen of iemand 
geschikt is voor een S-ICD op basis van de manuele vectorscreening. Dit is handig in de klinische 
praktijk omdat je dan geen aparte vector screening hoeft te doen. In hoofdstuk 10 hebben wij in een 
heterogene populatie onderzocht welke parameters op een standaard 12-afleidingen ECG geassocieerd 
zijn met S-ICD geschiktheid gemeten met AST. Wij vonden dat een QRS-duur van ≤130 ms, afwezigheid 
van QRS/T-discordantie in lead II en R/T-ratio ≥3.5 in lead II onafhankelijke voorspellers zijn voor S-ICD 
geschiktheid. Patiënten die aan alle drie de criteria voldeden (33% van de studiepopulatie) waren 100% 
geschikt voor een S-ICD op basis van AST. De belangrijkste boodschap van deze studie is dat indien 
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